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Opitz BBB/G syndrome (OS, MIM 300000 and MIM 145410) is a congenital disorder 
characterised by malformations of the ventral midline. BBB syndrome and G syndrome 
(Borden, 2000; Opitz, 1969b; Opitz, 1969a), formerly described as two different disorders, 
were merged into Opitz BBB/G syndrome subsequent to description of patients with a mixture 
of symptoms (Cordero and Holmes, 1978). The two cardinal phenotypic manifestations of OS 
are hypertelorism/telecanthus (abnormally widely spaced/increased innercanthal distance) and 
hypospadias (urethral cleft in male patients). However, they are often found to have in addition 
other typical features such as cleft lip and/or palate, laryngotracheoesophageal (LTE) 
anomalies, congenital heart defects, imperforate anus, agenesis of the corpus callosum, ear 
abnormalities, and mental retardation (Cox et al., 2000; De Falco et al., 2003; So et al., 2005).  
OS is genetically heterogeneous with an autosomal and an X-linked locus. The two 
forms are clinically indistinguishable (Robin et al., 1996). In 1997, Quaderi et al identified by 
positional cloning the MID1 gene in Xp22.3; MID1 harbours mutations in about 68% of patients 
with X-linked OS. In contrast, while the autosomal locus has been mapped by linkage analysis 
to chromosome 22, the responsible gene remains unknown (Robin et al., 1995).  
1.1 Ventral midline development  
The development of the ventral midline of the human body is a highly complicated 
multistep process during embryogenesis which involves formation, development, and correct 
positioning of structures in the midline of the body (e.g. heart, oesophagus, trachea or 
craniofacial structures). Many of the molecular mechanisms involved in the development of the 
ventral midline are unidentified. However, neural crest cell (NCC) migration and ephithelial-
mesenchymal transition (EMT) are thought to be fundamental processes during these stages 
of embryonic development (Schweiger and Schneider, 2003). 
Due to their importance during embryogenesis, NCCs have been considered the fourth 
germ layer, in addition to the three traditional germ layers, ectoderm, mesoderm and 
endoderm (Hall, 2000). Moreover, some scientists consider that migrating embryonic NCCs 
are the best evolutionary acquisition from vertebrates (Thorogood, 1989). 
NCCs derive from the ectoderm and originate during neurulation at the dorsal most 
region of the neural tube between the neural and non-neural ectoderm (Figure 1.1; Gilbert, 
2003). NCCs delaminate from the neural folds and migrate to different places, where they 
generate a prodigious variety of cells, such as neurons, pigment, smooth muscle, connective 
tissue, or bone, among others. Although the mechanisms involved in NCC formation and 
migration are highly conserved among vertebrates, the precise moment in which NCCs start 




migrate concomitantly with neural plate folding. In contrast, in frogs and birds NCCs start 
migrating only after neural tube closure (Jones and Trainor, 2005).  
NCCs are classified into four subpopulations that give rise to specific cell and tissue 
types (Gilbert, 2003; Jones and Trainor, 2005):  
 Trunk NCCs differentiate into neurons of the glia and peripheral nervous system, 
part of the enteric nervous system, and melanocytes.  
 Cranial NCCs give rise to cartilage, bone, cranial neurons, glia, and connective 
tissue of the face and, in addition, they produce pigment cells, and sensory and 
parasympathetic ganglia.  
 Cardiac NCCs participate in the formation of the heart and, additionally, 
generate pigment, skeletal, and neuronal cells 
 Vagal NCCs form nearly the entire gut, and the majority of neurons and glia of 
the enteric system. 
Each population occupies a different region along the anterior-posterior axis of the 
neural tube, from which they migrate along unique pathways, that are defined by a Homeobox 
gene (Hox) gradient (Le Douarin et al., 2004; Lumsden et al., 1991; Selleck and Bronner-
Fraser, 1995; Trainor and Krumlauf, 2001).  
As previously mentioned, NCCs undergo different processes common to all kinds of 
NCCs and to all species. After induction of neural plate folding, some previously 
indistinguishable neuroepithelial cells are induced by signals coming from the presumptive 
epidermis and neural tube (Mancilla and Mayor, 1996; Selleck and Bronner-Fraser, 1995). 
Figure 1.1. Neurulation 
Schematic representation of neural
tube folding upon induction from
neuroectoderm (purple), non-neural
ectoderm (blue) and paraxial
mesoderm (yellow). NCCs (green)
originate from the neural folds. Only
delamination of NCCs from the
dorsalmost part of the neural tube is





Induced cells then enter into EMT to finally delaminate and migrate (Duband et al., 1995; 
Knecht and Bronner-Fraser, 2002; Thiery, 2003). During all of these processes, contact-
mediated interactions between neural and non-neural tissue take place. All these events take 
place under a very complex temporospacial collaboration of many different morphogens, such 
as Wnt, transforming growth factor β family (TGFβ) (including bone morphogenic protein, 
BMP), Hedgehog (HH) family, fibroblast growth factor (FGF) family, Notch, and even retinoic 
acid and its receptors play a role here (extensively reviewed in Gammill and Bronner-Fraser, 
2003; Jones and Trainor, 2005; Knecht and Bronner-Fraser, 2002). All of these pathways 
participate repeatedly during the life of NCCs; NCC fate is not a sequence of events, but a 
combination of events and intercalation of pathways functioning concomitantly.  
Nevertheless, BMP, Wnt, and FGF signalling by activating transcription factors such as 
Slug or FoxD3 seem to control the early steps in the induction of NCCs (Barembaum and 
Bronner-Fraser, 2005; Huang and Saint-Jeannet, 2004; Nieto et al., 1994). Slug is one of the 
best-characterised NCC induction markers; it belongs to the Snail/Slug family, and is closely 
related to Snail. Slug and Snail are both expressed in NCCs in a vertebrate-specific manner 
(Barrallo-Gimeno and Nieto, 2005; Locascio et al., 2002; Nieto et al., 1994).  
After induction, NCCs undergo EMT, process during which epithelial cells lose their 
polarity and adhesion properties by down-regulation of cell adhesion molecules such as E-
cadherin (Pla et al., 2001), transform into mesenchymal cells, and acquire migratory 
properties. During EMT, an important reorganization of cytoskeletal structures and increase in 
expression of mesenchymal genes take place (Hay, 2005; Savagner, 2001). Important key 
players in EMT include again Snail/Slug. 
 Premigratory NCCs also respond to signals coming from the neural plate and non-
neural ectoderm that assure their survival. Induction of Foxd3, Sox9 and Sox10, Zic genes, 
Pax genes, Notch, Delta, Msx genes, Rhob and Twist is important here (Gammill and Bronner-
Fraser, 2003; Jones and Trainor, 2005; Steventon et al., 2005). Adjacent territories also have 
a strong influence on the delamination of NCCs. Thus, although other pathways like Wnt and 
FGF also participate (Morales et al., 2005), correct balance between BMP and its antagonist 





1.1.1 Craniofacial development 
Craniofacial development is one of the most complicated processes during development, 
which involves the formation of a large number of different tissues and the correct 
emplacement of the structures of the skull and face (Cohen, 2002; Wilkie and Morriss-Kay, 
2001). It begins with the formation of five paired prefacial structures known as branchial or 
pharyngeal arches, at the ventral surface of the embryo. Next, invading NCCs (Figure 1.2C) in 
combination with mesodermal cells form the facial prominences (maxilomandibular, lateral and 
frontonasal), which grow, fuse and expand into more mature craniofacial structures, including 
the skull (Figure 1.2A). From the first pair of pharyngeal arches emerge the maxillomandibular 
prominences (Figure 1.2A,B, in green), which give rise to the lateral middle and lower face, the 
sides of the lips and the lower jaw (only the mandibular prominence) (Cox, 2004; Tapadia et 
al., 2005). The frontonasal process (Figure 1.2A,B, in pink) contributes to the forehead, the 
Figure 1.2. Development of the face 
A. Frontal views of mouse embryos in which the facial prominences and the structures that
they generate are depicted. The maxilomandibular prominences are indicated in green,
frontonasal in pink and the lateral prominences in blue. B. Frontal view of a human child, the
origin of the different structures is indicated with different colours as for A. Figures adapted
from Tapadia et al 2005. 
C. Lateral view of the head indicating the migration of NCCs into the developing face. NCCs
are indicated in pink, neural tube in green. r: rhombomer, mb: midbrain, fb: forebrain, fnp:
frontonasal prominence, mx: maxillary prominence, md: mandibular prominence, ba: branchial




middle of the nose, and, in combination with the maxillary process, to the formation of the 
midlip and primary palate. Defective coordination of growth and fusion (governed by NCC 
invasion, EMT and programmed cell death (PCD)) of the prominences can result in cleft lip 
and palate (Cox, 2004; Kang and Svoboda, 2005; Kang and Massague, 2004; Schweiger and 
Schneider, 2003). The lateral prominences (Figure 1.2B, in blue) give rise to the lateral nasal 
structures.  
Invading NCCs arising from different areas along the anterior-posterior neural axis 
(Figure 1.2C, Kontges and Lumsden, 1996) play an important role during craniofacial 
development. Positional identity along the anterior-posterior axis is obtained through a Hox 
gene gradient that defines each rhombomer (the parts into which the hindbrain is divided) 
(Krumlauf, 1993; Santagati and Rijli, 2003). A complex and cautiously regulated coordination 
of signalling pathways coming from both epithelia and NCCs are of high importance for a 
successful completion of craniofacial structures (Helms et al., 2005; Noden and Trainor, 2005; 
Tapadia et al., 2005). 
1.1.2 Heart development 
At embryonic day 21, the heart is a single chambered tube formed by fusion of two 
simple epithelial tubes (Figure 1.3A). By day 28, cardiac looping occurs and the presumptive 
atria are placed anterior to the presumptive ventricles. Upon myocardial signals, cells from the 
adjacent endocardium detach and form the endocardial cushions, which divide the primitive 
tube into the atrioventricular channels. Concomitantly, the primitive atrium becomes divided by 
two septa that grow towards the endocardial cushion. Up to the eighth week of gestation, there 
is a continuous process of looping and remodelling until the septa close to form the four 
definitive chambers of the heart, at which point the circulatory and pulmonary systems become 
independent, with the pulmonary artery connected to the right ventricle and the aorta to the left 
ventricle (Figure 1.3A, Gilbert, 2003; Schweiger and Schneider, 2003). 
Cardiac NCCs, generated from the first to third somites, give rise to the smooth muscle 
of the aortic arches. In addition, they migrate through the third and more caudal branchial 
arches and invade the aorticopulmonary septum and endocardial cushions collaborating to 
achieve correct articopulmonary segmentation (Kirby et al., 1983; Waldo et al., 1998). Similarly 
to craniofacial development, induced cells producing the endocardial cushion (see above) 
undergo EMT (Runyan and Markwald, 1983), probably in parallel to PCD (Figure 1.3B, Keyes 
and Sanders, 2002). NCC invaded regions are commonly affected in patients with complex 





1.1.3  Ephrins as NCC pathfinders 
NCCs migrate in well-separated streams during development until they reach their site of 
differentiation. In addition to the earlier mentioned Hox genes, ephrin receptors (Eph 
receptors) and ephrins have been shown to be essential in delineating migratory routes of 
NCCs. Obstruction of single Eph receptors can cause a mixture of different streams, with 
severe developmental consequences (Helbling et al., 1998; Robinson et al., 1997; Smith et al., 
1997). 
Eph receptors, the largest family of membrane-bound receptor tyrosine kinases, interact 
with ephrin ligands, which are also membrane-bound proteins. Two classes of Eph receptors, 
A and B, have been described, distinguished by their predominant binding affinity to ephrin-A 
ligands (anchored to the membrane through glycosylphosphatidylinositol anchor, GPI anchor) 
or to ephrin-B ligands (transmembrane), respectively. On the cellular level, the interaction of 
Eph receptors with their ligands principally influences cytoskeletal organization and cell 
adhesion, and, consequently, cell migration (Pasquale, 2005). Furthermore, many 
developmental processes, such as morphogenesis, tissue border formation, vascularization, 
axon guidance or synaptic plasticity, mainly depend on correct Eph receptor-ephrin signalling 
(Davy and Soriano, 2005; Holder and Klein, 1999; Murai and Pasquale, 2004; Palmer and 
A 
B 
Figure 1.3 Heart development and contribution of neural crest cells 
A. Schematic showing the primitive heart tube, looping at day 28, and the four definitive chambers in
the newborn. B. Invading neural crest cells in the endocardial cushions. Figures adapted from




Klein, 2003). Since both Eph receptors and ephrins are membrane-bound proteins, cell-to-cell 
contact is required for them to interact. They interact in a “kiss and tell” fashion, thereby 
inducing forward and reverse signals that result in attraction and adhesion or repulsion of 
participating cells (Gauthier and Robbins, 2003; Kullander and Klein, 2002). For instance, 
ephrin-B1 can either attract or repel EphB-expressing NCCs (Santiago and Erickson, 2002) 
and, in this way, the flow of NCC streams is regulated.  
Eph receptors and ephrins are powerful patterning molecules. Interestingly, ephrin 
defects have more drastic effects in some cells than in others. Differential expression of ephrin 
genes in cells that should be the same makes them behave differently, and in the absence of 
ephrin expression, all the cells remain the same and their functions can be accomplished by 
redundant molecules (Compagni et al., 2003; Davy et al., 2004). A clear example is 
craniofrontonasal syndrome, where the loss of expression of ephrin-B1 (EFNB1), leads 
specifically to defects of the ventral midline, while other structures, where EFNB1 differential 
expression is probably not needed, remain unaffected (Twigg et al., 2004; Wieland et al., 
2004).  
1.1.4 Midline development and disease 
The development of the craniofacial structures is a very complicated process that is 
found altered in a multitude of congenital disorders (Wilkie and Morriss-Kay, 2001). 
Additionally, there is a high incidence (1 in 700 to 1 in 1000) of non-syndromic cleft lip and 
palate that involves a complex inheritance pattern (Prescott et al., 2001; Schutte and Murray, 
1999). Interestingly, OS is one of the few known causes of monogenic cleft lip and palate.  
Mutations of diverse genes participating in the establishment of the ventral midline result 
in overlapping phenotypes, demonstrating the complexity of this process and the concomitant 
participation of many pathways. An extensively studied example is holoprosencephaly (HPE) 
(Roessler and Muenke, 2001), which is characterised by defective forebrain development 
normally accompanied by cleft lip, cyclopia and overlying proboscis. Alterations in several 
members of the Sonic Hedgehog (Shh) pathway have been shown to cause HPE (Roessler 
and Muenke, 2003).  In addition, mutations in GLI3, a target gene of Shh signalling, cause 
Greig syndrome (OMIM 175700), which is characterised by hypertelorism and polydactyly. 
It has been suggested that defects in NCC migration and epithelial EMT lead to 
malformations in the ventral midline (Schweiger and Schneider, 2003).  DiGeorge Syndrome 
(DGS; OMIM 188400), also referred as to del22q11, is characterised by aortic arch defects, 
contruncal heart defects, and pharyngeal and craniofacial anomalies, all structures derived 
from of NCCs. Since loss of Tbx1 expression in mouse has been shown to generate a 
phenotype resembling DGS, TBX1 has been proposed to be the key gene in DGS (Jerome 




shown to severely affect neural crest and cranial nerve migratory pathways (Moraes et al., 
2005; Vitelli et al., 2002) 
Mowat-Wilson syndrome (OMIM 235730) is an autosomal dominant complex disorder 
caused by mutations in the ZFHX1B gene. The phenotype of Mowat-Wilson patients is 
characterised by craniofacial malformations, Hirschsprung disease, mental retardation, 
congenital heart disease, hypospadias and agenesis of the corpus callosum; all features are 
suggestive of a neurocristopahty affecting cranial, cardiac and vagal NCCs (Mowat et al., 
2003). 
In the previously mentioned craniofrontonasal syndrome (OMIM 304110), which is 
characterised by hypertelorism and broad nasal bridge, mutations in the EFNB1 gene also 
result in improper NCC migration (Twigg et al., 2004; Wieland et al., 2004). Moreover, 
defective NCC migration and EMT have also been proposed to be involved in the 
pathogenesis of OS (Cox, 2004; Richman et al., 2002; Short and Cox, 2006). 
1.2 X-linked Opitz BBB/G syndrome (OS) and MID1 
MID1 covers a genomic region of about 300 kb, from which nine exons are constitutively 
expressed to give an open reading frame (ORF) of approximately 2 kb (Figure 1.4). While the 
existence of 3´and 5´UTR alternative MID1 transcripts has been known for some time (Landry 
and Mager, 2002; Winter et al., 2004), 14 novel alternative exons were recently identified in 
the human MID1 gene (Figure 1.4, Landry and Mager, 2002; Winter et al., 2004).  
Most of the mutations identified in OS patients are located at the 3′ end of the ORF, 
hence affecting the C-terminus of MID1. With the detection of MID1 in 68% of X-linked OS 
patients, the majority of the identified mutations are nonsense and frameshift mutations. 
However, missense mutations, in-frame deletions and in-frame insertions have also been 
found (Figure 1.5, Schweiger and Schneider, 2003). 
The ubiquitously expressed MID1-gene encodes a 667 amino acid phosphoprotein, 
MID1 (Figure 1.5), with a molecular weight of approximately 72 kDa. MID1, also known as 
TRIM18, belongs to the RBCC protein family, characterised by an N-terminal tripartite motif 
Figure 1.4 . MID1 gene 
Dark red shows the nine constitutively expressed exons. Light red represents 3´and 5´UTRs. Light
orange boxes represent exons identified by RT- and RACE-PCR. Dark orange boxes represent
exons identified by NIXanalysis. Slashed boxes represent regions of high homology with mouse.




(TRIM) and an RFP-like domain at the C-terminus. The RBCC domain comprises a RING 
finger, two Bboxes and a coiled-coil domain (Schweiger and Schneider, 2003). 
1.2.1  The RBCC protein MID1 
The first RBCC domain was identified in Xenopus nuclear factor 7 (XNF7), a protein that 
participates in the dorso-ventral patterning of Xenopus during development (El-Hodiri et al., 
1997). The list of identified RBCC proteins has since then grown rapidly and today 
encompasses 68 members (Nisole et al., 2005; Reymond et al., 2001). 
RBCC proteins participate in various important cellular processes such as development, 
cell growth, and proliferation. In addition, some of them have antiviral properties by targeting 
retroviruses (Nisole et al., 2005). However, they are recently gaining attention due to the 
increasing number of proteins in this family involved in human disease. Well-studied examples 
include the proto-oncogenic proteins RFP (ret finger protein) (Hasegawa et al., 1996), PML 
(promyelocytic leukaemia) and TIF1-α, which gain oncogenic properties when fused to RET, 
retionic acid receptor alpha (RARα), or Braf (Borden et al., 1995a; Grignani et al., 1994; 
Jensen et al., 2001; Klugbauer and Rabes, 1999; Le Douarin et al., 1995). 
PYRIN/MARESNOSTRIN, which is mutated in familial Mediterranean fever (FMF) (consortium, 
1997), MUL, mutated in Mulibrey nanism (Avela et al., 2000), and MID1, mutated in OS, are 
some examples of RBCC proteins involved in monogenic disorders. 
Figure 1.5 .MID1 gene and protein 
Representation of the MID1 gene and protein. Exon coding for each of the MID1 domains are
indicated. Location and type of MID1 mutations identified in OS patients are shown (mutations
represented here were reported in (Cox et al., 2000; De Falco et al., 2003; Gaudenz et al., 1998;
Quaderi et al., 1997; Schweiger et al., 1999; So et al., 2005). Figure adapted from Schweiger and
Schneider, 2003. 















So far, the only more general function of RBCC proteins that could be defined is 
ubiquitin ligase activity mediated by the RING finger domain (Meroni and Diez-Roux, 2005). 
Additionally, some members of this family have been shown to orchestrate the formation of 
large macromolecular complexes (Borden, 1998; Saurin et al., 1996; Torok and Etkin, 2001). 
The RING finger domain of MID1 contains a cysteine rich metal binding domain 
corresponding to the RING finger consensus sequence (Figure 1.6A). This motif binds two 
zinc atoms through eight potential metal ligands to form a unique “cross brace” motif (Figure 
1.6B, Borden, 2000). 
Two Bboxes follow the RING domain in MID1 after a linker of forty-five amino acids, in 
agreement with the conserved relative position of different domains inside the RBCC motif. 
Bboxes, like RING fingers, are cysteine- and histidine-rich zinc binding motifs. On account of 
slightly differing consensus sequences, two different types of Bboxes have been described, 
Bbox type 1 (Bbox1) and Bbox type 2 (Bbox2) (Figure 1.6C, Torok and Etkin, 2001). The 
RBCC motif contains one or two Bboxes; when both are present, as in MID1, Bbox1 always 
precedes Bbox2, but if only one is present, it is always Bbox2 (Reymond et al., 2001). Bboxes 
and Bboxes2 include seven potential metal binding ligands, while Bboxes1 include eight 
potential metal binding ligands. 1H NMR studies performed on XNF7 Bbox have shown that 
they bind a single zinc atom in a tetrahedral disposition (Borden et al., 1995b). Curiously, 
Bboxes only exist in the RBCC protein family, suggesting that they fulfil an essential function 
of RBCC proteins. Thus far, however, no specific function apart from the mediation protein-
protein interactions has been identified (Reymond et al., 2001). 
Slightly overlapping and C-terminally situated to Bbox2 is the coil-coiled domain of MID1. 
Coiled-coil domains are bundles of α-helices, twisted around one another into a super coil or 
Figure 1.6. RING finger domain  
A. Consensus sequence of RING fingers. X can be any amino acid. B. Schematic representation 
of the cross-brace system. Cysteines are represented in red and histidines in blue. Zinc atoms 










RING Finger        C-x2-C-x11-16-C-x-H-x2-C-x2-C-x7-74-C-x2-C/D
Bbox1               C-x2-C-x7-12-C-x2-C-x4-C-x2-C/H-x3-4-H-x4-9-H







super helix, which participate in protein-protein interactions and, particularly, in dimerisation 
processes (Burkhard et al., 2001). Many RBCC proteins homo- and/or heterodimerise through 
the coiled-coil domain, (e.g. MID1, MID2, RFP, TIF) (Reymond et al., 2001). For MID1, apart 
from forming homodimers, it can also heterodimerise with MID2, a well-known homologue with 
the same subcellular localisation (Cainarca et al., 1999). Despite having different expression 
patterns during development, MID1 and MID2 have 89% amino acid identity and perform 
overlapping functions (Granata et al., 2005; Short et al., 2002) 
As mentioned previously, members of the RBCC protein family have been shown to 
participate in the formation of macromolecular complexes. PML is one of the most well-studied 
members; it forms parts of a multiprotein complex called PML nuclear bodies. The RING finger 
and Bboxes have been found to be necessary for nuclear bodies formation (Jensen et al., 
2001). The RFP protein and TIF1-α, two other members of the family, have also been shown 
to associate with PML nuclear bodies and, additionally, the RFP protein has also been shown 
to be involved in the formation of homomultiprotein complexes through its Bboxes and coiled-
coil domain (Cao et al., 1997).  
In the case of MID1, Cainarca et al demonstrated in 1999 that MID1 is part of a large 
macromolecular complex. Interestingly, mutations in the coiled-coil domain do no disrupt the 
complex, but produce even larger aggregates. However, most of the interaction partners of the 
complex remain unknown, and no other members apart from MID1 itself, MID2,  α4 (Liu et al., 
2001; Trockenbacher et al., 2001), and Mig12 (Berti et al., 2004) have been identified. 
An RFP-like domain, also known B30.2 domain, is located at the very C-terminal end of 
MID1. We have shown previously that MID1 interacts with microtubules through its C-terminal 
end, as evidenced by the detachment of MID1 from microtubules and subsequent formation of 
cytosolic aggregates when this domain is mutated (Schweiger et al., 1999). B30.2 domains are 
present in three different families of proteins: RBCC proteins, BTNs-receptor glycoproteins of 
the immunoglobulin superfamily and stonutoxin (STNX)- protein secreted with the venom 
expectorated by Synanceia horrida (Henry et al., 1998). As yet, attempts at elucidating a 
common function for B30.2 domains have been unsuccessful. However, it has been suggested 
that these domains, as in MID1, fulfil important roles in providing the correct subcellular 
location of RBCC proteins (Reymond et al., 2001). 
Between the RBCC motif and the B30.2 domain, an FNIII domain has been defined in 
the MID1 protein (Cox et al., 2000). FNIII domains are found in a huge variety of proteins such 
as proteins of the extracelullar matrix, cell adhesion molecules, enzymes, or muscle proteins. 
In spite of being highly conserved domains, there is no common function attributable to all 
proteins in which the domain is found. FNIII domains have a β-sandwich fold closely related to 
the immunoglobulin fold, and contain several highly conserved prolines. Varying numbers of 




proposed that the FNIII domain acts as an elbow linking the various functional sites of the 
MID1, and anchors the protein to the cytoplasmic region where it is needed, namely at the 
microtubules (Mnayer et al., 2005). However, these observations require further experimental 
proof. 
1.2.2 The MID1 function 
Apart from a microtubule stabilizing role (Schweiger et al., 1999), we could show 
previously that MID1 interacts with the α4 protein through its Bbox1 and that mutations in the 
coiled-coil domain or the C-terminus do not affect this interaction (Liu et al., 2001; 
Trockenbacher et al., 2001). α4, encoded by the IGBP1 gene, binds and negatively regulates 
the catalytic subunit of phosphatase 2A (PP2Ac) (Figure 1.7, Chen et al., 1998; Murata et al., 
1997). This mechanism was first observed in yeast, where TAP42 (yeast homologue of α4) 
regulates PP2Ac upon Target Of Rapamycin (TOR) signalling (see section 1.3, Nanahoshi et 
al., 1999; Raught et al., 2001). α4 is a cytosolic protein with a diffuse distribution, but in 
association with MID1, it is recruited to microtubules. Reciprocally, an excess of α4 can detach 
MID1 from microtubules and bring it to the cytosol, indicating that both proteins interact and 
collaborate in determining their subcellular localisation. The interaction between MID1 and α4 
leads to a spatial proximity of the ubiqutin ligase activity of MID1, mediated by its RING-finger 
domain, and microtubule-associated PP2Ac, which results in a ubiquitin-specific modification 
and degradation of the phosphatase (Figure 1.7). C-terminally mutated MID1 can no longer 
bind the microtubules and, therefore, the interaction of the MID1-α4 complex with the pool of 
microtubule-associated PP2Ac can not take place. As a result, PP2Ac can not be degraded 
and accumulates at the microtubules, resulting in the hypophosphorylation of downstream 
regulated microtubule-associated proteins (MAPs) (Schweiger and Schneider, 2003; 
Trockenbacher et al., 2001). 
 Interestingly, the phosphorylation status of MAPs targeted by PP2A has been shown to 
be involved in a variety of developmental disorders, such as Miller-Dieker syndrome, X-linked 
double cortex syndrome (Avila et al., 1994; Gong et al., 2000). In addition, a similar 
pathomechanism has been observed in Alzheimer´s disease (Trojanowski and Lee, 1995), 





1.2.3 Regulation of MID1 function 
Although MID1 is ubiquitously expressed, OS phenotype specifically affects the ventral 
midline, suggesting that MID1 function is carefully regulated in a tissue-dependent manner 
(Schweiger and Schneider, 2003). Moreover, a wide phenotypic variability among OS patients 
has been described (Cox et al., 2000; So et al., 2005) pointing at modifying factors that 
participate to regulate MID1 function. Three different mechanisms have been proposed for the 
regulation of MID1 function: 
A - Splicing mechanisms. MID1 produces a multitude of alternatively spliced 
transcripts that are differentially expressed in diverse tissues (Winter et al., 2004). The splice 
variants lead to loss-of-function through several mechanisms conserved in human, mouse and 
fugu. Some transcripts produce C-terminally truncated MID1 that binds more strongly to α4 
and have a dominant negative effect over MID1. Others contain premature stop codons that, in 
contrast to the previously described transcripts, lead to non-sense mediated decay (NMD). 
Interestingly, a splice variant lacking the Bbox2 domain has been shown to bind with higher 
affinity to α4, hinting at an important role of this domain in regulating the interaction of MID1 
with the PP2A complex. 
Figure 1.7. MID1 function  
Schematic representation showing α4-bound MID1 in association with PP2Ac after displacing A
and B subunits. In this conformation, microtubule-associated PP2Ac becomes ubiquitinated 
through MID1 E3 ubiquitin ligase function and is degraded by the proteasome. To the right, the 
situation in OS patients is depicted; despite binding α4, C-terminally truncated MID1 can no 
longer approach the microtubules and ubiquitinate PP2Ac. This leads to accumulation of the 
phosphatase and hypophosphoryilation of its downstream-regulated proteins. Figure adapted 














































B - Protein interaction. MID1 is a member of a multiprotein complex. Thus, the 
regulation of other members of the complex implies the regulation of MID1. Recently, it has 
been shown that α4 is expressed during development in tissues affected by OS, suggesting 
that the tissue-specific expression of α4 could contribute to regulate MID1 function (Everett 
and Brautigan, 2002). Similar observations have been made for Mig12 (Berti et al., 2004). 
It is also known that MID2 is functionally equivalent to MID1. It has been proposed that 
in some tissues, MID2 substitutes for MID1 to a greater extent than in others and, 
consequently, only those tissues with less MID2 activity would suffer from MID1 loss (Buchner 
et al., 1999; Granata et al., 2005; Short et al., 2002). 
C - Phosphorylation status. Having been shown to be a phosphoprotein, it has been 
proposed that MID1 phosphorylation status (or other post-transcriptional modifications) 
regulates its association with, and subsequent stabilization of, microtubules. In 2001, Liu et al 
showed that MAP kinase activity is required to maintain MID1 association to microtubules. 
Unfortunately, most of the mechanisms underlying MID1 posttranslational modification and 
regulation remain unknown. 
1.3 mTOR pathway 
In 1991, a screening of mutations conferring resistance to rapamycin in S.cerevisae led 
to identify TOR1, TOR2 (Target of Rapamcycin) and FPR1 kinases (Heitman et al., 1991). 
Rapamycin, a potent cell proliferation and growth blocker, and immunosuppressant, forms a 
complex with FKBP12 (FK506-binding protein of 12kDa; coded by FPR1) that binds and 
inhibits TOR. This mode of action is well-conserved from yeast to mammals. TOR is an 
evolutionary conserved serine/threonine kinase, member of the phosphatidilinositol kinase-
related protein kinase complex (PIKK). While the majority of lower eukaryotes have two Tor 
proteins, in higher eukaryotes only one orthologue is found (Jacinto and Hall, 2003). 
 mTOR, the mammalian TOR orthologue, is a large protein that forms large 
macromolecular complexes through its multiple protein-protein binding domains. So far, only 
three interaction partners of mTOR have been identified, RAPTOR (regulatory associated 
protein of TOR), GβL (G-protein β-subunit-like protein) and RICTOR (rapamycin-insensitive 
companion of TOR) (Hara et al., 2002; Kim et al., 2002; Kim et al., 2003; Sarbassov et al., 
2004). The RICTOR complex, like the Tor2 complex in yeast, specifically regulates the 
cytoskeleton, independent of rapamycin-sensitive pathways (Jacinto et al., 2004). 
As a key regulator of cell proliferation and growth, mTOR senses and integrates 
nutrients and growth factor signals to regulate protein translation and ribosome biogenesis 
(reviewed in Fingar and Blenis, 2004). Although the best-characterised downstream targets of 
mTOR are S6K1 and 4E-BP1 (Figure 1.8, Gingras et al., 2001), other upstream and 




Sonenberg, 2004). A complex pattern of signals regulates mTOR (Figure 1.8), probably 
because protein synthesis requires large amounts of energy, and the cell has to make sure 
that the conditions are adequate to proceed. mTOR activation is controlled by levels of 
nutrients (branched amino acids and energy) and growth factors, which activate PI3K 
signalling and regulate mTOR through a sequential pathway known as PI3K/Akt/TSC/Rheb 
pathway. Interestingly, PI3K can phosphorylate 4E-BP1 and S6K1 and, thus, control cell 
proliferation independently from mTOR (reviewed in Fingar and Blenis, 2004). 
 Activated mTOR, forming a complex with RAPTOR and GβL, and in collaboration with 
the PIK3 pathway, phosphorylates S6K at several residues. Once phosphorylated, S6K 
phosphorylates the 40S ribosomal protein S6 (rpS6). This mechanism was formerly believed 
to regulate 5´TOP mRNA translation, but recently, this has been shown to be unlikely (Tang et 
al., 2001a). However, it is clear that mTOR is involved in the induction of 5´TOP marked 
mRNA translation (Pende et al., 2004), and since many of these RNAs encode ribosomal 
proteins and elongation factors, the translational capacity of the cell as a total increases.  
4E-BP1, the second well-known target of mTOR, is a repressor of the translation 
initiation factor eIF4E. When activated, eIF4E recognizes the cap structure (m7GpppN) at the 
5´end of some mRNAs and initiates cap dependent translation by interacting with eIF4G, a 
scaffolding protein that recruits the translation machinery to the 5´end of mRNA (Gingras et al., 
Figure 1.8. mTOR pathway 
Schematic representation of upstream and downstream factors of mTOR and the pathways in




2001). Under mTOR activation and PIK3 signalling, 4E-BP1 is phosphorylated and 
disassembles from eIF4E, thereby allowing the initiation of cap-dependent translation.  
In addition, TOR regulates phosphatase activity by promoting the binding of TAP42 (type 
2A associated protein) to the catalytic subunit of PP2A and to SIT4 (type 2A related 
phosphatase) in a rapamycin-sensitive manner. This results in the inhibition of PP2A activity 
(Di Como and Arndt, 1996; Jiang and Broach, 1999). In mammals, a similar mechanism 
mediated by the TAP42 homologue α4 has been proposed (Chen et al., 1998; Schweiger and 
Schneider, 2003). Although it has been shown that mTOR regulates phosphatase activity and 
that α4 negatively regulates PP2A activity, the contribution of rapamycin to the α4-PP2A 
complex remains controversial (Dennis et al., 1999; Peterson et al., 1999). 
1.4 Aim of the study 
Upon binding the linker protein α4, the microtubule-associated RBCC protein MID1  
targets the microtubule-associated PP2Ac towards ubiquitin specific modification and 
degradation. In OS patients, which are characterised by ventral midline malformations, MID1 
harbours mutations in the C-terminal end, resulting in the loss of microtubule-association and 
formation of cytoplasmic clumps in the cell. Despite preserving its association with α4, C-
terminally mutated MID1 can not approach the vicinity of PP2Ac and therefore, the 
ubiquitination and degradation of microtubule-associated PP2Ac becomes disrupted, leading 
to hypophosporylation of its downstream targets. Recently, several OS patients have been 
found to hold mutations in the Bboxes in the N-terminal end of MID1. Although Bboxes are 
known to participate in protein-protein interactions, no common functional roles could be 
attributed to them thus far. For the MID1 protein, it has been shown that the first of the two 
Bboxes interacts with α4, and a regulatory role of this interaction has been suggested for the 
second Bbox. Consequently, any disruption of these domains interfering with α4-binding would 
be expected to lead to accumulation of PP2Ac, thus causing OS. During this thesis, a detailed 
study of the influence of Bbox mutations on the MID1-α4 and MID1-microtubules interactions 
by immunofluorescence, immunoprecipitation and yeast two-hybrid experiments was 
performed to further analyse the functions of the two Bboxes and thus, pave the way for a 
novel pathomechanism responsible for OS. 
Not only the Bboxes, but also, similar to other RBCC proteins, several other domains of 
MID1 have been proposed to participate in protein-protein interactions, thus forming a 
multiprotein complex consisting of as-yet-unknown protein components. Proteins belonging to 
the MID1 complex are potentially important players in the development of the ventral midline 
and the pathogenesis of OS. Consequently, another main focus of this study was to use 
affinity chromatography and mass spectrometry to biochemically purify the MID1 complex and 
identify associated proteins. Subsequently, the MID1 complex should be characterised.
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2 Materials and Methods 
2.1 Materials 
2.1.1 General reagents 
Reagent Manufaturer 
β-mercaptoethanol Merck 
Acetic acid 100% Merck  
Acetone Merck 
Agarose Invitrogen 
Amino acids  Sigma 
Ammonium persulfate BioRad 
Ampicillin Sigma 
Aqua ad inectabilia Baxter 
BACTO-Yeast extract BDSciences 
BACTO-Agar Difco 
BACTO-Triptone  Difco 
Biotin Sigma  
Biotin-16-UTP Roche  
Boric acid Merck 
Bovine Serum Albumin Serva / Sigma 
Bradford reagent Sigma 
Bromphenolblue Serva 
Chlorampenicol Fluka  
Chloroform  Merck 
Complete/Complete mini protease inhibitors Roche 
Coomassie G250/Coomassie R250 Serva 
DABCO (1,4-diazobicyclo-2,2,2-octane) Sigma 
DAPI (4,6-diamino-2-phenylindole-2HCl·H2O) Serva 
d-Biotine Sigma 
Deoxycholic acid sodium salt (DOC) Fluka 
Diethylpyrocarbonat Sigma  







Ethidium bromide Serva 
Fetal calf serum (FCS) Biochrom 
Ficoll Pharmacia 
Fixing solution  Agfa 
Formaldehyde Merck 
Glucose monohydrate/Sucrose Merck 
Glutamine Cambrex 
Glycerol merck 















KCl Sigma  
LiAc Sigma 
LiCl Sigma 
Lipofectamine 2000 transfection reagent Invitrogen 
Lysozyme Boehringer-Ingelheim 
M280 streptavidine coated magnetic beads DYNAL 
Methanol Merck 
MgCl2 Merck/ PerkinElmer 
MgSO4 Merck 
Milk powder Nutricia-Zoetermeer 














PIPES Sigma  
Polyfect Qiagen 
Polyhomoribopolymers agarose (poly-rG, poly-rU, poly-rC, poly-rA) Sigma 
Prime RNAase inhibitor Eppendorf  
Protein agarose A/G Roche  
RNA guard  Amersham Pharmacia biotech 
RNA loading dye Fermentas 
Rothiphorese gel 30 Roth 
Roty-Nylon Plus membrane Roth 
SDS (sodium dodecylsulfate) BioRad/ Serva 
siRNA oligos Qiagen/Dharmacon 
Streptavidine-AP  Roche 
Taxol (Paclitaxel) Sigma  
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Taxol (Paclitaxel) Sigma 
TEMED GIBCO BRL 
Trichloro acetic acid (TCA)  Sigma  
Tris-(hydroxymethyl)-aminomethane Merck 




Vivaspin 500  Vivascience 
X-Gal Appligene 
Xylencianolblue Sigma 
Yeast base without amino acids Difco 
Zeocin Invitrogen 
Table 2.1. General reagents  
2.1.2 Enzymes  
Enzyme Concentration Manufacturer
Cloned Pfu DNA polymerase 2,5 U/µl Stratagene  
DNAse I 1 U/µl Promega 
Proteinase K 10 mg/ml Roche  
Restriction endonucleases 10-20 U/µl New England biolabs / Fermentas 
RNAse A 10 mg/ml Roche  
Superscript II reverse transcriptase 200 U/µl Invitrogen 
T4 DNA ligase 400 U/µl Promega 
Tag DNA polymerase  5 U/µl House made 
Thrombin, restriction grade  1,58 U/µl Novagen 
Table 2.2. Enzymes  
2.1.3 Kits 
Kit Manufacturer 
Advantage 2 PCR Kit Clontech  
Endofree Plasmid Maxi Kit Qiagen 
Profound Pull-Down Biotinylated Protein: Protein Interaction Kit  Pierce 
Qiaprep Spin Miniprep Kit Qiagen 
Qiaquick Gel Extraction Kit Qiagen 
Quick Change Directed Mutagenesis Kit Stratagene 
RiboMAX Large Scale RNA Production System-T7 Promega 
RNeasy Mini Kit Qiagen 
Termination Ready Reaction Mix PerkinElmer 
Table 2.3. Kits 
2.1.4 Instruments and Disposables 
Instrument/disposable Manufacturer
0,025 µm filters Millipore 
Centrifuge Rotanta 46R/Rotina 4R Hettich zentrifugen 
Centriplus/Centricon Millipore 
Concentrator 5301 Eppendorf 
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Cover slips Menzel Glaser
Electrophoresis power supply 2 House made 
Extra thick blot paper BioRad 
Filter paper Schleicher and schuell 
Fixogum Marabu 
Gene Pulser cuvettes/ Gene pulser I-Pulser chamber BioRad 
Handee Mini Spin Columns Pierce 
Horizontal gel apparatus Horizon® 11.14 and 20.25 Life technologies 
Hypercassete Amersham biosciences 
Inverted microscope Elipse TS100 Nikon 
L8-70M ultracentrifuge Beckmann 
Microscope slides Roth 
Phase lock gel light Eppendorf 
pH-meter Knick 
Photometer Ultrospec II LKB biochrom 
Pipett boy Integra biosciences 
Pipettes Gilson 
Potter B. Braun Melsungen 
Power Pac 300 electrophoresis power supply BioRad 
PVDF membrane Roche 
QIAshredder Qiagen 
RNA tips Biozym 
Rnase ZapWipes Ambion 
Rotors TLA120.1, TLS-55, SW40 Beckmann 
Single use filter unit Minisart Sartorius 
Slide-A-Lyzer mini dyalisis unit Pierce 
Sonicator, SONOPLUS Homogenisator HD2070 Bandolin electronics 
Sorvall RC-5B refrigerated superspeed centrifuge Sorvall 
Steril plastic disposables for cell culture TRP 
Table centrifuge 5415C Eppendorf 
TL100 ultracentrifuge Beckmann 
UV stratalinker 1800 Stratagene 
UV trasiluminator UVPinc 
UVette Eppendorf 
Table 2.4. Instruments and disposables 
Note: Instruments and disposables not included in table 4 are indicated in the 
corresponding sections. All reusable lab ware was autoclaved before use. 
2.1.5 Antibodies 
Antibody WB IF IP Animal  Purchased from 
Anti-α4 1:200   Rabbit Self-produced (Trockenbacher et 
al., 2001) 
Anti-MID1 1:1000   Rabbit Self-produced (Winter et al., 2004) 
Anti-Actin 1:500   Rabbit Sigma 
Anti-Tubulin MCA 77s 1:1000 1:3000  Rat Serotec 
Anti-Tubulin MCA 78s 1:1000 1:3000  Rat Serotec 
Anti-c-myc monoclonal 1:500 1:500  Mouse Clontech 
Anti-c-myc polyclonal 1:500 1:800 1,5 µg Rabbit Santa Cruz 
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Anti-V5 1:3000 1:800  Mouse Invitrogen 
Anti-FLAG-polyclonal 1:400  1,6 µg Rabbit Sigma 
Anti-FLAG-monoclonal 1:1000 1:500  Mouse Stratagene 
Anti-Nucleophosmin 1:1000   Mouse Zymed 
Anti-EF-1α 1:1000   Mouse Upstate 
Anti-Lamin A+C 1:350   Mouse Chemicon 
Anti-Annexin II 1:1000   Mouse  BD-transduccion laboratories 
Anti-Hsp90 1:2000   Rat Stressgene 
Anti-Hcs70 1:10000   Rat Stressgene 
Anti-RACK1 1:2500   Mouse-IgM BD-transduccion laboratories 
Anti-HuR 1:1000   Mouse  Santa Cruz  
Anti-GFP 1:500   Mouse Roche 
Ribosomal antibodies 1:1000   rabbit Gift from J. Stahl (Lutsch et al., 
1990) 
Anti-Rabbit HRP 1:2000   Donkey Amersham 
Anti-Rabbit HRP non-
reduced 
1:25000   mouse Sigma  
Anti-Mouse HRP 1.5000   Goat Dianova 
Anti-Mouse IgM -HRP 1:2500   Donkey  Dianova  
Anti-Rat HRP 1:1000   Rabbit Serotec 
Anti-Rat HRP 1:1000   Goat  Santa Cruz 
Anti-Rabbit Cy3  1:1000  Goat Dianova 
Anti-Mouse Cy3  1:1000  Donkey Dianova 
Anti-Rat Cy3  1:1000  Donkey Dianova  
Anti-Rabbit FITC  1:250  Goat Dianova 
Anti-Mouse FITC  1:1000  Goat Dianova 
Normal mouse IgG     Santa Cruz 
Table 2.5. Primary and secondary antibodies 
2.1.6 Vectors 
Vector Host Tag Resistance/ Selection Use Manufacturer  
pCMV Tag 2A-C  Mammalian  Flag Kanamycin IF, IP Stratagene 
pCMV Tag 3A-C Mammalian Myc Kanamycin IF, IP Stratagene 
pBUD CE4 Mammalian  Myc / V5 Zeocin IF, IP Invitrogen 
pEGFP Mammalian GFP Kanamycin IF Clontech  
PinPoint Xa E. coli Biotin/HIS 
(incorporated) 
Ampicillin  Protein 
expression 
Promega 



















Table 2.6. Vectors 
2.1.7 Buffers and Media 
Buffer/Media Composition  
APS 10% 10% w/v APS in water, aliquoted and stored at -20°C 
Annealing buffer 100 mM KAc, 30mM Hepes-KOH pH 7,4, 2 mM MgAc2 
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Blocking buffer 5% milk powder in PBST 
Blotting buffer 1 x 5x blotting buffer: MeOH: bidest H2O 1:1:3 
Blotting buffer 5 x 29,11g Tris; 14,65g Glycin; 18,75ml SDS in 1l bidest water 
Colloidal coomassie staining 1g CBB G-250 in 100 ml bidest H2O; 100 g (NH4)2SO4 and 20 g 
H3PO4 (85%) in 800 ml bidest H2O. Mix both solutions and adjust 
the volume to 1 l bidest H2O. 
Coomassie 1 g Coomassie blue R250, 500 ml H2O, 100 ml HAc, and 400 ml 
methanol. Mix and filter through a filter paper 
Destaining Coomassie 500ml H2O, 100ml HAc, and 400 ml methanol. 
DPEC H2O 0,1% DEPC was overnight stirred in water and afterwards 
autoclaved. 
Dropout solution 10x 200 mg/l L-Adenine Hemisulfat salt, L-Arginine HCl; L-Histidine 
HCl Monohydrate, L-Methionine, L-Tryptophane, L-Uracil; 300 
mg/l L-Isoleucine, L-Lysine HCl, L-Tyrosine; 500 mg/l L-
Phenylalanine; 1000 mg/l L-Leucine; 1500 mg/l L-Valine; 2000 
mg/l L-Threonine; in 1l Bidest; autoclave  
-TL/-HTL Dropout solution Dropout solution without leucine and threonine/ and histidine 
Elution buffer (HIS) 50 mM NaH2PO4; 300 mM NaCl; 250 mM imidazole. Adjust to pH 
8,0 using NaOH 
Ethidium bromide 10 mg/ml EtBr in bidest H2O 
Hepes Sucrose (HS) buffer         4 mM Hepes, 0,32 M sucrose in bidest H2O, filter sterilized, 
stored at –20°C. 
HSNM buffer 4 mM buffer, 0,32 M Sucrose, 100 mM NaCl, 5 mM MgCl2 in 
DEPC-H2O 
IP1 buffer 150 mM NaCl; 10 mM Tris pH 7,5; 1% NP40; autoclaved  
IPTG  100 mM in bidest, filter sterilized and stored at -20°C 
Laemmli buffer  25 mM TRIS p.a, 190 mM Glycin, 0,1% SDS in bidest H2O 
LB (Luria Bertani) medium  15 g Agar; 10g Tryptone; 5g yeast extract in 1l bidest water; 
autoclaved 
DNA-Loading buffer (LX, LB) 15% Ficoll, 0,25% Bromphenolblue or Xylenecyanol in bidest H2O 
Lysis buffer 
(QIAexpressionist)  
50 mM NaH2PO4; 300 mM NaCl; 10 mM imidazole    adjust to pH 
8,0 using NaOH 
Magic mix 2x  48% Urea (BioRad), 15mM Tris-HCl pH 7,5, 8,7% Glycerin, 
1%SDS, 0,004% Bromphenolblue, 143 mM β-mercaptoethanol  
(add fresh) 
Microtubule assembly buffer  0,1 M PIPES ph 6,8; 1 mM MgSO4; 2 mM EGTA; 2 mM DTT; 0,1 
mM GTP 
MOPS 10 x 0,4 M MOPS; 0,1 M NaAc; 10 mM EDTA pH 7,0 
Mounting medium 90% glycerol; 0,1 M Tris-HCl pH 8,0; 2,3 % DABCO 
Paraformaldehyde 3,7% formaldehyde in 1,2 PEM Buffer 
Paraformaldehyde 3,7% In 1,2 x PEM. Dissolve at 60°C. Store at -20°C 
PBS 1 x 137 mM NaCl; 2,7 mM KCl; 10,1 mM Na2HPO4; 1,8 mM KH2PO4 
PBST  1 x PBS; 1:1000 Tween 20 
PEM 10X 1 M PIPES, 0,5 M EGTA, 0,02 M MgCl2  in bidest H2O, adjust pH 
7 with 10N NaOH and autoclave 
RNA loading buffer 1 µl MOPS, 5 µl loading dye, 1,5 µl 37% formaldehyde, 10 µl 
DEPC.water 
SDS-PAGE buffer 5x 15% ß-Mercaptoethanol, 15% SDS, 1,5% Bromphenolblue, 
50%glycerol 
Separating gel buffer  1,5 M Tris-HCl, 0,4 % SDS pH 8,8 
SSC 10x  3M NaCl, 0,3M Na-citrate in bidest H2O, adjust pH 7 with 1M HCl, 
filter 
Stacking gel buffer 0,5 M Tris-HCl, 0,4 % SDS pH 8,8 
Sucrose cushion 0,2 g sucrose; were dissolved by shaking at 37°C in 280 µl MT 
buffer, afterwards 4µl dGTP (100 mM)  and 1µ taxol (5 mg/ml) 
were added 
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TAE buffer 50 x 50 mM EDTA, 5,71% v/v acetic acid,  2M Tris-HCl 
TBS 10 mM Tris-HCl (pH 8,0); 150 mM NaCl 
TBST buffer 10 mM Tris-HCl (pH 8,0); 150 mM NaCl; 0,05% tween 20 
TE 10 mM Tris-HCl pH 7,5; 1 mM EDTA 
TES 10 mM Tris-HCl pH 7,5; 5 mM EDTA; 0,2 % SDS 
TKM buffer 20 mM Tris, 100 mM KCl, 5 mM MgCl2 in DEPC-H2O 
Wash buffer 
(QIAexpressionist) 
50 mM NaH2PO4; 300 mM NaCl; 20 mM imidazole    adjust to pH 
8,0 using NaOH 
Washing buffer for column HS buffer with 250 mM NaCl, 0.5% Tween 
YPD buffer 20 g/L BACTO-tryptone, 10 g/L yeast extract, 20 g/L Bacto-Agar 
(only for plates) 






Table 2.7. Buffers and media 
2.1.8 Cell lines 




Human epithelial cells from cervical 
carcinoma 
COS-7 
Transformed African Green Monkey
Kidney Fibroblast Cells 
855/02 Human fibroblasts from OS patient  
756/01 Human fibroblast (man) 
18/98 Embryonic human fibroblasts 
DMEM, 10% FCS, 2mM 
L-glutamine, 100 µg/ml 
streptomycin, 100 units/l 
penicillin 
Table 2.8. Cell lines 
2.1.9 Bioinformatic tools and Databases 
The bioinformatic databases and tools used during this thesis are indicated in Table 2.9 
including their online resource: 
Tool name Type URL/Programm 




ENSEMBL Sequence retrieval and analysis http://www.ensembl.org 
ExPaSy Proteomics Server http://www.expasy.org/ 
GCG package DNA sequences analysis http://www.accelrys.com/products/gcg_wisconsin_package 
STADEN package DNA sequences analysis http://www.hgmp.mrc.ac.uk/Registered/Option/staden.html 
GenBank Genome database http://www.ncbi.nlm.nih.gov/Genbank/ 
Online Mendelian 
Inheritance in Man (OMIM) 
Database of human genes 
and genetic disorders http://www.ncbi.nlm.nih.gov/Omim 
Primer3 Primer design http://frodo.wi.mit.edu/cgi 
PubMed Medline biomedical articles http://www.pubmed.org 
RZPD (Resource zentrum 
Primary Database) Clone collections http://www.rzpd.de 
STADEN package DNA sequences analysis Version 1999.0 
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Swiss-Prot Protein knowledgebase http://www.expasy.org/sprot/ 
UCSC Human Genome 
Working Draft Genome Browser http://genome.ucsc.edu/ 
Table 2.9. Bioinformatic tools and databases 
2.1.10 Patients 
The first patient was born to consanguineous parents and presented with hypertelorism, 
broad nasal bridge, strabismus, cleft lip and palate, hypospadias and small ears with a right 
pre-auricular pit. He was found to have a de novo 388G>A mutation in MID1, predicting an 
A130T change in the Bbox1 domain. 
The second patient had hypertelorism, down-slanting palpebral fissures, broad nasal 
bridge, posteriorly rotated ears, cleft lip and palate, and hypospadias. He was found to harbour 
a de novo 433T>A MID1 mutation, predicting a C145S change in the Bbox1 domain. 
2.2 Nucleic acid methods 
2.2.1 Polymerase chain reaction (PCR) 
PCR was used for the amplification of DNA fragments of known sequence using either 
genomic DNA or cDNA as template. If not otherwise stated, each PCR reaction was prepared 
as follows: 
Component Amount  
DNA/cDNA  100 ng /3 µl  
PCR buffer, 5 µl               
MgCl2 (25 mM)  x µl                
dNTP mix (each dNTP 2,5 mM)  2µl               
Forward + reverse primer (each 10 pmol/µl) 2µl                
Taq polymerase   1µl                
Aqua ad inectabilia.  50 µl             
Table 2.10 Components of PCR reactions 
The following thermal profile was used for the amplification: 
Step Temperature Time Cycles
Initial denaturation 95°C 4 min 1x 
Denaturation 95°C 30 sec 
Annealing Primer specific  30 sec 
Elongation 68°C/72°C 1 min/kb amplified DNA 
2 min/kb for Pfu polymerase
29x 
Final elongation 68°C/72°C 10 min 1x 
Storage 4°C Infinite  
Table 2.11. Thermal cycle reactions for PCR reactions 
The amount of MgCl2, Taq polymerase used and annealing temperature are indicated for 
each pair of primers in the corresponding sections. 
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Touchdown PCR was performed for fragments with sequences difficult for simple 
amplification. 
Step Temperature Time Cycles 
Initial denaturation 95°C 4 min 1x 
Denaturation 95°C 30 sec 
Annealing (TA+10°C)-1°C cycle 30 sec 
Elongation 68°C/72°C 1 min/kb amplified DNA 
10x 
Denaturation 95°C 30 sec 
Annealing Primer specific (table) 30 sec 
Elongation 68°C/72°C 1 min/kb amplified DNA 
29x 
Final elongation 68°C/72°C 10 min 1x 
Storage 4°C infinite  
Table 2.12. Touch down PCR thermal cycle 
PCR reactions were carried out in a PTC200 Peltier Thermal cycler (Biozym). 
All PCR products were evaluated by DNA electrophoresis. When required, PCR 
products were purified either directly with the QIAquick PCR purification kit, or run on an 
agarose gel and subsequently extracted with the Gel Extraction Kit. DNA was eluted with 30-
50 µl EB buffer (Qiagen) diluted 1:10 in bidest water. 
2.2.2 Agarose gel electrophoresis 
1% - 2% w/v ultrapure agarose gels in TAE buffer were used to separate RNA or DNA 
samples. 0,5 µg/µl EtBr was added to the gels to visualise DNA or RNA via UV light. 1 µl of 
loading buffer* was added per each 9 µl of DNA solution before loading the samples on the 
gel. Samples were run at 80-150 V in an electrophoretic chamber for 30-60 min depending on 
the fragment size. Different DNA/RNA molecular weight markers were used according to the 
size of the analysed products. Fragments were visualised, and pictures were taken, with the 
E.A.S.Y Win32 gel documentation system (Herolab). The following DNA/RNA ladders were 
used, the sizes of the fragments characterised is indicated: 
DNA/RNA ladders Fragment size Manufacturer 
Hyperladder I 300 - 7000 bp Bioline 
Hyperladder V /100bp DNA Ladder 50 –500bp Bioline/GIBCO  
0,24-9,5 KB RNA Ladder all  Invitrogen 
Table 2.13. Nucleic acids ladders 
*Note: LX was used for DNA fragments bigger than 1 kb and LB for fragments shorter 
that 1 kb. RNA samples were run in RNA loading buffer and heated for 10 min at 70°C prior to 
loading. 1 µl of RNA ladder was treated in the same way. 
2.2.3 RNA preparation and cDNA synthesis 
RNA was prepared with the RNeasy kit according to manufacturer´s instructions. For 
subsequent removal con contaminant DNA in the sample, 1 µg of RNA was digested with 1 µl 
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DNAse I in 2 µl DNAse buffer and bidest H2O up to 20 µl. The reaction took place for 30 min at 
37°C. For purification, samples were subjected to phenol:chloroform extraction and EtOH 
precipitation. RNA samples were kept at –20°C. 
For cDNA synthesis, 2 µg of RNA were mixed with 2 µl dNTPs (2,5 mM each), 6 µl 
pd(N)6 (100 ng/µl) and DEPC-H20 up to 31µl of total volume. The reaction was incubated for 5 
min at 70°C and quickly chilled on ice. Next, 10 µl of 5x 1st strand buffer, 5 µl of 0.1 M DTT 
and 1 µl of RNA guard were added, and the mixture was incubated for 2 min at 42°C. The 
samples were divided into two aliquots of 23,5 µl. To one of the aliquots 2 µl of Superscript II 
were added. The second aliquot was kept as negative control for the reaction. RNA was 
reverse-transcribed by incubation for 1 h at 42°C and the enzyme was subsequently 
inactivated at 70°C for 15 min. cDNAs were stored at –20°C. 
2.2.4 Phenol:Chloroform extraction 
To DNA or RNA containing solutions one volume of phenol:chloroform (1:1) (TE pH:7.5 
saturated phenol for DNA, H2O saturated phenol pH:4,5 for RNA) in a Phase Lock Gel (PLG) 
light expender was added. The mixture was rotated for 10 min and centrifuged at 16000 x g for 
5 min. To the aqueous upper phase, one volume of chloroform was added, and the phases 
were again mixed for 10 min and centrifuged for 5 min at 16000 x g. The upper phase was 
transferred to a new eppendorf tube and DNA or RNA was precipitated with EtOH. 
2.2.5 EtOH precipitation of nucleic acids 
For EtOH precipitation of nucleic acids, 2,5 volumes of 95% EtOH, 1:10 LiCl for RNA or 
NaAc for DNA, and 1:100 glycogen were added to the samples. The mixture was placed at –
20°C for > 30min and subsequently centrifuged for 20 min at 16000 x g at 4°C. Afterwards, the 
pellet was washed with 200 µl 70% EtOH and centrifuged for 10 min at 16000 x g at 4°C. The 
pellet was air dried and resuspended in TE buffer pH 75. 
2.2.6 Cloning 
2.2.6.1 Cloning of pEGFP constructs and mutagenesis 
5´-gctaagcttcgatggaaacactggagtcag-3´ and 5´-tcgaattctcggcagctgc-
tctgtgca-3´ primers, containing HindIII and EcoRI sites respectively, were used to amplify 
MID1 cDNA from either control or patient fibroblast carrying the 388G>A (A130T) mutation 
RNA. 1 mM MgCl2, Pfu Taq polymerase and 54°C annealing temperature were used. PCR 
products and pEGFP-C1 vector were digested with the corresponding restrictions enzymes for 
1 h at 37°C, run in an agarose gel, excised and purified with the Gel Extraction Kit (Qiagen). 
The products were ligated overnight at 16°C with T4 DNA ligase.  
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For the ligation an insert-vector ratio of 3:1 was used as follows: 
The MID1 splice variant, Ex2d.7, was generated in pEGFP-C2 from a pBUDCE4-Ex2d.7 
clone available in the laboratory (Winter et al., 2004). The insert was extracted with SalI and 
HindIII restriction enzymes and ligated into pEGFP-C2 (which provides the correct ORF) as 
described above. 
The constructs lacking the RING and the RING plus the Bboxes were amplified with the 
primers 5´-gctcaagcttgggaaagcatcagtgagcggg-3´ and 5´-gctcaagcttgggccttgt-
gtaaactggttgg-3´as forward primers respectively, both containing HindIII restriction site, 
and 5´-tcgaattcttcacggcagctgcacagt-3´as reverse primer for both, which contained 
EcoRI restriction site. 1 mM MgCl2, Pfu polymerase and 57°C annealing temperature were 
used. PCR products were ligated into pEGFP-C1 vector as described above. 
Mutagenesis experiments were performed to produce the remaining mutated constructs 
according to the instruction manual provided with the QuickChange® Site Directed 
Mutagenesis Kit. In brief, 50 ng of template were amplified in 5 µl of 10x reaction buffer with 
1,25 µl (125 ng) of each primer, 1 µl of dNTP mix and 1 µl Pfu Turbo polymerase in a 50 µl 
reaction in bidest H2O. 
The following thermal profile was used for the amplification 
Step Temperature Time Cycles 
Initial denaturation 95°C 4 min 1x 
Denaturation 95°C 30 sec 
Annealing 55°C 30 sec 
Elongation 68°C 2 min/kb plasmid length 
12-18x* 
Storage 4°C Infinite  
Table 2.14. Thermal profile for mutagenesis reactions 
*Note: 12 cycles for point mutations, 16 cycles for single amino acid changes and 18 
cycles for multiple amino acids deletions or insertions. 
Non-mutated plasmids DNA were restricted with Dpn I (10 U/µl) for 1 h at 37°C and 
subsequently, 1 µl of the reaction was chemically transformed into XL1-Blue supercompetent 
cells. Plasmid DNA from the mutated constructs was prepared as described in section 2.2.7. 
Controls for the transformation and for the amplification reaction were included for every 
reaction. 





























































Deletion of Bbox2+ 
7aa+532CA>GC gccacctcatcctcagcctccaagcacacag 
18 
Table 2.15. Oligos used for mutagenesis 
2.2.6.2 Preparation of the pCMVTag2C and pBMT116 constructs 
The MID1 (wild-type and mutated forms) cDNA from the different constructs in the 
pEGFP-C1 vector was cut out with HindIII and SalI and ligated into the multiple cloning site of 
pCMVTag2C. 
For the cloning in the pBMT116 vector, the different MID1 inserts from the pEGFP-C1 
clones were amplified with the 5´-tggctggaattcgaaaacactggagtcagaactg-3´ and 5´- 
aggtcgacggattcacggcagctgctctgtgc-3´ primers, containing EcoRI and SalI restriction 
sites respectively. PCR products and pBMT116 vector were digested, purified and ligated as 
described above. 
A pBMT116 clone including MID1 splice variant Ex2d.7 was already available in the 
laboratory (Winter et al., 2004) 
2.2.6.3 α4/44aa peptide clones 
pGAD10-α4, pBudCE4-α4 and pCMVTag3a-α4 were already available in our laboratory 
(Trockenbacher et al., 2001; Winter et al., 2004). 
For the cloning of the 44aa peptide into the PET32a vector, the 44aa peptide sequence 
was amplified with 5´-atctgggtaccaggcctccagtgaaaccc-3´ and 5´-gcaagcttgtt-
atgctccatatttccgatgttg-3´primers, which contained restriction sites for KpnI and HindIII 
respectively. 1,5 mM MgCl2, Pfu polymerase and 55°C annealing temperature were used. 
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PCR product was digested and cloned into the multiple cloning site pET32a vector as 
described above. 
For cloning the 44aa peptide into the PinpointTM–Xa vector, the primers 5´- 
gctgggatccggaggcctccagtgaaaccc-3´ and 5´- ggagatctgttatccatatttccgatgttg-
3´, containing BamHI and BglII restriction sites respectively, were used for amplification of the 
insert. 1 mM of MgCl2, Pfu polymerase and 58°C annealing temperature were used. Both 
reverse primers contained a stop codon. 
To incorporate the His-Tag, 1 µl (100 picomoles) of the following oligos: 5´-
agtttcaagaggatcgcatcaccatcaccatcacgg-3´ and 5´-gatcccgtgatggtgatggtgat-
gcgatcctcttga-3´ containing the BamHI and HindIII restriction sites respectively were 
annealed in 48 µl annealing buffer. The following thermal reaction was performed: 
Step Temperature Time 
Initial denaturation 95°C 4 min 
Annealing  70°C 10 min 
Cooling - 0.1°C / sec down to 4°C 
Final step 4°C 10 min 
Storage 4°C infinite 
Table 2.16. thermal profile to anneal oligos 
Annealed oligos were digested with BamHI and HindIII and ligated into the multiple cloning site 
of the Pinpoint vector already containing the 44aa peptide (N-terminally located with respect to 
the peptide). 
2.2.7 Plasmid DNA isolation and transformation 
2.2.7.1 Plasmid DNA isolation 
Single bacterial colonies carrying the plasmid of interest were grown overnight at 37°C 
with vigorous shaking in 5 ml LB medium with the appropriate antibiotic (Table 2.6). Next day, 
plasmids were prepared using the Miniprep Kit (Qiagen) according to the manufacturer 
instructions. 
 When larger amounts of DNA were required, 5 ml of LB/antibiotic were inoculated with a 
single colony, and incubated during 8 hours. 0,5 ml of this culture were used to inoculate 100 
ml of LB/specific antibiotic, which was incubated overnight at 37°C with vigorous shaking. Next 
day, plasmid DNA was prepared using either the Maxiprep Kit or the Endofree Maxiprep Kit 
(for plasmids required for transfection of eukaryotic cells) according to the manufacturer´s 
instructions. 
To verify whether the obtained plasmids contained the expected fragments, the 
constructs were digested with corresponding restriction enzymes and checked on agarose 
gels. Clones carrying inserts of the right size were sequenced. 
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2.2.7.2  Chemical transformation 
Plasmid DNA (10 ng of supercoiled or 100 ng of ligation product) was incubated with 100 
µl of chemically competent cells (DH 5α, XL-1 blue) for 30 min on ice, heat shocked at 42°C for 
1 min 30 sec and chilled on ice for 2 min. Cells were incubated for 1 h in 1 ml LB with vigorous 
shaking at 37°C. Afterwards, cells were plated onto selective agar plates containing the 
appropriate antibiotic and incubated overnight at 37°C. 
2.2.7.3  Electroporation 
40 µl of competent cells (BL21, JM109) were added to plasmid DNA that had been 
previously dialysed, and the mixture was placed in a 1 mm electroporation cuvette. 
Electroporation took place at 25 µF capacity, 1,7 V voltage and 200 Ω resistance with a time 
constant of about 4,5 msec. Immediately, 1 ml LB was added to the transformed cells. The 
solution was incubated at 37°C with vigorous shaking for 1 h and afterwards, cells were  plated 
onto selective agar plates containing the appropriate antibiotic and incubated overnight at 
37°C. 
2.2.8 Transfection 
2.2.8.1 siRNA transfection 
1x106 cells in 75 cm2 culture flasks were seeded the previous day to transfection. A solution 
“A” containing 40 µl of siRNA oligo and 1,3 ml of OptiMEM, and a solution “B” containing 40 µl 
of Oligofectamine and 375 µl of OptiMEM were prepared. After 8 min incubation at RT, both 
solutions were mixed and incubated for 20 min at RT. In the meanwhile, cells were washed 
with PBS, and 2 ml of fresh medium without antibiotics were added to the cells. The 
transfection mix was slowly added onto the cells, and the cells were incubated at 37°C in a 
humidified incubator with 5% CO2 v/v for 48h. 
2.2.8.2 Polyfect transfection of plasmid DNA 
1x105 COS-7 cells in a 6 well plate with cover slips for immunofluorescence experiments 
(1,5x106 in a 75 cm2 flask or 3x106 in a 150 cm2 flask for immunoprecipitation experiments) 
were seeded the day previous to transfection. Transfection was performed according to 
manufacturer´s instructions. Briefly, a transfection mix containing 1,5 µg of plasmid DNA (20 
µg, 30µg), 100 µl OptiMEM, (750 µl, 1,2 ml) and 10 µl polyfect (75 µl, 100 µl) was prepared 
and incubated for 10 min at RT. In the meanwhile, cells were washed with PBS and 1,5 ml of 
fresh medium without antibiotics (12 ml, 16 ml) were added to the cells. After 10 min, 0,6 ml of 
fresh medium (4,8 ml, 6 ml) were added to the transfection mixture and after mixing, the 
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solution was slowly placed onto the cells. Cells were incubated at 37°C in a humidified 
incubator with 5% CO2 v/v for 24h. 
Blue indicates the amounts used for 75 cm2 cell culture flasks and orange for 150 cm2 
cell culture flasks. 
2.2.8.3 Lipofectamine transfection of plasmid DNA 
 3x106 in a 150 cm2 flask were seeded the day previous to transfection. A solution “A” 
containing 15 µg of plasmid DNA and 2,5 ml OptiMEM, and a solution “B” with 50 µl 
lipofectamine and 2,5 ml OptiMEM were prepared and kept for 5 min at RT. Subsequently, 
solutions were mixed and incubated at RT for 20 min. In the meanwhile, cells were washed 
with PBS and 18 ml of fresh medium without antibiotics were added. Transfection mixture was 
slowly added to the cells, which then were incubated at 37°C in a humidified incubator with 5% 
CO2 v/v for 24h. 
2.2.9 Sequencing 
2 ng DNA per 100 bp DNA length for PCR products, or 100 ng of plasmid DNA, were mixed 
with 6 µl H2O, 1 µl sequencing primer (10 pmol/µl) and 3 µl “Terminator ready reaction mix”.  
Thermal profile used for amplification and labelling of probesin indicated in Table 2.17: 
Step Temperature Time Cycles 
Pre-denaturation 96°C 1 min 1x 
Denaturation 96°C 10 sec 
Annealing Primer specific (table) 5 sec 
Elongation 60°C 4 min 
25x 
Storage 4°C Infinite  
Table 2.17. Thermal cycle for sequencing reactions 
Sequencing reactions were purified with EtOH. To a 10 µl reaction, 25 µl of absolute 
EtOH were added and thoroughly mixed by inversion of the tube. After 10 min incubation, 
samples were centrifuged for 45 min at 4000 rpm at RT. Supernatants were discarded and 
100 µl of 70% EtOH were added to the samples. After inverting the tubes a few times, 
samples were centrifuged for 15 min at 4000 rpm at RT. The ethanol was removed and the 
samples were air-dried. The samples were analysed in an ABI377 DNA sequencer. 
Primers used for sequencing are indicated in Table 2.18  
Primer Sequence (5´→ 3´) Ta Vector 
Sp6 atttaggtgacactatag 47 Pinpoint 
Pinpoint  cgtgacgcggtgcagggcg 67 Pinpoint 
T7 gtaatacgactcactatagggc 58°C pCMV 
T3 aattaaccctcactaaaggg 56°C pCMV 
S*Tag  cggttctggttctggccata 58°C PET32a 
T7terminator gctagttattgctcagcggt 58°C PET32a 
GFPfor gacaaccactacctgagcac 58°C pEGFP 
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GFPrev tgtttcaggttcagggggag 58°C pEGFP 
BMT116r gttggggttattcgcaac 52°C PBMT116 
BMT116r cataagaaattcgcccg 52°C PBMT116 
Table 2.18. Sequencing primers 
The following primers were used for the precise sequencing of MID1 mutations : Ex2r-1r , 
2RT-8, 2RT-9, 2RT-10A, 2RT-4, Ex2f1, 3´-RACE1, Ex3-r1, 2RT-19, 2RT-11, 2RT-13, 2RT-17, 2RT-6, 
2RT-18, 2RT-12. They were already available in the laboratory and have been described 
previously (So et al., 2005; Winter, 2003; Winter et al., 2004).  
Sequences were analysed by using the databases indicated in section 2.1.9 
2.3 Protein methods 
2.3.1 Bradford assay 
A starting 10 µg/ml BSA solution was prepared by diluting a 5 mg/ml BSA stock solution 
1:500 in the working buffer (specific for each experiment), which had been previously diluted 
1:1000 in bidest water (2 µl 5 mg/ml BSA + 998 µl 1:1000 buffer). 
BSA standard solutions were prepared by diluting the 10 µg/ml BSA solution in 1:1000 
working buffer as indicated in Table 2.19:  
BSA standard curve 
(Name-µg/ml) 




S6-10 ---- ---- 
S5-7.5 150 50 
S4-5 100 100 
S3-4 80 120 
S2-2 40 160 
S1-1 20 180 
 
Table 2.19. Standard BSA curve preparation     Figure 2.1. Disposition of samples in Falcon plate 
2 x 80 µl of each sample, a blank (only 1:1000 buffer) and the standards (S) were placed 
into a Falcon microtitre plate as shown in Figure 2.1, 20 µl of Bradford reagent were added 
with a multichannel pipette and the samples were extensively mixed. The reaction proceeded 
for 1-5 min. Bubbles were carefully removed and the absorbance at 595 nm of each probe was 
measured in an anthos 2020 spectrophotometer (anthos), which also calculated the protein 
concentration by correlation with the BSA standard curve. 
2.3.2  SDS-PAGE Gel 
For the separation of proteins according to their molecular weights, samples were run in 
SDS-PAGE gels. 5 ml of separating gel and 1 ml of stacking gel were prepared per SDS-
PAGE gel as showed in Table 2.20:  
 




Component volumes in ml per 5ml of separating gel/1ml stacking gel 
                  Separating gel 
Components 
10% 12% 15% stacking gel 
Bidest H2O 1,9 1,6 1,2 0,68 
Rothiphorese gel 30 1,7 2 2,5 0,17 
Separating gel buffer 1,3 1,3 1,3 0,13 stacking buffer 
Ammonium persulfate 0,05 0,05 0,05 0,01 
TEMED 0,002 0,002 0,002 0,001 
Table 2.20. SDS gels composition 
Separating gels were poured in between a short plate and a spacer plate using the 
Protean III system, covered with isopropanol and allowed to polymerise for 45 min at RT. 
Afterwards, the isopropanol was removed and the gels were washed with bidest H2O. The 
stacking gel was then added on top of the separating gel, and a comb was incorporated in 
between the 2 glass plates to form the wells. They polymerised for 30 min. 
2.3.3 Western blot  
Protein samples were mixed with either 5x SDS-PAGE buffer or 2x magic mix and 
denatured for 5 min at 95°C before loading. The separation of the samples was performed in 
1x Laemmli buffer at 200 V for 50-70 min using a Mini-PROTEAN 3 electrophoresis system 
(Bio-Rad). After running, gels were equilibrated for 15 min in 1x blotting buffer.  
Different protein markers were run with the samples, according to the size of the proteins 
in study. Table 2.21 indicates the sizes covered by each marker and the study in which they 
were used:  
Protein ladders  Size Study  Manufacturer  
   Kaleidoscope 10-250 KDa MID1 complex  BioRad 
    Rainbow 14,3-220 KDa MID1 complex Amershan Biosciences 
    See Blue Plus2 4-250 KDa Peptide expression Invitrogen  
Table 2.21. Protein markers 
The blotting PVDF membrane was equilibrated for 3 sec in MeOH, 2 min in bidest H2O 
and 15 min in 1x blotting buffer. Proteins were then blotted onto the membrane in a Trans-Blot 
SD Semi-dry Transfer Cell (Bio-Rad) at 15 V for 30 min. To saturate the unbound regions on 
the blot, it was incubated in PBST/5% milk powder for 30 min at RT or overnight at 4°C. Then, 
it was incubated with the primary antibody diluted in PBST/1%BSA for 1 hour at RT or 
overnight at 4°C followed by three wash steps of 5 min each in PBST. The corresponding HRP 
conjugated secondary antibody was diluted in PBST and, subsequently, added to the blot for 
30 min, followed by three washing steps as before. Protein signals were detected by 
incubating the blots with the Western Lightning Chemiluminescence Reagent Plus 
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(PerkinElmer) for 1 min and subsequent exposure to Fuji Medical X-Ray films in a 
hypercassette. Blots were developed in a Curix 60 automatic film processor (Agfa). 
2.3.4 Silver staining 
Silver staining was performed using the SilverQuest Silver Staining Kit, following 
manufacturer´s instructions. Shortly, gels were fixed for 20 min to overnight in 40 ml EtOH/10 
ml HAc/50 ml H2O, washed in 30 ml EtOH/70 ml H2O, sensitised in 30 ml EtOH/10 ml 
sensitizer, 60ml H2O again washed in 30 ml EtOH/70ml H2O and for a second time in water, 
stained with 1 ml stainer solution, 100 ml H2O, washed in water, developed in 10 ml developer 
solution/1 drop developer enhancer solution/90 ml H2O and stopped with 10 ml stopper 
solution directly added to the developing solution when the expected signals were detected. 
Finally, gels were washed with H2O. The whole procedure was performed at RT. 
2.3.5 Coomassie/Colloidal coomassie staining 
For colloidal Coomassie staining (CBB), gels were fixed overnight in 2% H3PO4/50% 
MeOH on a shaking platform.  
Next day, the CBB stock solution was throughfully mixed and diluted with methanol 4:1 
(CBB:MeOH) while stirring. Gels were allowed stain until bands were observed (12 hours to 4-
5 days). Finally, gels were washed with bidest H2O. The whole procedure was performed at 
RT. 
For standard Coomassie staining, gels were incubated for >1 h in Coomassie staining 
solution and subsequently destained for 1 h in destaining solution.  
2.3.6 Immunofluorescence 
105 cells COS-7 per well were seeded onto cover slips in six well plates. Next day, they 
were transfected with the corresponding endofree prepared plasmid DNA using polyfect 
(section 2.2.8.2) and allowed to grow for 24 or 48 hours. Afterwards, the medium was removed 
and cells were washed in 1.2 x PEM, fixed in 3,7% paraformaldehyde for 10 min at RT and 
shortly washed in 1x PBS. Next, they were permeabilized with 0,2 % Triton-100 in 1x PBS for 
10 min at RT and washed 3 times in 1x PBS. To block unspecific interactions, cover slips were 
incubated for 20 min at RT in 1x PBS-0,5% BSA. Primary antibodies were diluted in PBS-0,5% 
BSA, added onto the covers slips and incubated for 1 h in a humid chamber, followed by three 
washings in 1x PBS for 5 min. The corresponding Cy3-labelled secondary antibodies were 
diluted in 1x PBS and added to the cover slips for 30 min, followed by 3 washes as before. 
Finally, cover slips were placed onto a 12 µl drop of 0,5 µg/ml DAPI in mounting medium 
previously added onto a slide, dried by pressing the slide between two pieces of Whattman 
paper and fixed to the slide with Fixogum. 
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Cells were visualised by fluorescence microscopy with a Zeiss Axioskop epifluorescence 
microscope equipped with single band pass filters for excitation of green, red and blue 
fluorescence (Chroma Technologies), and 63x or 100x plan-neofluolar lenses. Digital black 
and white images were recorded with a cooled CCD camera (Hamamatsu Photonics) and 
merged into RGB-images by the ISIS immunofluorescence image analysis system 
(MetaSystems).  
2.3.7 Microtubule assembly experiment 
Microtubules were polymerised in vitro from HeLa cell extracts according to previously 
reported protocols (Kimble et al., 1992; Vallee, 1982). 3x107 HeLa cells were incubated in ice 
cold PBS for 10 min at –20°C and for 30 min at 4°C to depolymerise the microtubules. After 
washing twice with ice-cold PBS, cells were disrupted with 1,8 ml of ice-cold microtubule 
assembly buffer (plus a complete mini tablet each 10ml of buffer) and centrifuged at 55000 
rpm for 1 h at 4°C in a TL100 centrifuge. The pellet was discarded, to the supernatant 18 µl of 
dGTP (100 mmol) and 7,2 µl taxol (5 mg/ml) were added, and the microtubules were allowed 
to polymerise for 30 min at 37°C. In the meanwhile, a 50% sucrose solution (0,2 g sucrose, 1 
µl Taxol, 4 µl dGTP in 280 µl microtubule assembly buffer) was prepared. Polymerised 
microtubules were added on top of 180 µl of the sucrose solution, and centrifuged at 25000 
rpm for 30 min at 37°C in a TL100 centrifuge. The supernatant was discarded, and 
polymerised microtubules were washed by resususpension in microtubule assembly buffer 
with taxol and pelleted again at 25000 rpm for 30 min at 37°C in a TL100 centrifuge. The pellet 
was finally resuspended in 50 µl microtubules assembly buffer, 0,5 µl dGTP and 0,25 µl Taxol 
and left for some minutes in the fridge. Polymerised microtubules were stored at –80°C. 
2.3.8 Immunoprecipitation 
During the study of the Bboxes, for the immunoprecipitation of MID1-FLAG or α4-myc 
polyclonal anti-FLAG or anti-myc antibodies were used as follows:  
COS-7 cells overexpressing MID1-FLAG were homogenised by sonication in IP1 buffer, 
supplemented with proteinase inhibitors. Nuclei and cellular debris were pelleted for 15 min at 
12000 x g at 4°C. 1 mg of cytosolic protein extract in 1 ml IP1 buffer was placed in a new 
eppendorf tube. A preclearing step to avoid unspecific absorption of the agarose beads was 
performed by incubation the solution with 50 µl of 50% protein A agarose suspension 
(previously washed for 3 times in IP1) for > 2 h at 4°C with rotation. Beads were pelleted by 
centrifugation for 1 min at 3000 rpm in a table centrifuge at 4°C and the supernatant was 
transferred to a new eppendorf tube. 1,5 µg of anti-myc or 1,6 µg of anti-FLAG (Table 2.5), 
were added to the sample which was incubated overnight at 4°C on a rocking platform. Next 
day, 75 µl of 50% protein A agarose suspension were added and the mixture was incubated 
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for > 2h at 4°C on a rocking platform. Agarose beads were pelleted by centrifugation for 1 min 
at 3000 rpm in a table centrifuge, followed by 3 washings with 500 µl of IP1 buffer. Beads were 
boiled for 5 min at 95°C in freshly prepared SDS buffer (20 µl IP1, 3,8 µl 1M DTT, 2 µl 10x 
Laemmli buffer and 5 µL 5x SDS-PAGE buffer per sample). Immunoprecipitated proteins were 
analysed on 10 % SDS gels and Western blots with anti-FLAG or anti-myc monoclonal 
antibodies. 
For the immunoprecipitation of MID1-FLAG for the verification of the novel members of 
the MID1 complex, the following protocol was used: 
HeLa cells overexpressing MID1-FLAG were lysed in TKM buffer, supplemented with 
proteinase inhibitors and 1% NP40, incubated for 15 min on ice and passed 5 times through a 
27¾ Gauge needle. Nuclei were pelleted for 15 min at 12000 x g at 4°C. 4 mg of cytosolic 
extract were precleared with 25 µl of protein-A/G agarose and 10 µg of mouse IgG for 1,5 h at 
4°C on a rocking platform. Beads were pelleted by centrifugation for 1 min at 3000 rpm in a 
table centrifuge at 4°C and the supernatant was transferred to a new eppendorf tube. MID1-
FLAG immunoprecipitation took place overnight with 75 µl of anti-FLAG M2 coated beads in 1 
ml TKM buffer. Anti-FLAG M2 agarose matrix had been previously equilibrated in TKM buffer, 
blocked with 1 mg/ml BSA for 30 min and washed again with TKM buffer. Next day, agarose 
beads were pelleted by centrifugation for 1 min at 3000 rpm in a table centrifuge and washed 3 
times with 500 µl TKM buffer supplemented with 0,2 % NP40 for 10 min at 4°C rotating. Bound 
proteins were finally eluted for 45 min with 200 µl of 3 x FLAG (400 µg/ml). 40 µl were directly 
analysed by Western blotting, and the remaining 160 µl of the elution fraction were 
concentrated in vivaspin 500 disposable with a cut-off membrane of 5 kDa for 20 min at 15000 
x g at 4°C. Concentrated fractions were analysed on 10% SDS page and Western blotting with 
the panel of antibodies for the respectivecomplex members. Note: Western blots shown in the 
result section correspond to the concentrated fractions.  
2.3.9 Yeast two-hybrid experiments 
2.3.9.1 Yeast transformation 
Several colonies of the L40 yeast strain were inoculated in 500 µl of YPD medium, 
vigorously vortexed for 3 min, transferred to flasks containing 50 ml YPD medium and  was 
incubated for 16 h at 30°C with shaking (225 rpm). 
Next day, 19 ml of the overnight cultures were diluted in 300 ml of YPD medium in a 2 l 
flask to produce a OD600 of 0,2 to 0,3 and incubated until OD600 had reached 0,4-0,6 
(approximately 3,5 h). Cells were then placed in 50 ml tubes and centrifuged for 5 min at 1000 
x g. The supernatant was discarded and pellets were washed with 50 ml of TE buffer and 
centrifuged again. The supernatant was discarded and cells were resuspended in 1,5 ml of 
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freshly prepared 1x TE/1x LiAc. Then 0,1 µg of plasmid DNA and 0,1 mg of herring testes 
carrier DNA (previously denaturated for 20 min at 95°C) were mixed in an eppendorf tube and 
mixed by vortexing with 0,1 ml of the freshly prepared yeast competent cells. 600 µl of 
PEG/LiAc were added, and the solution was vortexed for 10 sec before being incubated for 30 
min at 30°C. Afterwards, 70 µl of DMSO were added and the solution was mixed by inversion. 
Cells were heat shocked for 15 min at 42°C and consequently chilled on ice for 1-2 min. Cells 
were then centrifuged for 5 sec at 14000 rpm in a table centrifuge, the supernatant was 
discarded and the cells were resuspended in 500 µl of TE buffer. Finally, transformed yeast 
were placed on plates with -Leu/-Trp selections medium and incubated for 3-4 days at 30°C. 
For the selection of colonies presenting interaction of both plasmids, several colonies were 
placed on plates with -His/-Leu/-Trp selective medium and incubated again 3-4 days at 30°C. 
For each construct, each experiment was repeated at least twice. As controls, empty 
pGAD10 was cotransformed with pBMT116-MID1, empty pBMT116 with pGAD10-α4 and both 
empty vectors together. 
2.3.9.2 β-Galactosidase activity 
β-galactosidase activity was assayed by the o-nitrophenyl- -D-galactopyranoside 
(ONPG) method (Fields and Sternglanz, 1994). A colony from the selective medium containing 
plates was inoculated into 5 ml cultures containing the corresponding selective medium (-His/-
Leu/-Trp or -Leu/-Trp), well mixed by vortexing and incubated for 16-18 h at 30°C with shaking 
(225 rpm). 
Next day, ONPG was diluted in Z buffer to a concentration of 4 mg/ml by stirrig for 1-2 
hours. Cell clumps in the overnight culture were dissolved by vortexing and diluted in YPD-
medium until the OD600 was 0,2-0,3 (approximately 10 ml). The culture was incubated for 3-5 h 
at 30°C with shaking (225 rpm). After 2 h, the OD600 was measured every 30 min until the 
cultures had reached the mid-log phase (OD600 0,5-0,8).  
1,5 ml of the cultures were split into three tubes and centrifuged at 10000 x g. 
Supernatants were discarded and cell pellets were resuspended in 300 µl of Z buffer. 0,1 ml of 
each probe was transferred to a new eppendorf tube, hold for 1 min in N2 and then placed for 
1 more minute in a water bath at 37°C. Freezing/thawing cycles were repeated twice. 
To the probes 700 µl of Z buffer+ β-mercaptoethanol (0,27 ml β-mercaptoethanol in 100 
ml Z buffer) were added and subsequently 160 µl of ONPG in Z buffer. A blank probe was 
performed in parallel with only 100 µl of Z buffer. When the probes turned yellow, Na2CO3 was 
added to stop the reaction.  Time passed between ONPG addition and stop of the reaction was 
measured. 
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The Photometer was calibrated with the blank sample at a wavelength of 420 nm and 
subsequently the OD420 of the samples were measured. 
For calculating the β-galactosidase units the following equation was used: 
 
2.3.10 Cell culturing and trypisnation  
HeLa or COS-7 cells were grown in the previously described media. For seeding cells, 
they were trypsinised and counted with the cell counter and analysis system CASY1 (Schärffe 
system). 
Trypsination 
1 ml per each well in a six well plate (4 ml for a 75cm2 flask and 8 ml for a 150cm2 flask) 
of medium from the cells was kept. After removing the remaining medium, cells were washed 
with sterile PBS. Next 0,5 ml (2 ml, 4 ml) of trypsin (prewarmed at 37°C) were added to the 
cells and incubated for 3 min at 37°C. When cells were loosened, the trypsine was inactivated 
by adding medium. Cells were then centrifuged at 1200 x g for 10 min at 4°C, the supernatant 
was discarded, and the pellet was washed with PBS and pelleted again. When not used 
immediately, cell pellets were frozen with liquid N2 and kept at –80°C. 
For cell seeding, cells were counted after trypsination and the necessary amount 
indicated for each experiment was mixed with fresh medium and place in the cell culture flasks 
or plates. 
2.4 Preparation of the 44aa peptides 
Two different 44aa peptides of α4 were prepared: 
Biotinylated 44aa peptide: created in the PinPoint vector system. Used for the 
production of the column. 
44aa peptide: created in the PET32 vector system, containing a Trx, His and S-Tag. 
After tags removal peptide was called free 44aa peptide. The last was used for elution of the 
column. 
2.4.1 Growth of E.Coli cultures  
Pinpoint vector constructs were expressed in JM109 E.coli cells (Promega) and PET32a 
constructs in BL-21Codon-Plus (DE3)-RIL (Novagen) E.coli cells. 
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20 ml of LB medium with antibiotic (PET32 vector system: 50 µg/ml ampicillin and 34 
µg/ml chloramphenicol; PinPoint vector system: 50 µg/ml ampicillin, 2 µM biotin) were 
inoculated with a colony and grown overnight with vigorous shaking. Next day, 1 l culture with 
antibiotic was inoculated 1:50 with the overnight culture. The culture was grown until OD600 
was 0,5-0,7 and then induced with 0,1 mM IPTG during 2 h for the PET32 vector system and 4 
h for the PinPoint vector system. An aliquot of each culture was resuspended in magic mix and 
directly analysed on a Coomassie stained 15 % SDS gel. Cells were harvested by 
centrifugation for 20 min at 4000 x g. When not directly used, cell pellets were frozen in liquid 
N2 and kept at –80°C.  
For the establishment of optimal conditions for protein expression 5 ml cultures were 
performed as described above. Different conditions tested are indicated in the result section. 
2.4.2 Preparation of cleared E.Coli lysates  
Cell pellets were resuspended in native condition lysis buffer (QiaExpressionist) at 3 
ml/gram wet weight. Lysates were 2x frozen in liquid N2/thawed on ice and sonicated 5x at 
50% power for 10 sec with 10 sec cooling period between each burst. Lysates were 
centrifuged at 10000 x g for 20 min at 4°C. An aliquot of the pellet was kept for analysis and 
the rest was discarded. The supernatant was kept at –80°C. 
2.4.3 Purification of 6xHis tagged proteins from E.Coli  
1 ml of 50% Ni-NTA slurry was added to each 4 ml of cleared lysate, and it was gently 
mixed for 1h on a rotary platform at 4°C. The lysate Ni-NTA mixture was loaded into a 
propylene column with the bottom outlet capped. The bottom cap was removed and the flow 
through collected; afterwards, the column was washed twice with 8 ml of washing buffer 
(QiaExpressionist) per each ml of packed column volume. Finally, peptides were eluted with 1 
ml elution buffer (QiaExpressionist) per each ml of packed column volume. For future use, 
protein samples were dialysed (or concentrated with a centricon) into the required buffer. 
2.4.4 Thrombin digestion 
For thrombin digestion the peptide was previously dialysed in HS buffer. 
Optimal conditions were established after testing different enzyme concentrations and 
reaction times (see result section) following manufacture’s instructions (Novagen). Final 
conditions were used as follows: 10 µg of protein were digested with 1 µl of Thrombin (0,02 
U/µl) in a 50 µl reaction in bidest water from 4 h to overnight at 4°C. For bigger amounts of 
proteins, the reactions were scaled up with the same ratio of components. When necessary, 
thrombin was removed by dialysis or centricon (Millipore). 
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To cleave the free 44aa peptide from the tags, Ni-NTA agarose was used. 1 mg of 
digested peptide was incubated with 300 µl of Ni-NTA slurry and equilibrated in HS buffer for 1 
h at 4°C in a rocking platform. The flow-through was collected and free peptide was 
concentrated in a centricon device with a 3 kDa cut-off membrane. 
2.5 Chromatography column and Mass spectrometry 
For generating the column, 50 µg of biotinylated 44aa peptide in TBS were incubated 
with 250 µl of washed streptavidin coated agarose slurry (ProFound pull down kit) for 1 h at 
4°C rotating in a 500 µl final volume reaction. A control column without peptide was performed 
in the same way. Beads were blocked with free biotin for 5 min, washed with HS buffer and 
again blocked with 1 mg/ml BSA overnight at 4°C. Beads were place in a Handee-mini spin 
tube to create the columns, followed by washing with 100 volumes of HS and 2 volumes of 
washing buffer (250 mM NaCl/0,05% Tween), and eluted with an excess of free peptide after 
thrombin digestion (section 2.4.4). Columns were again washed as before and equilibrated in 
HS buffer.  
Cytoplasmic HeLa extracts from 1x107 cells, previously subjected to α4 knock down 
(section 2.2.8.1), were obtained by lysis in HS buffer for 15 min on ice, potter disruption for 10 
times and centrifugation for 10 min at 3000 rpm at 4°C in a table centrifuge. Approximately 4 
mg of cytoplasmic extracts were incubated with the columns overnight at 4°C on a rocking 
platform. Next day, columns were washed as before and eluted 3x 15 min with excess of free 
peptide. The eluted fractions were dialysed against 20 mM TRIS pH 8, run in a 10% SDS gel 
and stained with colloidal Coomassie. Differential bands (1-12, indicated in the results section 
3.2.3) were excised, trypsinised and analysed by mass spectrometry. 
Mass spectrometry was performed by the service group in the SFB 577. Briefly, the 
peptide mixture in the cut bands was identified by chromatographic separation on a LC 
Packings 75 µm PepMap C18 column (Dionex) using a capillary liquid chromatography 
(CapLC) system delivering a gradient to formic acid (0.1%) and acetonitrile (80 %). The eluting 
peptides were ionised by electrospray ionisation on a Q-TOF hybrid mass spectrometer 
(Micromass). The instrument, in automated switching mode, selects precursor ions based on 
intensity for peptide sequencing by collision induced fragmentation tandem MS. The MS/MS 
analyses were conducted using collision energy profiles that were chosen based on the m/z 
value of the precursor. The mass spectral data were processed into peak lists containing m/z 
value, charge state of the parent ion, fragment ion masses and intensities, and correlated with 
the SwissProt database using Mascot software (Perkins et al., 1999). 
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2.6 Sucrose gradients 
2.6.1 Discontinuous gradients 
HeLa cells, with and without overexpressed MID1-FLAG, were lysed for 15 min on ice in 
TKM buffer supplemented with 1 mM DTT, 0.5 % NP40 and 1 U/µl sample of Prime RNase 
inhibitor and passed 10 times through a 27¾ Gauge needle. Cell debris and nuclei were 
discarded by centrifugation 10 min at 12000 x g at 4°C. Approximately 2 mg of protein 
dissolved in 900 µl of buffer were added on a sucrose discontinuous gradient, formed by 500 
µl of a 50% sucrose solution in TKM and 600 µl of a 20% sucrose solution of TKM. 
Centrifugation was performed in a TLA 100.2 rotor at 55000 rpm for 270 min at 4°C (for 
overexpressing cells) or 15 hours at 30000 at 4°C in a TLS55 rotor (for non-overexpressing 
cells) in a TL100 ultracentrifuge.  
Ribosome studies: 
0.5% DOC, 0.5 M KCl, 30mM EDTA treatment: to 2 mg of concentrated cytoplasmic 
extracts, the necessary amounts of 10% DOC, 1 M KCl, or 0,5 M Na2EDTA were added to 
have a final concentration of protein of 2 mg/ml in TKM buffer (supplemented with 1 mM DTT, 
0.5 NP40 % and Prime RNase inhibitor) with 0,5% DOC, 0,5 M KCl or 30 mM EDTA. 
Ribosomes were run through a TKM sucrose gradient, as previously described, for 15 hours at 
30000 at 4°C in a TLS55 rotor.  
RNase A/DNAse I treatments: cytoplasmic extracts were obtained as previously 
described, excpt that Prime RNase inhibitor was not included. To 2 mg of cytoplasmic extracts 
either 500 µg/ml of RNAseA, 50 units of DNAse I or 12 µl of RNA guard were added and the 
volumes of the reactions were brought up to 1 ml in TKM buffer (supplemented with 1 mM 
DTT, 0.5 NP40 %). Ribosomes were run through a TKM sucrose gradient, as previously 
described, for 15 hours at 30000 rpm at 4°C in a TLS55 rotor.  
Puromycin/cycloheximide: HeLa cells in culture were treated either 0,1 mg/ml puromycin 
for 6 hours or with 0,35 mM cycloheximide for 20 minutes at 37°C in a humidified incubator 
with 5% CO2 v/v for 48h. Cell extracts were prepared, and sucrose gradient run, as previously 
described. 
2.6.2 Linear sucrose gradient 
3x107 HeLa cells were lysed for 15 min on ice in TKM buffer supplemented with 1 mM 
DTT, 0.5 % NP40 and 1 U/µl sample of Prime RNase inhibitor, passed 10 times through a 
27¾ Gauge needle and centrifuged for 15 min at 12000 x g to eliminate the nuclei and cellular 
debris. The cytoplasmic homogenate was sedimented in a 15%-45% (w/v) sucrose gradient by 
centrifugation for 120 min at 38000 rpm at 4°C in a Beckmann SW40 rotor. 1 ml fractions were 
collected starting from the bottom of the centrifuge tube with a 2132 Microperpex peristaltic 
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pump a 2111 multirac system (LKB Bromma). The absorbance of the fractions was measured 
with a 2138 UVI-CORD (LKB Bromma). Fractions were analysed by Western blotting either 
directly, or after being precipitated overnight with trichloroacetic acid and 5 µg BSA as carrier.  
15%-45% linear sucrose gradients were prepared in TKM buffer in a 14 x 95 mm Ultra-
Clear centrifuge tube (Beckmann) with a gradient master (Biocom). 
2.7 RNA-Protein binding experiments 
2.7.1 Homopolymer binding assay 
MID1-FLAG overexpressing HeLa cells were homogenised in HSMN buffer, 
supplemented with proteinase inhibitors and 1 U/µl Prime RNase inhibitor, in a potter-
elvehjem. Binding of overexpressed MID1 to homoribopolymers was performed as previously 
described (Brown, 1998; Siomi et al., 1993b; kiledjian and dreyfuss, 1992; Swanson and 
Dreyfuss, 1988). Briefly, 100 µg of cytosolic extract were incubated with 5 µg of 
homoribopolymer coated beads in 500 µl of HSMN buffer during 30 min at 4°C. Beads were 
pelleted and washed 3 times for 5 min at 4°C with 500 µl HSMN buffer before being 
resuspended in magic mix. Bound proteins were eluted by boiling the sample at 95°C for 5 min 
and analysed by Western blotting with anti-FLAG antibody.  
For the different treatments performed the standard procedure was the same, except 
that this time 2 µl of poly-rG agarose coated beads were used. After lysis, cytosolic extracts 
were modified according to each experimental condition as follows: 
For the different salt treatments the concentration of NaCl in the cytosolic extracts was 
adjusted to 250 mM and 500 mM with 1 M NaCl. For heparin treatments, heparin from a 100 
mg/ml stock solution in HSMN buffer was added to the samples in order to have a final 
concentration of 1 or 2 mg/ml. For the competition experiments with free homopolymer, 5 or 50 
µl of a 10 mg/ml solution of the corresponding free homopolymer (poly-rU or poly-rG) was 
added to create a 1:1 or 1:10 bound:free homopolymer solution. 
2.7.2 Ephrin mRNAs-MID1 binding experiments 
2.7.2.1 Amplification of G-quartets and EFNB1 mRNA 
All forward primers contained the T7 promotor sequence (5´-ccaagcttctaatacgac-
tcactatagggaga-3´) to allow subsequent in vitro transcription of the PCR product. PCRs 
were performed with advantage polymerase. PCR conditions and primers for the different 
amplification reactions are given in Table 2.22. TD indicates PCRs that were performed with a 
touchdown thermal programm. 
Primer Sequence (5´→3´) Annealing Ta (°C) 
EFNB1a T7cccatgctcttgtgccttcc 65 
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 gtcctgggaaggtggcaag3  
EFNB1b T7ggtcagccaggaagcatagg 64 
 tgggacaccttgcccagtg  
EFNB1c T7cttaattggctgttgcctgg 64 
 gtaaggagagaacagggtgg  
EFNB1d  T7cctagcacaggtgggtaac 64 
 agccgtgctggcaaggaactg  
EFNB1bAS T7tgggacaccttgcccagtg 64 
 ggtcagccaggaagcatagg  
EFNB2a T7ggtgccctttagccagatg 66-55 TD 
 cctttccaactttctgtttcag  
EFNB2b  T7cgatgtgcaggaagaaaagcc 64 
 gtaccacaacagtcctgcc  
EPBH1  T7gtcagtcaccaacggcaatgg 66-55 TD 
 tcagctgagaagccagtctct  
EPBH2a  T7ctaatggactccactacagc 66-55 TD 
 caaacacgttgcacacctgg  
EPBH2b T7gttgatcctgcatctgggtttg 55 
 gtcaaagtgtcacttcattgtc  
EPBH3a T7ctcatggacacaaaatgggtaac 66-55 TD 
 gcacattacacacctggtatg  
EPBH3b T7cttcctgctctccagcag 66-55 TD 
 ctgctctccgcctacctg  
EPBH3c T7gatttgttctgggggctgag 65 
 cacatcccatctctggctctg  
EPBH4a T7gatgagagcgagggctgg 66-55 TD 
 ctgcttctctcccattgctc  
EPBH6a  T7gcagcagcttcttaaccagc 66-55 TD 
 gtttctgggtcaatcttaccct  
EPBH6b T7ggaagcaagcttagctgtacac 64 
 tgggcagccccttcagtag  
EFNB1-3´UTR T7gaagatggctcggcctggg 74-64 TD 
 gtgccgggcactcagaccttg  
EFNB1+1Gq T7gaagatggctcggcctggg 74-64 TD 
 gtcctgggaaggtggcaag  
EFNB1+2Gq T7gaagatggctcggcctggg 74-64 TD 
 tgggacaccttgcccagtg  
EFNB1+3Gq T7gaagatggctcggcctggg 74-64 TD 
 gtaaggagagaacagggtgg  
EFNB1+4Gq T7gaagatggctcggcctggg 74-64 TD 
 agccgtgctggcaaggaactg  
EFNB1+3Gq rev T7agccgtgctggcaaggaactg 74-64 TD 
 gaagatggctcggcctggg  
EFNB1+4Gq rev T7gtaaggagagaactgggtgg 74-64 TD 
 gaagatggctcggcctggg  
Table 2.22. Primers for amplification of G-quartets and ephrin mRNAs 
 As template for the PCR reactions, the IRATp970C0237D6 clone containing EFNB1 
coding sequence or cDNA from embryonic human fibroblasts were used. 
 PCRs were checked on agarose gels and purified by gel extraction before RNA 
transcription was performed. Longer PCRs fragments were additionally digested with 
Proteinase K by incubation with 100 µg/ml proteinase K, 0.5 % SDS in 50 mM TRIS-HCl (pH 
7,5) and 5 mM CaCl2 for 30 min at 37°C. Subsequently, they were purified by 
phenol:chloroform extraction. 
Materials and Methods 
-47- 
 
2.7.2.2 In vitro transcription of biotinylated RNA 
Amplified transcripts were in vitro transcribed with the RiboMAXTM Large scale RNA 
production system-T7 from Promega, following the manufacture´s instructions with some 
modifications. Briefly, 2µg of purified PCR product were transcribed for 4 h at 37°C in the 
following reaction mixture: 
Reaction components Sample reaction 
T7 transcription buffer 4 µl 
rNTPs (25 mM rATP, rGTP, rCTP, 1,6 mM biotin-rUTP, 2,5 mM UTP) 6 µl 
PCR template 2 µg 
RNA polymerase enzyme mix 2 µl 
DEPC-H2O Up to 20 µl 
Table 2.23. In vitro transcription  
Transcribed RNA was purified by phenol:chloroform extraction and precipitation with 
ethanol. Products were kept in nuclease free TE. 
RNA concentration was measured with a NanoDrop ND-1000 Spectrophotometer 
(PEQLAB) or with a Gene Quant RNA/DNA calculator (Pharmacia). The efficiency of the 
biotinylation was tested by Dot Blotting. 
2.7.2.3 Biotinylation efficiency dot blot 
6 x 10 µl of 6x SSC buffer were pipetted onto a piece of parafilm. To the first dot, 1 µl 
RNA was added, then, 1 µl of this first dot was taken and applied to the next dot, and 
successively like that until the sixth dot, which had a final dilution of RNA of 1:106.  
1 µl of each dot was transferred to a Roty-Nylon Plus membrane. The RNA was cross-
linked to the membrane with a UV linker. The membrane was blocked in PBS-5% BSA for 15 
min, followed by incubation with 1:1000 streptavidin-AP in PBS and 5% BSA for another 15 
min. The blot was then washed and the AP activity was developed by incubation with freshly 
prepared NBT-BCIP in the dark until signals appeared. Membranes were finally washed with 
H2O and kept in a plastic bag. 
Note: NBT-BCIP was prepared by dissolving a tablet in 10 ml DEPC water. 
2.7.2.4 RNA-PROTEIN binding assay 
1 or 2 µg of RNA (G-quartets or longer EFNB1 fragments) were incubated with 150 µg of 
cytosolic protein extract from HeLa cells (cells were lysed as described in section 2.6.1) 
containing overexpressed MID1-FLAG in 450 µl of TKM buffer with proteinase inhibitors and 
30 µl of Prime RNase Inhibitor for 1 hour at 4°C. Subsequently, the mixture was incubated for 
2 h at 4°C with 40 µl of 50% slurry of M280 streptavidin coated magnetic beads. Beads were 
washed 3 times with TKM buffer for 10 min at 4°C and bound proteins were eluted by boiling 
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the beads in magic mix for 10 min at 95°C. Bound proteins were tested by Western blotting 
with the respective antibodies. 
Note: for the experiment with the cDNA containing varying numbers of G-quartets, the 
concentration of KCl in TKM buffer had to be adjusted to 50 mM to observe specific binding. 
2.7.3 Biofinformatics 
Bioinformatic approaches were performed by the bioinformatics department at the Max 
Planck Institute for Molecular Genetics (Berlin). Briefly, Bioperl and Ensembl-API (both 
available from CVS-concurrent version systems) were used to create a programm to screen all 
the gene entries of the ENSEMBL database (Version v37. human) for the presence and 





3.1 Characterisation of the Bboxes of MID1 
As previously described, most of the so far characterised OS patients harbour mutations 
in the C-terminal domain of MID1, that disrupt the association with microtubules and result in 
aggregation of the mutant protein in cytosolic clumps. In contrast, these mutations do not 
affect the interaction with α4, regulatory subunit of PP2A, which is then recruited to the 
cytoplasmic clumps, leading to accumulation of microtubule-associated PP2Ac (introduction 
section 1.2.2). Except for microtubule-association of the C-terminus and α4-binding properties 
of the Bbox1 domain of MID1, functions of other MID1 regions (including Bbox2) are largely 
unknown.  
Knowing that MID1 interacts with α4 through the Bbox1 domain (Trockenbacher et al., 
2001), and assuming that Bbox2 might participate in the regulation of the MID1 protein 
function (Winter et al., 2004), a series of experiments was performed in order to elucidate and 
characterise the function of the two Bboxes of MID1.  
3.1.1 Mutations in Bbox1 disrupt MID1-α4 interaction 
Mutation analysis on DNA from OS patients is being performed on a regular basis in our 
laboratory. Recently, two new mutations located in exon1 of MID1 were identified in two 
unrelated patients. One patient was found to have a 388G>A mutation, predicting a change of 
an alanine into a threonine at position 130 (A130T) in the Bbox1 domain of MID1. The second 
patient had a 433T>A mutation, predicting a cysteine to serine change at position 145 (C145S) 
also located in Bbox1. Both were de novo mutations. 
To date, only two mutations in the Bboxes of MID1 have been described in the literature, 
namely deletion of a valine, theronine and cysteine at positions 135 to 138 (∆VTC) in Bbox1 
(De Falco et al., 2003; Pinson et al., 2004) and an amino acid change of a cysteine into a 
phenylalanine at position 195 (C195F) in Bbox2 (De Falco et al., 2003), both resulting in 
severe OS phenotypes. The novel mutations described in this thesis were also identified in 
severely affected individuals, supporting an important role of the Bboxes for the correct 
functioning of MID1. Since MID1 interacts with α4 through its Bbox1 domain, it was first tested 
whether mutations in this domain lead to disruption of the MID1-α4 interaction.  
The following N-terminally green fluorescent protein (GFP)-tagged MID1 constructs 
carrying different mutations in the Bbox1 domain were used in this study: 
• A130T, C145S: novel identified mutations in OS patients in our laboratory. 
• ∆VTC: published mutation in Bbox1 (above described). 




   These constructs, as well as wild-type MID1, were co-expressed in COS-7 cells 
together with V5-tagged α4, and their subcellular localisation was examined by 
immunostaining. While MID1 constructs were followed by the presence of the GFP-tag, anti-
V5 and subsequent anti-mouse Cy3 labelled antibodies were used to assess α4 localisation 
(subsequent experiments were done in the same manner). As previously reported 
(Trockenbacher et al., 2001), α4 alone localised diffusely in the cytosol (Figure 3.1A) and in 
the presence of wild-type MID1, it was tethered to the microtubules (Figure 3.1B-wild-type). As 
expected, in contrast to the wild-type form (Figure 3.1B, wild-type), Bbox1 mutated or 
deleterious MID1 forms were unable to bind α4 in vivo (Figure 3.1B, ∆Bbox1, 130T, C145S 
and ∆VTC). While point mutated MID1 could still bind to microtubules, α4 remained spread all 
over the cell. Of note, deletion of the entire Bbox1 also seemed to slightly influence 
microtubule binding-properties of the protein. 
Figure 3.1. Bbox1 mutated MID1 and α4 localisation 
A. Cytosolic localisation of α4-V5 overexpressed in COS-7 cells, stained with anti-V5 and
subsequent anti-mouse Cy3 labelled antibody. B. COS-7 cells co-expressing different MID1
constructs (wild-type, deletion of Bbox1, A130T and C145S mutations and deletion of VTC (∆VTC))
and α4 were immunostained. GFP shows MID1 localisation in green and α4-V5 is stained in red













 For further verification, co-immunoprecipitation experiments were performed in COS-7 
cells co-expressing different N-terminally FLAG-tagged MID1 (MID1-FLAG) constructs 
(A130T, ∆Bbox1 and wild-type) and N-terminally myc-tagged α4 (α4-myc) (Figure 3.2A). 
Immunoprecipitation experiments were performed with anti-FLAG and anti-myc antibodies 
(Figures 3.2B and 3.2C respectively) and Western blots of the precipitates were developed 
with the corresponding antibodies, anti-myc or anti-FLAG respectively. Cells expressing α4-
myc alone were used as background control. Co-precipitation of α4 and MID1 could only be 
shown with wild-type MID1 but not with either of the mutant proteins (Figure 3.2B-lower lane 
and 3.2C-upper lane), independently of the antibody used for the immunoprecipitation. Both 
blots were also incubated with the antibodies used for immunoprecipitation, proving that MID1-
FLAG had been pulled down with anti-FLAG (Figure 3.2B-upper lane) and α4-myc with anti-
myc (Figure 3.2C-lower lane). 
In addition, yeast two-hybrid experiments based on β-galatosidase activity measurements 
were performed to quantify the putative binding affinities of different Bbox1 mutants to α4. 
Different MID1 constructs in pBMT116 vector, corresponding to wild-type, A130T, C145S and 
∆Bbox1, were used as baits to screen for interaction with the α4 protein cloned in pGAD10. A 
cut-off value of 5 β-galactosidase units was defined, and measurements above this value were 
B 
Figure 3.2. MID1 with altered Bbox1 do not co-immunoprecipitate with α4  
A. COS-7 cells were transfected with wild-type MID1-FLAG or FLAG-tagged MID1 constructs lacking
Bbox1 or carrying an A130T mutation and α4-myc. As background control, α4-myc was
overexpressed alone. Cell lysates were separated on an SDS-gel, blotted and probed with anti-FLAG
(upper line) and anti-myc (lower lane). B. Immunoprecipitation of MID1 constructs with anti-FLAG
antibody. Precipitates were separated on an SDS-PAGE gel, blotted and probed with anti-FLAG
(upper line) or anti-myc (lower lane). C. Immunoprecipitation of α4 with anti-myc antibody.
Precipitates were separated on an SDS-PAGE gel, blotted and probed with anti-FLAG (upper lane) or


































































































































































































considered as clear interaction. Accordingly, measurements below 5 units were considered as 
no interaction. 
With β-galactosidase measurements below 5 units, both mutants (C145S and A130T), 
as well as the construct lacking Bbox1, did not interact with α4 (Figure 3.3), while wild-type 
MID1 showed clear interaction. This data fully supported the results of the 
immunofluorescence and immunoprecipitation experiments, confirming that mutations in the 
Bbox1 domain of MID1 disrupt the interaction of the protein with α4 and that Bbox1 is 
responsible for the interaction between MID1 and α4. 
3.1.2 Analysis of the structure of the Bbox2 domain 
In addition to the OS related mutations described in Bbox1, one mutation has been 
identified so far in the Bbox2 domain of MID1 in an OS patient (De Falco et al., 2003). 
However, the effects of such mutations on the MID1 protein function have not yet been 
studied. Additionally, previous experiments in our group have shown that a mutated form of 
MID1 harbouring a single amino acid change in Bbox2, glutamine to arginine at position 192 
(Q192R), while binding to microtubules, is unable to co-localise with α4 in vivo. Since Bbox1 
alone is sufficient for MID1 to interact with α4, Bbox2 was proposed to act as a regulator of 
this interaction (Winter, 2003).  
 A first theoretical impression of the importance of these residues (Q192 and C195) in 
Bbox2 with respect to the structure of the domain, was acquired by comparison with a model 
of a previously reported Xenopus Bbox (Borden et al., 1995b). As outlined in the introduction 
section, Bboxes contain seven conserved histidines or cysteines and is arranged in a 
particular fashion, having two perpendicular β-strands connected by a flexible loop (Figure 
3.4B) and a hydrophobic core. Four of the conserved Cys/His bind one zinc atom, as indicated 
Figure 3.3. Yeast two-hybrid analysis of Bbox1 mutant’s interaction to α4 
The strength of the interaction between α4 and the indicated constructs was quantified by measuring
the activity of a β-gal reporter. A cut-off value of 5 units, indicating the value above which clear 




in figures 3.4B and 3.4C (sphere). According to this arrangement, it was predicted that C195 
in MID1 Bbox2 (indicated with an arrow in Figure 3.4C) would form a part of the conserved 
core of residues, and that it is placed in the flexible loop of the domain. This structure has 
been proposed to probably participate in the correct positioning of the coiled-coil domain and, 
subsequently, the C-terminal end of MID1 (Borden et al., 1995b). Evolutionary conservation 
confirms the predicted important structural roles of this residue (Khuri et al., 2001; Mnayer et 
al., 2005). Interestingly, while also located in the above described loop, Q192 was not found to 
be a conserved residue.  
 
3.1.3 C195F, mutated MID1 form found in an OS patient, disrupts 
MID1-α4 interaction 
In order to test for putative consequences of a mutation such as C195F in Bbox2 with 
respect to the association of MID1 to α4 in vivo, N-terminally GFP-tagged C195F-MID1 was 
overexpressed in COS-7 cells together with V5-tagged α4. Subcellular localization of both 
proteins was subsequently assayed by immunostaining as previously described. Confirming 
predictions, C195F-MID1 mutant protein not only lost α4 binding properties, but also its 
microtubule-binding affinity, probably due to major structural changes of the entire protein. In 
immunostained cells, while α4 appeared diffusely distributed in the cytosol, C195F mutant 
Figure 3.4. Bbox2 domain 
A. Comparison of Bbox2-MID1 and Bbox-XNF7 sequences. B, C. Stereo view and α-carbon
representation of the Bbox domain from XNF7 (from Borden et al., 1995). A white arrow indicates






protein accumulated in cytosolic aggregates (Figure 3.5A). The pictures clearly prove a loss of 
interaction of the two proteins, α4 and C195F MID1 in vivo. 
For further research, immunoprecipitation experiments were performed with cytosolic 
extract from COS-7 cells co-expressing FLAG-tagged C195F-MID1 and α4-myc (Figure 3.5B). 
Immunoprecipitation with anti-FLAG and subsequent Western blotting of the precipitates with 
anti-myc, showed that both wild-type and C195F mutated MID1 interact with α4 in vitro (Figure 
3.5C-lower lane). Similarly, a clear MID1 band was seen in both samples wild-type and 
C195F-mutant after immunoprecipitation of α4 with anti-myc and anti-FLAG incubation of the 
Western blots of the precipitates (Figure 3.5D-upper lane). Both blots were also incubated with 
the antibodies used for immunoprecipitation, confirming the efficiency of the precipitation 
reactions (Figure 3.5C-upper lane, Figure 3.5D-lower lane). In other words, unexpectedly, 
B C D
A 
Figure 3.5. C195F-MID1 and α4 association 
A. COS-7 cells co-expressing C195F mutated GFP-MID1 and V5-α4 (GFP-MID1 in green and 
V5-α4 in red). The nucleus is stained in blue with DAPI. B. Western blots showing the presence 
of the indicated constructs overexpressed in COS-7 cells C. Immunoprecipitation of MID1 
constructs (wild-type, C195F and empty sample) with anti-FLAG antibody. Precipitates were 
separated on a SDS-PAGE gel, blotted and probed with anti-FLAG (upper lane) or anti-myc 
(lower lane) D. Immunoprecipitation of α4 with anti-myc antibody. Precipitates were separated on 










































































































































these data indicate that while not being strong enough to disrupt the interaction of Bbox1 with 
α4 in vitro, a mutation such as C195 into F leads to misplacement and missfolding of MID1 
that, consequently, can no longer interact with α4 in vivo. 
3.1.4 Bbox2 mutants do not interact with α4 in vivo 
All observations made thus far pointed towards a relevant structural and functional role 
for the Bbox2 domain of MID1, which would not only play a important role in the interaction of 
MID1 with α4 but also with microtubules. To further characterise the function of this domain, 
site directed mutagenesis of selected amino acids was performed, and the influence of these 
mutations on the known functional abilities (α4- and microtubule-binding) of MID1 was studied. 
Mutated residues were chosen according to their putative effect on the MID1 structure 
predicted by comparison with the 3D-structure of XNF7 Bbox and the Bbox2 consensus 
sequence. 
The following N-terminally GFP-tagged MID1 constructs were used in this study: 
C175A: Cysteine-175 is located at the N-terminal end of Bbox2 and immediately 
precedes a loop/turn. It is conserved and participates in zinc binding. It was mutated into 
alanine, a hydrophobic amino acid. 
C198A: Cysteine-198 is located in the flexible turn. It is conserved and participates in 
zinc binding. It was also mutated into alanine. 
H178Y: Histdine-178 is located in the middle of the N-terminal loop. It is conserved and 
participates in zinc binding. It was mutated into tyrosine, another polar amino acid that 
contains an aromatic ring. 
V183T: Valine-183, a hydrophobic amino acid would be the first amino acid of the first β-
strand. It was mutated into threonine, a polar amino acid. 
Q192R: Glutamine-192, a polar hydrophilic residue would be located at the loop region. 
It was mutated into arginine, a basic amino acid. 
∆Bbox2: deletion of the entire Bbox2 domain.  
∆Ring: deletion of the RING finger domain. 
∆Ring-Bboxes: deletion of the RING finger domain and both Bboxes. 
Splice variant-Ex2d.7: MID1 splice variant which has been shown to bind α4 more 
strongly than full-length MID1 (Winter et al., 2004).  
Splice variant-Ex2d.7-C175A: splice variant with a C175A mutation in Bbox2. 
Splice variant-Ex2d.7-H178Y: splice variant with a H178Y mutation in Bbox2. 
Immunostaining experiments were performed in the same manner as described 
previously; the different GFP-MID1 constructs were co-expressed with α4-V5 in COS-7 cells 




C195F, the missense mutations C175A, C198A, H178Y and the deletion of the entire Bbox2, 
all of which are predicted to have drastic structural effects on the MID1 protein, produce 
aggregates that hardly interact with microtubules and do not interact with α4 (Figure 3.6A). In 
contrast, V183T and Q192R, non-conserved residues that are expected not to have such as 
significant effect on the MID1 protein structure as the previous mutations, showed a clear 
interaction with microtubules, but not with α4.  
The splice variant Ex2.d7 has been previously shown to have much higher binding 
affinity to α4 than full length MID1 in a ß-galactosidase based yeast two-hybrid assay, and 
therefore, it was proposed to participate in the regulation of the MID1 protein function (Winter 
et al., 2004). This splice variant has a protein truncation stop signal after the coiled-coil domain 
and, in addition, exon1 is shortened, therefore losing most of the Bbox2 domain (only the 
seven first amino acids of the domain are kept).  
Ex2d.7 does not interact with microtubules but appears diffusely distributed similar to α4, 
although they both seem to co-localise, as previously reported (Winter et al., 2004). In this 
case, none of the mutations, C175A or H178Y, contained in the Bbox2 part seemed to have 
strong effects; localisation of the protein was not modified and no clumps were formed (Figure 
3.6B, middle and lower panels). However, as both proteins showed diffuse pattern in the 
cytosol, it was difficult to charge if they interact by immunofluorescence. For this reason, ß-






Figure 3.6. Bbox2 mutants do not interact with Bbox2 in vivo 
A. COS-7 cells co-expressing different MID1 constructs with mutations in the Bbox2 domain or
the complete deletion of the domain and α4 were immunostained. GFP shows the localisation
of MID1 in green, and α4 is labelled in red with Cy3. Merge signals are shown to the right
Nuclei are visualized in blue with DAPI staining. B. Constructs carrying the Ex2d.7 splice

















   Most of the Bbox2 mutants, as well as the deletions of any of the Bboxes, exhibited 
difficulties to interact with microtubules, suggesting that not only an intact C-terminus but also 
the Bboxes are essential for the correct folding and positioning of MID1 at the microtubules. It 
has previously been shown that mutations in the coiled-coil domain do not misplace MID1 or 
affect its interaction with α4. A mutated C-terminal domain, while abolishing microtubule-
association, has also no influence on α4 binding (Liu et al., 2001; Schweiger et al., 1999; 
Trockenbacher et al., 2001). However, no data about putative effects of the RNG finger 
domain are available yet. Thus, a MID1 construct lacking the RING domain and a second one 
lacking the RING and the Bboxes domains were examined by immunostaining for microtubule-
association. In addition, the α4 binding properties of the construct lacking exclusively the 
RING were studied. It was observed that, while the absence of the RING did not have any 
effect on the position of MID1 at the microtubules or its binding with α4, the additional absence 
of the Bboxes led to misplacement of the protein (Figure 3.7). This result confirms again that 
the Bboxes are necessary not only for proper α4 interaction (as shown in sections 3.1.1 and 
3.1.4), but also for providing the correct emplacement of MID1 at the microtubules, even when 
the C-terminal end of the protein remains unaltered.  
Figure 3.7. RING domain  
A. COS-7 cells overexpressing MID1 constructs lacking the RING domain or the RING domain
and the two Bboxes. GFP-tag confers MID1 green colour. B. Co-expression of a GFP-MID1
construct lacking the RING finger domain (in green) and α4-V5 (in red). Merge signal is shown to









3.1.5 Bbox2 mutants interact with α4 in vitro 
  Further characterisation of a putative interaction of Bbox2 MID1 mutants with α4 
required a study of the in vitro situation, which would help to clarify whether Bbox2 mutants do 
not interact with α4 in vivo because they are not well positioned, or because the interface of 
the α4 binding site is affected. Immunoprecipitation experiments with anti-myc antibody were 
performed with different N-terminally FLAG-tagged Bbox2 mutants co-expressed with myc-
tagged α4 in COS7-cells (Figure 3.8A). Apart from a MID1 construct lacking the entire Bbox2 
and the previously described constructs carrying point mutations in the Bbox2 domain, a 
construct including only the first seven amino acids of the domain, resembling the earlier 
described splice variant (section 3.1.4) was included. A construct carrying the mutation ∆VTC 
A 
Figure 3.8. Co-immunoprecipitation of Bbox2 mutated constructs with α4 
A. Western blots showing the presence of the indicated construct overexpressed in COS-7 cells.
Note: lanes 2 and 8, upper panel shows overexpression of MID1-FLAG alone and the lower panel α4
alone B. Immunoprecipitation of MID1 constructs carrying mutations in Bbox2, in Bbox1 (∆VTC, lane
10) or in the coiled-coil domain (L295P, lane 3) with anti-myc antibody. Precipitates were separated
on a SDS-PAGE gel, blotted and probed with anti-FLAG (upper line) or anti-myc (lower line). Control























































































































































































































































































































































































































































































in Bbox1 was included as negative control for MID1-α4 binding. As positive control, a 
construct carrying a mutation in the coiled-coil domain, L295P (So et al., 2005), that was 
previously shown not to interfere with α4 binding (Schweiger et al, unpublished data), was 
used. Western blots developed with anti-FLAG antibody and with anti-myc antibody proved 
the efficiency of the precipitation reaction. Samples only expressing FLAG-tagged wild-type 
MID1 were used as background control. 
As expected, the construct carrying a mutation in Bbox1 (∆VTC) did not interact with 
α4, agreeing with the results from section 3.1.1 (Figure 3.8B-lane10), and the L295P 
mutation maintained unaltered its association with α4 (Figure 3.8B-lane3). Similarly to what 
was observed for the C195F mutant, all the Bbox2 mutants studied (C198A, V183T, H178Y, 
Q192R, C175A and deletion of Bbox with and without extra seven amino acids) were able to 
interact with α4 in vitro (Figure 3.8B-lanes 4,5,6,9,11,12,13), associating to α4 with similar 
intensity as L295P.  
For further characterisation, β-galactosidase activity was measured in yeast two-hybrid 
assays to quantify the strength of the interaction between the different constructs and α4. 
Similarly to what was done for the Bbox1, a cut-off value at 5 units β-galactosidase activity 
was assigned. Measurements above this value were considered as interaction between the 
MID1 construct and α4. In confirmation with all the in vitro immunoprecipitation results 
obtained, all constructs tested were able to interact with α4 in the yeast system (Figure 3.9). 
The splice variant, Ex2d.7 with and without C175A mutation, was also tested and showed 
higher binding affinity than all the other constructs (Figure 3.9). However, since unexpectedly 
all the Bbox2 mutated constructs interact with α4 in vitro and given that both splice variant 
and α4 are spread in the cytosol in immunofluorescence experiments, at this point it is not 





In summary, the results obtained during this thesis show that the Bbox2 domain 
considerably influences the interaction between α4 and MID1 in vivo. Single point mutations 
lead to complete disruption of this interaction in vivo but not in vitro. Furthermore, amino acid 
changes in the conserved core of amino acids in Bbox2 appear to affect the protein to a 
greater extent and lead to dissociation of the mutant protein from the microtubules, and 
disruption of the interaction between MID1 and α4. 
Figure 3.9. Yeast two-hybrid analysis of Bbox2 mutants -α4 interaction 
The strength of the interaction between α4 and the indicated constructs was quantified by
measuring the activity of a β-galactosidase reporter. A cut-off value of 5 units, indicating the value




3.2 Characterisation of the MID1 multiprotein complex 
The elucidation of previously reported multiprotein complexes has allowed a much 
better understanding of the function of their main component proteins. Well-characterised 
examples are PML, FMRP or Staufen (Brendel et al., 2004; Ceman et al., 1999; Hodges et 
al., 1998; Sternsdorf et al., 1997). As mentioned earlier, MID1 forms part of a 
macromolecular complex, the composition of which was mainly unknown. Therefore, the 
elucidation of its components could shed light on different functions in which MID1 might be 
involved. 
In this thesis, affinity chromatography was the method of choice to identify protein 
components of the macromolecular MID1 complex. For the preparation of the 
chromatography column, a peptide that was recombinantly produced in E.coli in a PinPoint 
vector system was used (see section 3.2.2). This peptide covered the MID1 binding region in 
the α4 protein, which had been recently narrowed down to 44 amino acids (44aa peptide) 
(Figure 3.10; R. Schneider and A. Köhler, unpublished data). Unfortunately, MID1 could not 
be used for the preparation of the column, as it contains many cysteines that impede the 
correct folding of the protein in E.coli. 
3.2.1 44aa peptide of α4 production in the PET32a vector system 
Conditions for the expression of the 44aa peptide in E.coli were first established with 
the PET32a vector system, a very efficient protein expression system. Moreover, with this 
vector a His-tag suitable purification through Ni-NTA agarose and a Thioredoxin tag and a S-
Tag that improve the solubility of the peptide could be incorporated to the peptide (Figure 
3.12A). Several temperatures and concentrations of IPTG for induction of protein expression 
were tested in order to establish optimal conditions in the BL21 strain of E.coli (Figure 3.11, 
induction conditions). An aliquot of each culture was lysed under denaturing conditions with 
SDS-PAGE buffer or magic mix and analysed on a 15 % Coomassie stained SDS gel (Figure 
3.11A). Having observed no difference in any of the tested conditions 2 h after induction, the 
minimum amount of IPTG (0.1 mM) at 37°C were taken as the conditions of choice. To test 
the solubility of the peptide produced under those conditions, cells were lysed in native 
conditions lysis buffer (see Methods section), and the soluble fraction was separated from 
Figure 3.10. α4 peptide 




the insoluble by centrifugation at 10000 x g. Aliquots of the soluble and insoluble fractions, as 
well as induced and non-induced cells (lysed with SDS buffer), were analysed on a 15% 
Coomassie gel, and it was confirmed that the peptide was soluble under native conditions 
(Figure 3.11B). Subsequently, the peptide was purified through Ni-NTA and aliquots of each 
fraction (flow through, washes and elutions) were run on a 15% Coomassie stained SDS gel 
(Figure 3.11C).  
 
Figure 3.11. 44aa peptide production in PET32a vector system 
A. Different temperatures and IPTG concentration tested for optimal 44aa peptide. Arrows 
show the size of the expected peptide B. Test of solubility properties of the peptide; induced 
and non-induced cells, as well as the soluble and insoluble fractions, are shown C. Native 






Although a stop codon had been introduced after the 44aa peptide coding sequence, 
the purified peptide presented with more than one band in the Coomassie gel (Figure 3.11C, 
Elutions 1-4). Therefore, the peptide was digested with thrombin in order to find out if the 
additional bands were degradation products, the result of translation from a later initiation 
codon or gel artefacts (Figure 3.12). Upon thrombin restriction, two bands of 14,7 kDa and 
7,8 kDa were expected, and variations on the sizes of the obtained bands would indicate the 
source of the additional bands. Different conditions, including different incubation times and 
enzyme concentration, were tested for optimal digestion of the purified peptide at 4°C (Figure 
3.12B). Samples were run on 15% SDS gels and silver stained. While the control experiment 
without enzyme remained intact, after 2 hours most of the peptide had been already digested 
with all enzyme concentrations tested. Interestingly, thrombin digestion resulted in two well-
defined bands at the expected sizes (green arrows), confirming that the additional bands 
free-44aa peptide 
Figure 3.12. Peptide with the PET32-vector system and thrombin cut 
A. Tagged 44aa peptide obtained in the PET32-vector system; thioredoxin, His and S·Tag are
indicated, as well as the 44aa peptide of α4. Thrombin restriction site is indicated as well as the
predicted sizes of the resulting fragments (14,7 and 7,8 kDa-free peptide). B. Different enzyme
concentrations (0.02 and 0.04 units) and time (2, 4 and 24 hours) were tested to establish
optimal conditions for digestion of the 44aa peptide with thrombin. Lanes 1,2,4,5,6,7 show two
bands corresponding to the resulting fragments of the thrombin digestion (green arrows). Lane
3 and 8 show the undigested peptide. 




Enzyme units 0.04 0.040.02 0.02
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observed in the undigested peptide are probably due to gel artefacts. No degradation of the 
undigested peptide (yellow arrows) was observed even after 24 hours at 4°C in untreated 
controls. 
The free 44aa peptide was subsequently used for elution of the chromatography 
column (see below) and for that purpose, thrombin was used to cleave the thioredoxin-tag 
and the His-Tag as previously described (Figure 3.12A). The free 44aa peptide, only 
including the S-Tag, was recovered by trapping the fragment including the tags in Hepes 
sucrose buffer (HS buffer) equilibrated Ni-NTA agarose and collecting the flow through 
containing the 44aa peptide. 
3.2.2 α4 peptide production in the PinPoint vector system 
With the pinpoint vector system, a biotinylated peptide can be produced which can then 
be immobilized on streptavidin-coated agarose beads. Thus, the sequence corresponding to 
the 44aa peptide including a stop codon was cloned into the PinPoint -Xa vector, and a His-
RGS tag was additionally included in order to purify the peptide through Ni-NTA agarose. To 
set up optimal expression time the biotinylated peptide was overexpressed in E.coli (strain 
JM109) in the presence of 2 µM biotin upon induction with 0.1 mM IPTG for one, two, three 
or four hours. An aliquot from each culture was run in a 15% SDS-PAGE gel and checked by 
Coomassie staining (Figure 3.13A). Although the approximately 22 kDa big peptide started to 
be expressed 2 hours after induction, at least three to four hours were necessary to obtain 
the highest expression levels. As a control, the same vector without the peptide was used, 
showing a similar induction pattern. 
Having established the expression conditions, the peptide was purified through Ni-
NTA agarose and its purity was tested on a 15% Coomassie gel (Figure 3.13B). Of note, two 








Figure 3.13. Biotinylated 44aa peptide  
A. Schematic representation of the
biotinylated 44aa peptide.B. Time course of
expression of the biotinylated 44aa peptide.
Arrows are indicating the size of the
biotinylated 44aa peptide and the control
peptide respectively. C. Biotinylated 44aa-
peptide and control after purification






























































































































































































3.2.3 Affinity chromatography column 
For preparing the affinity chromatography, the biotinylated 44aa peptide was bound to 
streptavidin coated agarose beads and subsequently blocked with BSA to reduce unspecific 
interactions. In parallel, a control experiment without peptide was performed. After blocking, 
the columns were extensively washed first with free 44aa peptide and, then, with 100 
volumes of HS buffer and 2 volumes of washing buffer (250 mM NaCl/0,05% Tween), 
followed by equilibration in HS buffer. Afterwards, cytosolic HeLa extracts were added to 
both columns (with and without peptide). In order to avoid competition for MID1 between 
endogenous α4 and the biotinylated 44aa peptide bound to the column, endogenous α4 had 
been previously knocked-down by siRNA (Figure 3.14).  
 After extensive washing, MID1 and its interaction partners were eluted with free 44aa 
peptide (section 3.2.1). Eluted proteins were dialysed to remove the excess of peptide and 
analysed on a 10% SDS gel that was subsequently colloidal Coomassie stained. Bands 
absent in the control gel were cut out and analysed by electrospray ionisation mass 
spectrometry (ESI-MS). Figure 3.15 shows the colloidal Coomassie stained gel and the 
protein identities of the analysed bands, after correlation of the obtained peptides with the 
Swiss-Prot database. 
Tubulin beta-5-chain identification (Figure 3.15) resembled microtubule binding ability 
of MID1 shown before in our lab (Schweiger et al., 1999) and served as a proof of specificity. 
In addition, several heat shock proteins, namely Heat shock protein HSP 90-beta (Hsp90), 
Heat shock cognate protein 71kDa protein (Hsc70) and 60 kDa heat shock protein (Hsc60), 
being Hsp90 the most abundant, were identified. Unfortunately, MID1 detection was hindered 
by a very strongly encountered E.coli heat shock protein (Heat shock protein 70, E.coli) that 
has the same molecular size and was also present in the control sample. In addition, 
Figure 3.14. α4 knock-down 
 Western blots of HeLa cell lysates after α4 knock down or a control experiment without 
siRNA. Endogenous anti-α4 antibody was used for detection. Incubation with anti-actin 
























elongation factor 1-alpha1 (EF-1α), Annexin A2 (ANXA2), Q subcomponent binding protein 
(p32), RACK1, Nucleophosmin (NPM) and several ribosomal proteins of the small 40S 
subunit (S3, S8) were found. Table 1 shows a summary of already reported functions of the 
proteins identified after mass spectrometry. 
  
Figure 3.15. Colloidal coomassie results 
Colloidal Commasie staining of proteins eluted from the chromatography column coated 
with biotinylated 44aa peptide (left lane) compared to the control column without peptide 









Heat shock protein 
HSP90-beta 
 
Hsp90 P08238  •RNA binding protein 
•Cell cycle progression 
as chaperon of cell cycle 
regulation and Polo-like 
kinases  
•Centrosome duplication 
•Buffer of insulin-like 
growth factor and 
insuline signalling  
•Participates in the 
reduction of Huntingtin 
aggregates  
(Burrows et al., 2004; 
de Carcer, 2004; de 
Carcer et al., 2001; 
Lange et al., 2000; 
Meares et al., 2004; 
Nakai and Ishikawa, 
2001; Sittler et al., 
1998)  
 
60 kDa heat shock 







(Bukau and Horwich, 
1998; Gupta and 
Knowlton, 2005; Voos 
and Rottgers, 2002) 
Heat shock cognate 





(Jana et al., 2000) 
Tubulin beta-5 chain 









EF-1α P04720 •Peptide chain elongation 
•Cytoskeleton regulation 
•Interaction with mitotic 
apparatus  
•Regulation of 
microtubules dynamics  
•Associates with 
Huntingtin aggregates  
 
(Condeelis, 1995; 
Mitsui et al., 2002; 
Moore R.C and R.J., 
2000; Moore RC et al., 
1998; Negrutskii and 




40S ribosomal protein 
SA (p40) (34/67 kDa 
laminin receptor) 
SA P08865 •Tumor cell growth and 
proliferation  
•RNA processing and 
ribosome maturation 
(Ford et al., 1999) 
Annexin A2 ANXA2 P07355 •RNA-binding protein 
•Mediator of Ca2+ 
regulated endocytosis 
and exocytosis. 
Regulation of ion 
channels 
•DNA binding 
•Inhibition of cell 
adhesion  
(Balch and Dedman, 
1997; Filipenko et al., 











activated C kinase 
1 
RACK1 P25388 • RNA binding protein 
• Scaffold protein  
• Regulation of cycle 
progression  
• Constituent of the 
eukaryotic ribosomes. 
• Positioning of 
ribosomes where 
translation is required, 
eg. Focal adhesions 
• Regulation of STAT3 
activation through 
insulin-like growth factor 
1 and insuline signalling  
• Intracellular Ca2+ 
regulation 
• Regulation of integrin-
mediated adhesion  
(Cox et al., 2003; 
Mamidipudi et al., 
2004a; Mamidipudi et 
al., 2004b; McCahill et 
al., 2002; Nilsson et 
al., 2004; Sklan et al., 




S3 P23396 • Constituent of the 
small ribosome subunit; 
DNA repair 
• Apoptosis/cell growth 
regulation  
(Jang et al., 2004; 
Stahl, 2001; Wittmann-
Liebold and Graack 
2001) 
Q subcomponent 
binding protein  
p32 Q07021 • Chaperon – PKC µ 




• Splicing modulation 
(Chattopadhyay et al., 
2004; Krainer et al., 
1991; Storz et al., 
2000)  
40S ribosomal 
protein S8   
S8 RS8_HUMAN • Constituent of the 







NPM Q9BYG9 • RNA binding protein  
• Ribosome biogenesis  
• Regulation of 
transcription,  
• DNA replication and 
apoptosis Centrosome 
duplication  
• Cytoplasmic nuclear 
trafficking 
• Cancer pathogenesis  
• Pre mRNA processing 
(Fankhauser et al., 
1991; Grisendi et al., 
2005; Okuda, 2002; 
Shinmura et al., 2005; 
Tarapore et al., 2002; 
Tarapore et al., 2006; 
Wang et al., 1994); 
 
 
Table 3.1 Previously reported functions of novel identified MID1 interaction partners 
Name, short name, accession numbers from the Swiss-Prot data base and functions of the different 




3.2.4 Confirmation of novel MID1 interaction partners 
In order to verify the association of the proteins identified by MS with MID1, co-
immunoprecipitation experiments were performed with HeLa extracts overexpressing N-
terminally FLAG tagged-MID1 (MID1-FLAG). Agarose-beads coated with anti-FLAG antibody 
were used to immunoprecipitate MID-FLAG, and bound proteins were specifically eluted with 
3 x FLAG-peptide. Precipitated proteins were analysed on Western blots incubated with 
endogenous antibodies for the respective proteins and anti-FLAG to detect MID1-FLAG 
itself. As negative control, the same immunoprecipitation experiment was performed with 
cytosolic HeLa extracts without MID1-FLAG expression. 
In the presence of MID1-FLAG, all the proteins studied could be pulled down with the 
anti-FLAG coated beads (Figure 3.16, left lane). On the contrary, in the control experiment 
only background binding was observed (Figure 3.16, right lane), confirming specific 
association of MID1 with the identified proteins. 
3.2.5 The MID1 protein complex is found in purified microtubules 
As mentioned previously, association of MID1 with microtubules has previously been 
demonstrated (Schweiger et al., 1999), which was again confirmed here by the identification 
Figure 3.16. Co-immunoprecipitation of MID1-FLAG with the novel interaction partners 
On the left lane precipitates of HeLa cells with MID1-FLAG overexpression were loaded and on
the right lane, precipitates of HeLa cells without FLAG-MID1 overexpression. Antibodies used














of Tubulin β-5 chain in the protein complex. In order to test whether the other components of the 
MID1 complex  associate to microtubules as well, microtubules were purified from HeLa cells 
lysates through subsequent polymerisation/depolymerisation steps with taxol and carefully 
washed. The presence and enrichment of the different proteins in the pure microtubule fraction 
was tested on Western blots incubated with antibodies detecting the respective members of the 
complex. Bands in purified microtubules were compared to total HeLa cell lysates loaded with 
the same amounts of protein (Figure 3.17). 
A tubulin α/β enrichment in the purified fraction compared to the lysate, indicated 
successful isolation of microtubules (Figure 3.17). An enrichment in S3, NPM and RACK1 was 
also observed, corroborating the interaction of the complex with microtubules. Moreover, 
considerable amounts of EF-1α and ANXA2 were found at the microtubules, although 
interaction of these proteins depends on Ca2+ and this factor was not considered. Finally, only 
small amounts of Hsp90 and Hsc70 were found in the microtubules fraction, indicating a weaker 
interaction of those proteins with the complex. 
3.2.6 The MID1 complex associates with both ribosomal subunits 
Among the newly identified MID1 complex members, it was remarkable the presence of 
ribosome related proteins such as S3, S8, p40 and RACK1, which have been found to be 
constituents of the small ribosomal subunit. Additionally, EF-1α, an important member of the 
translation machinery, several heat shock proteins, NPM (involved in ribosome biogenesis) and 
Figure 3.17. Microtubule association 
Left lane shows the lysate used for the 
purification of microtubules, right lane 
































ANXA2 (another ribosome-associated protein) were found in the complex. All these data 
together indicated that the MID1 complex associates with ribosomes. However, interaction with 
the big ribosomal 60S subunit, had not been observed in the already performed experiments.  
 In order to test if the MID1 complex also associates with the big ribosomal subunit, MID1-
FLAG overexpressed in HeLa cell lysates was immunoprecipitated with anti-FLAG antibody, 
following the same procedure as in section 3.2.4 Instead, this time MID1-FLAG 
immunoprecipitates were examined by Western blot for the presence of L5, a ribosomal protein 
component of the big ribosomal subunit 60S (Figure 3.18). 
While only background binding was observed in the control sample (Figure 3.18, right 
lane), clear co-immunoprecipitation of L5 and MID1-FLAG was seen in FLAG-MID1 
overexpressing HeLa cells (Figure18, left lane). This result confirms the association of the MID1 
protein complex with both ribosomal subunits. 
3.2.7 MID1 associates with intact ribosomes 
Previous experiments strongly indicated that the MID1 complex associates with 
ribosomes. To further characterise this association, HeLa cytosolic extracts overexpressing 
MID1-FLAG were run through discontinuous sucrose gradients (20%-50%) by 
ultracentrifugation in a fix-angle rotor to, consequently, separate the ribosomal fraction from the 
rest. Four distinct fractions of the resulting gradient were studied on Western blots developed 
with antibodies corresponding to the different members of MID1 complex. The first fraction was 
the top of the gradient with no sucrose, the second was the 20% sucrose layer, the third was 
the interface between the 20% and the 50% layer, and the ribosomal pellet resolved in urea and 
SDS containing magic-mix (see Method section) was the fourth fraction. The lysate was 
additionally loaded on the SDS gel. 
Figure 3.18. Association of FLAG-MID1 with the big ribosomal subunit, 60S 
MID1-FLAG immunoprecipitates were examined for the presence of L5, member
of the big ribosomal subunit. Immunoprecipitates from HeLa cells without MID1-







As shown in Figure 3.19, Hsp90, Hsc70, EF-1α, NPM, ANXA2, α4 and MID1-FLAG co-
sediment in the ribosomal pellet, which is indicated by the presence of the ribosomal protein S3, 
another a member of the complex. However, not all the members of the complex showed the 
same affinity. α4, the best-characterised MID1 interaction partner, was mainly found in the 
ribosomal pellet together with MID1 and NPM. Other members of the complex, such as Hsc70, 
Hsp90 and EF-1α, were found in all the fractions, indicating that probably only a pool of those 
proteins associate with the MID1 complex and the ribosome. Interestingly, only small amounts 
of ANXA2 were found in the ribosomal pellet, which could be due to Ca2+ dependency of 
ANXA2 properties. All experiments described were performed under cold-shock conditions, so 
that microtubules remained depolymerised and could not pellet with the ribosomal fraction. 
3.2.8 MID1 forms part of a ribonucleoprotein complex 
Taking together that the MID1 complex associates with ribosomes and that some of the 
identified proteins are RNA binding protein or closely related to RNA (namely NPM, ANXA2, 
Figure 3.19. MID1 complex associates with ribosomes 
Four different fractions of a 20%-50% discontinous sucrose gradient were loaded
on SDS-gels together with the lysate used for the preparation (left lane), different
antibodies were used for the detection of several members of the MID1 complex.
Top: upper part of the gradient; Interphase: 20% sucrose layer; Bottom: interface






















































RACK1), it was reasonable to think that the MID1 complex could be the core of a 
ribonucleoprotein (RNP) complex, composed of proteins and RNA.  
To test this possibility, the influence of RNA on the association of the MID1 complex with 
ribosomes was assayed by running discontinuous 20%-50% sucrose gradients in a fixed-angle 
rotor with MID1-FLAG overexpressing cytosolic extracts, which were pre-treated with RNaseA, 
DnaseI or RNAguard (RNase inhibitor). Subsequently, Western blots of the different fractions 
(same as before) were incubated with the panel of antibodies recognizing the respective 
members of the complex. S3 was used again as marker of the ribosomal fraction. 
While in the presence of RNAguard MID1-FLAG associated with ribosomes (Figure 
3.20A), after treatment with RNaseA, MID1-FLAG could not sediment with the ribosomal fraction 
anymore (Figure 3.20B). Surprisingly, in spite of the presence of a cocktail of protease inhibitors 
in the sample, MID1 also disappeared from the lysate. Given that it was present in the lysate 
before treatment , this suggests that MID1 is not stable without RNA. Probably it precipitated or 
was degraded by proteases that were not inhibited by the used cocktail (Complete mini, see 
methods section) and that only can access the protein when it is not bound to RNA. On the 
other hand, DNaseI treatment (Figure 3.20C) did not affect MID1 stability or ribosome 
association.  
EF-1α and NPM, proteins of the complex closely related to ribosomes, showed a pattern 
similar to MID1-FLAG. Before RNaseA treatment they were present in the lysate, and after 
treatment, they disappeared and, consequently, were not found in the ribosomal pellet (Figure 
3.20B). Other proteins like Hsc70 and ANXA2, while being present in the lysate after RNase 
treatment, they lost their association to the ribosomal pellet in the absence of RNA (Figure 
3.20B). As expected, neither RNaseA nor DNaseI treatment affected the sedimentation 





3.2.9 Characterisation of the association of MID1-FLAG with 
ribosomes 
Having shown that the MID1 complex associates with ribosomes in an RNA-dependent 
manner, a battery of different conditions were tested to further characterise this association. 
Thus, discontinuous sucrose gradients were run,  this time using a swing-out rotor in order to 
allow a more precise definition of the different phases.  
3.2.9.1 Salt and detergent treatments 
In order to analyse if the MID1 complex association to ribosomes is influenced by salt or 
detergent, cytoplasmic extracts of HeLa cells overexpressing MID1-FLAG were treated with 0.5 
mM KCl or 0.5% deoxycholate (DOC). Same fractions were studied as previously described on 
Western blots developed with anti-FLAG antibody. 
A B C
Figure 3.20. The MID1 complex requires RNA to associate with ribosomes 
Discontinuos 20%-50% sucrose gradients were run with cytosolic HeLa cell extracts after RNA
guard treatment (A) or treatment with RNase A (B) or DNAse I (C). The lysate and four different
fractions, corresponding to the top of the gradient, the interphase (20% layer), the bottom
(interface between 20% and 50%) and the ribosomal pellet, were tested on Western blots with









































































































































































































































 Again, without treatment, MID1-FLAG sediments with S3 in the ribosomal pellet (Figure 
3.21A). However, the better definition of the phases, due to a slower sedimentation process in 
the swing-out rotor, leads to a major retention of MID1-FLAG in the different fractions. After 
addition of 0.5% DOC (Figure 3.21B) or 500 mM KCl (Figure 3.21C) to the cytosolic extracts, 
most of MID-FLAG was washed off from the ribosomal pellet. Of note, KCl had stronger 
consequences than DOC.  
3.2.9.2 EDTA treatment 
For further characterisation, HeLa cell lysates were treated with EDTA, which destroys 
ribosome integrity, and compared to detergent treatment. In contrast to S3, which as an integral 
component of the small ribosomal subunit remained in the ribosomal pellet, EDTA presence 
lead to dissociation of MID1-FLAG from the ribosomes (Figure 3.22). This indicates that active 
ribosomes are necessary for association with MID1-FLAG. 
 
Figure 3.21. Characterisation of MID1 complex association with ribosomes 
The lysate (left lanes) and four different fractions of a 20%-50% discontinous sucrose 
gradient were loaded (left lane). Top: upper part of the gradient containing the lysate; 
Interphase: 20% sucrose layer; Bottom: interface between 20% and 50%. 
Results without treatment (A), with 0.5% DOC (B) and 500 mM KCl (C) are shown, from left 






















































































































































3.2.9.3 Puromycin and cycloheximide treatments 
   Finally, effects of puromycin compared to cycloheximide were likewise examined. While 
puromycin provokes the disassembly of the ribosomes from RNA leading to disruption of 
polyribosomes, cycloheximide stops translation by blocking polyribosome run-off. Same 
experiments as before were done but, in order to reduce complexity, only the interphase, the 
lysate and the ribosomal pellet were examined. 
As predicted, cyclohexidime treatment preserved the association of MID1-FLAG with the 
ribosomal fraction (Figure 3.23). In contrast, puromycin caused dissociation, indicating that the 
MID1 complex associates with active polyribosomes and that their disruption leads to MID1 
dissociation from the ribosomal fraction.  
Figure 3.22. EDTA effect on ribosome association of the MID1 complex 
The lysate (left lanes), and four different fractions of a 20%-50% discontinous sucrose
gradient are shown. Top: upper part of the gradient containing the lysate; Interphase:
20% sucrose layer; Bottom: interface between 20% and 50%. Western blots were
probed with anti-FLAG (upper lane) and anti-S3 (lower lane) 





































































































The lysate (left lane), the interphase and
the ribosomal pellet fractions of a 20%-
50% sucrose gradient are shown.
Western blots were probed with anti-
FLAG (upper lane) and anti-S3 (lower
lane). Left panel shows the effects of


















































































































3.2.10. Endogenous MID1 and other components of the complex 
associate with ribosomes 
Having established MID1-FLAG association with ribosomes, the endogenous situation 
was analysed and this time, additional members of the MID1 complex were included in the 
study. Same procedure as before with a swing-out rotor, and KCl and DOC treatments, was 
followed, but this time HeLa cell extracts did not contain MID1-FLAG.  
As shown in Figure 3.24, endogenous MID1 associates with ribosomes (tracked by the 
presence of S3) similar to overexpressed MID1-FLAG (Figure 3.24) and, accordingly, DOC and 
KCl  (Figure 3.24, middle and right panels) washed off the protein from ribosomes, with KCl 
exhibiting a stronger influence. Interestingly, not all the complex components showed the same 
sedimentation properties in the gradient after salt and detergent treatment. While Hsp90 was 
washed off from the ribosomes with KCl, and partly with DOC, Hsc70 sedimentation properties 
were not affected under any of the experimental conditions tested. Some other members of the 
complex such as NPM and RACK1 are closely related to ribosomes and, as expected, their 
association with the ribosomal fraction was not affected with any of the treatments (Figure 3.24). 
Figure 3.24. Endogenous situation 
The lysate (left lane) and four different fractions of a 20%-50% discontinous sucrose gradient
were loaded on a 10 % SDS-gel and probed on Western blots with different antibodies. Top:
upper part of the gradient containing the lysate; Interphase: 20% sucrose layer; Bottom:
interface between 20% and 50%. 
The effects of adding 0.5% DOC or KCL are shown compared to the situation without treatment











































































































































3.2.11 MID1 associates with polyribosomes 
In section 3.2.9, it was shown that disruption of polyribosomes with puromycin or 
disassembly of ribosomal subunits with EDTA leads to dissociation of MID1 from the ribosomal 
fraction, suggesting that the MID1 complex associates not only with active ribosomes but also 
with active polyribosomes. To verify this, HeLa extracts were run through a continuous 15%-
45% sucrose gradient in an SW40 swing-out rotor. Fractions were collected while measuring 
RNA absorbance at 254 nm, indicative of ribosomes or polyribosomes presence, precipitated, 
and analysed by Western blots incubated with anti-MID1 and with anti-S3, as a ribosomal 
marker. 
The first peak of the chromatogram (Figure 3.25A) from the left corresponds to the top of 
the gradient, which contains the lightest ribosomal subunit, 40S. The next big peak corresponds 
to the entire ribosome, 80S. The big subunit, 60S, is found overlapping with 80S as a little 
deviation of the peak to the left. The last fractions of the gradient contain polyribosomes; at least 
eight peaks corresponding to different amounts of associated ribosomal monomers are 
observed. 
S3 was again used as a ribosomal marker. Co-sedimentation of the two proteins, MID1 
and S3 throughout in all fractions of the gradient could be observed (Figure 3.25), confirming 
that MID1 had gone through the entire gradient (Figure 3.25). Consequently, it could be 
demonstrated that the MID1 complex associates with active polyribosomes and forms a big 




3.2.12 MID1 associates with homoribopolymers 
Knowing that the MID1 complex associates with ribosomes in an RNA dependent manner 
(section 3.2.8) and that some members of the complex, such as ANXA2, bind directly to RNA 
(Filipenko et al., 2004), a possible direct interaction between the MID1 complex and RNA was 
studied. 
 A classic way to assay RNA binding properties of a protein is to test it for interaction with 
homoribopolymers. Some to date well-established RNA binding proteins like Fragile mental 
retardation protein (FMRP), ANXA2 or poly(A)-binding protein have been thereby characterised 
(Brown et al., 1998; Burd et al., 1991; Filipenko et al., 2004). Likewise, the MID1 protein 
complex was analysed for RNA binding properties. Following standard procedures, cytosolic 
HeLa cell extracts overexpressing MID1-FLAG were incubated with homoribopolymers - rU, rG, 
rA and rC. After extensive washing, bound proteins were boiled off and analysed on Western 
blots with a panel of antibodies detecting the respective proteins of the complex. Incubation of 
the membrane with anti-HuR antibody, a protein known to interact with U-rich stretches (Lopez 
de Silanes et al., 2004), was used as control to confirm the specificity of the reaction. 
A254 
Figure 3.25. Sucrose gradient 
A. Chromatogram showing absorbance of the sucrose gradient at 254 nm. Fractions
containing 40S ribosomal subunits, 80S ribosomes and polyribosomes are indicated. B.
Western blot of the different fractions developed with anti-MID1 antibody. Anti-S3 was











Specific bands corresponding to FLAG-MID1, Hsp90, Hsc70, EF-1α and RACK1 were 
detected in the rG-homopolymer- (Figure 3.26) and, although much weaker, in the rU-
homopolymer sample. As expected, HuR showed a stronger binding to poly-rU 
homoribopolymers, confirming the specificity of the interaction. 
3.2.13 Characterisation of the Poly-rG-MID1 binding 
 In order to characterise the interaction of the MID1 complex with poly-rG, a series of 
different experimental conditions was tested. Increasing amounts of NaCl and heparin were 
used to check the resistance of the interaction to ionic forces. Competition assays by increasing 
amounts of free poly-rG and free poly-rU were also performed. 
Although much weaker compared to the non-treated control, MID1-FLAG could still 
associate to poly-rG in the presence of 250 mM NaCl and 1 mg/ml heparin (Figure 3.27A), 
increasing NaCl concentration up to 500 mM and heparin up to 2 mg/ml destroyed almost the 
entire interaction.  
Competition experiments with free poly-rG and polyrU confirmed the specificity of the 
reaction between the MID1 complex and immobilized homopolymers. As shown in Figure 
3.27B, addition of free poly-rG or free poly-rU 1:1 already produced a notable decrease of the 
interaction with agarose bound poly-rG.  The addition of free homoribopolymers 1:10 led to 
almost total disruption of the association on the MID1 complex to bound poly-rG. 
Figure 3.26. The MID1 complex associates with homoribopolymers 
HeLa cell cytosolic extracts were incubated with poly-rU,-rG,-rC and –rA
homoribopolymers. Western blots of the bound proteins incubated with the indicated



















































In order to test if the zinc-binding protein domains of MID1, RING and/or Bboxes, are 
involved in the association of the protein complex with RNA, cell extracts of HeLa cells 
overexpressing MID1-FLAG, FLAG-tagged constructs lacking Bbox1 or Bbox2 and GFP-tagged 
constructs with MID1 lacking either the RING-finger domain or the RING-finger and both 
Bboxes were incubated with poly-rG homoribopolymers. As described above, after extensive 























































































Figure 3.27. RNA binding properties of MID1 
A. Influence of increasing concentrations of NaCl and heparin on the association of MID1
complex with poly-rG. B. Competition experiments with increasing amounts of free poly-rG.
The ratio given is bound:free poly-rG. In both cases, bound proteins were boiled off and the
presence of MID1-FLAG was confirmed on Western blots incubated with anti-FLAG
antibody. 
Figure 3.28. MID1 direct interaction with RNA  
Pull-down experiments with poly-rG and HeLa cell extracts overexpressing different MID1
consruct. Western blots of lysates and poly-rG pull-downs were incubated with anti-FLAG or
































































































All mutant MID1 proteins associated with poly-rG stretches, (Figure 3.28), showing that 
neither the RING-finger nor the Bboxes are directly involved in the association of the MID1 
complex with RNA. 
3.2.14 MID1 complex binds ephrin mRNA via G-quartet structures 
In order to get an idea of specific mRNAs that might be associated to the MID1 complex 
described, a candidate strategy applying phenotype and protein function comparisons was 
used. As outlined earlier, patients with craniofrontonasal dysplasia present with mutations in the 
ephrin-B1 gene (EFNB1), a member of the ephrin family of proteins (Twigg et al., 2004; Wieland 
et al., 2004). The phenotype of this patients highly resembles facial features of patients with OS. 
The remarkable phenotypic overlap of the two syndromes, plus a functional overlap of ephrins 
and MID1 during NCC migration, makes ephrins attractive candidates to be related to the 
MID1/α4 complex. Specifically, as the MID1/α4 complex might play a role in localising RNAs to 
distinct subcompartments of the cell, it is reasonable to consider the mRNAs of Eph receptor 
and ligand genes as potential targets of this complex. Given that the MID1 protein complex had 
been shown to bind poly-rG, EphB receptor and ephrin-B mRNAs were screened for the 
presence of G-quartets, which are G-rich motifs that were first described in mRNA targets of the 
fragile X mental retardation protein (FMRP) complex and that have been shown to be 
responsible for RNA localisation. Based on G-quartet sequences described in the literature 
(Brown et al., 2001; Darnell et al., 2001; Ramos et al., 2003) combined with re-analysis of 
known target genes of FMRP (Brown et al., 2001; Kaytor and Orr, 2001), a consensus 
sequence for the prediction of G-quartet structures was extracted (Figure 3.29A). Based on 
Bioperl regular expressions, an algorithm for the prediction of such mRNA structures was made 
in collaboration with the bioinformatics department at Max Planck Institute for Molecular 
Genetics (http://genereg.molgen.mpg.de/cgi-bin/regEchse/regEchse.pl). Following this 
algorithm, EphB receptor and ephrin-B mRNAs, as well as the 3´and 5´UTR of all genes 




In two ephrins, six G-quartet like structures were identified, EFNB1a-d and EFNB2a, b 
(Figure 3.29B). To note, in EFNB1, the gene mutated in patients with craniofrontonasal 
dysplasia, four G-quartet like structures were spotted. Moreover, nine different G-quartet like 
structures were found in five different Eph receptors, EPBH1, EPBH2a,b, EPBH3a-c, EPBH4 
and EPHB6a,b (Figure 3.29B). Interestingly, while one or more G-quartets were found in either 
the 5´or 3´ UTR in 22% of all genes from the ENSEMBL database, only 1,33% of the analysed 
genes contained more than three G-quartets (Table2).  
Table 3.2. G-quartet predictions 
Number of 3’ or 5’ UTRs containing varying numbers (1, 2, 3 or >3) of G-quartet structures from a set of 
30686 genes available in ENSEMBL. 
a-TGG{A}   AGG{C}  AGG{GC} TGG at position 2071
b-TGG{GGTA}AGG{GGC} AGG{CC} AGG at position 2388
c-TGG{GGGG}TGG{AGGG}AGG{TG} AGG at position 2673
d-TGG{GC}  TGG{GGCC}TGG{AAAG}AGG at position 2911
a-AGG{GAG} TGG{GGC} TGG{GGAA}AGG at position 1745
b-TGG{GAA} AGG{AAC} AGG{CT}  TGG at position 2005
a-AGG{GAAA}AGG{ACC} AGG{GTCA}AGG at position 3203
a-AGG{G}   TGG{GAAG}AGG{TGAG}TGG at position 140
b-TGG{TCAC}AGG{G}  TGG{TTT} TGG at position 3806
a-TGG{G}  TGG{GAAG}AGG{TGAG}TGG at position 616
b-AGG{TCC} TGG{C}  AGG{GTC} AGG at position 3745
c-AGG{GC} AGG{C}   AGG{GGC} AGG at position 3986
a-TGG{GTG} TGG{TCC} TGG{TCC} TGG at position 1724
a-AGG{G} TGG{CTGT}TGG{AGGA}AGG at position 5 









Figure 3.29. G-quartets in ephrin genes 
A. Consensus sequence for the prediction of G-quartets B. G-quartet motifs identified in five
Eph receptor and two ephrin mRNAs 
A
B
Number of G-quartet motifs 1 2 3 >3 Total found
3' UTR 3053 1128 443 357 4981
5' UTR 1342 235 66 51 1694




3.2.15 Binding of the G-quartets to the MID1 Complex 
Subsequent to identification of G-quartet like structures in the ephrin genes, it was tested 
whether these structures indeed associate with the MID1 complex. Some of the identified G-
quartet motifs were PCR amplified with primers including the T7 promotor sequence at the 5´ 
end. Primer sequences were chosen such that approximately fifty base pairs were flanking both 
ends of the G-quartet in order to allow proper folding of the structure. Obtained PCR products 
were purified and in vitro transcribed in the presence of biotinylated-UTP. Subsequently, the 
transcripts were incubated with cytosolic extracts of HeLa cells overexpressing MID1-FLAG. 
Biotin transcripts were pulled down with streptavidin coated magnetic beads, and extensively 
washed. Bound proteins were finally boiled off and checked on Western blots that were probed 
with anti-FLAG antibody (Figure 3.30).  
All four G-quartets of EFNB1 (EFNB1a-d), EFNB2a and motifs of several Eph receptors 
(EPBH6a, b, EPBH3c, EPBH2b and EPBH1) were tested for MID1 complex interaction (Figure 
3.30). While most of them were confirmed to associate with MID1-FLAG (Figure 3.30), two of 
them, EPBH4 and EPBH6a, did not show association with MID1-FLAG. The specificity of the 
reaction could be further confirmed by controls done with the antisense sequence of one of the 
motifs, EFNB1b, or with a sample that did not contain RNA. 
Posterior incubation of the blots with different antibodies allowed the study of other 
member of the complex. Thus, incubation with anti-EF-1α, anti-NPM, anti-S3 and anti-RACK1 
showed association of all of them to the G-quartets tested (Figure 3.31). Hsp90, a weaker 
interaction partner of the complex, and ANXA2, the RNA association of which has been 
described to be Ca2+ dependent, showed only background binding. Lysates were loaded to 
confirm the presence of all proteins. 
Figure 3.30. MID1 association with G-quartet structures in ephrin genes 
PCR amplified, in-vitro transcribed and biotinylated G-quartet sequences were incubated with
MID1-FLAG overexpressing HeLa cells lysates. Bound proteins were boiled off and the
presence of MID1-FLAG was confirmed on Western blots incubated with anti-FLAG antibody.











































































































































































































































































One of the motifs, EFNB1b, was further characterised by studying the effect of salt on the 
interaction of G-quartets with MID1-FLAG. Same experiment as before was done but in the 
solution increasing amounts of salt were added (100-500 mM). A Western blot of the bound 
proteins probed with anti-FLAG antibody shows decrease in the EFNB1b-MID1 association with 
increasing amounts of salt, probing the specificity of the interaction (Figure 3.32). 
 
3.2.16 MID1 complex associates with EFNB1 mRNA 
Finally, it was studied whether the MID1 complex associates with the entire mRNA of 
EFNB1, including the G-quartet containing 3´UTR. In addition, biotinylated transcripts containing 
none, one (+1Gq), two (+2Gq), three (+3Gq) or all four G-quartets (+4Gq) (Figure 3.33A) were 
analysed. Two antisense transcripts containing three (+3GqAS) and four (antisense) G-quartets 
(+4GqAS) and a sample without RNA were used as negative control. 
Biotinylated transcripts were incubated with extracts of HeLa cells overexpressing MID1-
FLAG and subsequently pulled down with streptavidin-coated beads. After washing, bound 
Figure 3.32. Influence of salt in EFNB1b-MID1
interaction. 
HeLa cytosolic cell lysates with increasing
amounts of NaCl were incubated with
biotinylated-EFNB1b and pulled down with
streptavidin coated beads. Bound proteins were
analysed by Western blot with an anti-FLAG







































Figure 3.31. Association of components of the MID1 complex with G-quartets 
The presence of different members of the complex in the elution fractions from the previous
































































































































proteins were boiled off, and the presence of MID1-FLAG was tested by Western blot analysis 
with anti-FLAG antibody. As shown in Figure 3.33B, MID1-FLAG associated with G-quartet 
containing transcripts in an additive manner; that is, the probe having a single G-quartet present 
almost no association to MID1, and the binding increased with increasing numbers of G-
quartets. Maximal binding was obtained in the sample with four G-quartets. As expected, the 
probe without the 3´UTR did not bind to the MID1 complex, similarly to the sample without RNA. 
None of the antisense transcripts, which corresponded to the longest probes, showed any 
binding to the MID1 complex. This demonstrated that the reason for the additive effect is not the 




Figure 3.33. EFNB1 mRNA associates with the MID1 complex 
A. Biotinylated transcripts used in the experiment. B. Association of MID1 with EFNB1
mRNA including increasing numbers of G-quartets. Biotinylated transcripts were incubated
with extracts of HeLa cells overexpressing MID1-FLAG and subsequently pulled down with
streptavidin coated magnetic beads. Bound proteins were boiled off and the presence of





























































































The RBCC protein MID1, which is involved in ventral midline development, has been 
shown to form a macromolecular cellular complex, whose components were, up to now, mainly 
unknown. Several domains of the MID1 protein are putative protein–protein interaction domains 
that potentially contribute to the formation of this complex. However, apart from their 
participation in protein binding, no other function could be assigned to them so far. In order to 
shed light on the functions exerted by some of the domains of MID1, both Bboxes were 
characterised during this thesis. These studies allowed the identification of a novel 
pathomechanism for the development of OS.  
In addition, after identifying the MID1 complex partners via affinity chromatography and 
mass spectrometry (MS), the MID1 protein was characterised as the core of a novel translation 
unit that associates with microtubules. Therefore a new panel of functions for the MID1 protein 
was introduced. 
4.1 A novel pathomechanism for OS caused by mutations 
in the Bboxes domains of MID1 
In a broader context, Bboxes have been shown to play an important role for the correct 
positioning of RBCC proteins within the cell and to participate in protein-protein interactions 
(Cao et al., 1997; Reymond et al., 2001). Determining the solution structure of the Bbox of 
XNF7 in Xenopus revealed a novel zinc-binding fold; however, no functional clues could be 
deduced from this structure. In this thesis, the basic functions Bbox1 and Bbox2 of the RBCC 
protein MID1 were elucidated and, in addition, the dependence of Bbox1 function on an intact 
Bbox2 in vivo was described.  
Recently, we showed that the microtubule-associated MID1 protein targets the pool of 
microtubule-associated PP2A towards ubiquitin specific modification and degradation. This can 
only be achieved after bringing the catalytic subunit of PP2A into close proximity to the MID1 
RING finger domain via the α4 protein as adapter. MID1 mutations causing OS are mostly 
clustered in the C-terminal end of the protein and lead to disruption of microtubule-association 
of MID1, which then forms clumps in the cytosol and, therefore, leads to accumulation of PP2Ac 
at the microtubules. We could further show that the binding of α4 takes place through the Bbox1 
of MID1 and that the cytoplasmic clumps consisting of C-terminally mutant MID1 harbour, in 





 In this thesis, two novel mutations in the Bbox1 region of MID1, namely A130T and 
C145S, both causing full-blown OS were described. Several lines of evidence indicate that 
these mutations specifically compromise the protein-protein interaction interface between MID1 
and α4 without producing major changes in the overall structure of MID1. Mutations in the 
Bbox1 domain of MID1 seem not to disturb the structure of the entire protein, which can still 
perfectly bind to microtubules. In addition, circular dichroism (CD) spectra of intact and A130T 
mutated Bbox1 have shown no significant differences in their overall structure (R. Schneider, 
unpublished data). However, when examining the interaction with α4, it becomes obvious that 
mutations in this domain generate a MID1 form that is unable to bind α4. Hence, while Bbox1 
mutated MID1 associates to microtubules, co-expressed α4 remains evenly distributed in the 
cell, can not be pulled down by MID1-immunoprecipitation and does not interact with MID1 in 
yeast two-hybrid experiments. Homology modelling of the MID1 Bbox1 structure based on the 
XNF7 structure shows that the respective leucine corresponding to A130 (Figure 4.1, 
underlined) is on the surface of Bbox1, intriguingly located at the bottom of a hydrophobic 
pocket (Borden et al., 1995b). This suggests that α4 might bind MID1 via this pocket, and that 
the exchange of the small hydrophobic alanine to the more bulky and slightly hydrophilic 
threonine could severely interfere with correct high binding affinity between α4 and MID1. On 
the other hand, using the same XNF7 model, residue C145 would participate in zinc binding. 
Since the ability to bind zinc is critical to maintain a native 3D structure of a protein, an 
exchange of the excellent metal ligand cysteine into a serine, would hinder the interaction 
between α4 and MID1. This change probably interferes with the correct folding of the domain 
and presentation of the hydrophobic core to α4, despite not having major apparent effects on 
the structure of the entire MID1, as it appears intact in immunofluorescence experiments. 
Figure 4.1. Homology with XNF7 Bbox 
Comparison of Bbox1- and Bbox2-MID1 sequences with Bbox-XNF7 sequence. Conserved
cysteines and histidines including their positions are indicated in bold. A130 in Bbox1 is
underlined. Zinc binding residues are indicated in red (Borden et al., 1995b). C139 and
corresponding aspartic acid are indicated in blue. 
C119QFC122DQDPAQDAVTKC137VTCEVSYC142DEC145LKAT  H150PNKKPFTGH158
C6 SEH9                     DERLKLYC17 KDDGTLSC25    VI C28 RDSL  H34   ASH37 
MID1-Bbox1
XN F7-Bbox




Although yeast two-hybrid experiments with MID1 deletion constructs clearly indicated 
that exclusively Bbox1 is responsible for the binding to α4 (Trockenbacher et al., 2001), further 
analysis of Bbox2 mutations revealed that there is a clear regulatory influence of the Bbox2 on 
the interaction between α4 and MID1 in vivo. During this thesis, the study of a MID1-Bbox2 
mutation (C195F), which has been found in an OS patient and affects a conserved residue 
(Figure 4.1), by immunofluorescence showed loss of MID1 colocalisation with microtubules and 
complete failure to bind α4 in vivo. However, immunoprecipitation and yeast two-hybrid 
experiments showed that α4-binding in vitro remains intact, which points at specific intracellular 
conditions that are mediated by the Bbox2 and are disturbed by this mutation.  
Interestingly, when the study was extended to different engineered mutations, it was 
observed that the influence of Bbox2 mutations on in vivo binding abilities of MID1 change with 
the character of the particular mutation. While mutations disturbing conserved amino acids 
(Figure 4.1, amino acids in bold) hamper MID1 association with microtubules and α4, mutations 
affecting non-conserved amino acids only disrupt MID1 interaction with α4. These differences 
can probably be explained by more severe effects that some amino acid exchanges have on the 
global structure of the protein.  
Most of the conserved residues included in this study, apart from being conserved, were 
supposed to participate in zinc binding, as predicted by comparative analysis with the XNF7 
Bbox (C175, H178 and C198, marked in red in Figure 4.1). In C175A, H178Y or C198A mutated 
MID1, the unfair trade of a metal ligand residue, such as cysteine or histidine, for a residue 
unable to bind metal atoms, such as alanine or tyrosine, is likely to affect the correct stability 
and folding of the domain. Consequently, the disturbance of the overall structure of MID1 due to 
mutations in these residues denotes that intact zinc-binding plays a highly important role in the 
in vivo function of the Bbox2, as it appears not only to regulate α4-MID1 interaction, but also to 
influence the correct folding and positioning of the entire protein.  
Nevertheless, the C195F mutation, despite not affecting a known zinc-binding site in 
Bbox2 residue, had similar drastic consequences as the above described mutations. It has been 
previously suggested that the conserved region between this cysteine and C187, which forms a 
flexible loop, composes another divalent metal binding site that involves interaction with another 
domain (Borden, 1998; Borden et al., 1995b). Given that the Bbox1 also contains some 
unligated putative metal ligands, such as C134, C139 or C142, it could well be that both 
domains cooperate to bind a zinc ion (Figure 4.1). Such an arrangement would also explain the 
strong influence that mutations in the Bbox2 domain exert on Bbox1 protein binding.  
Mutations affecting non conserved residues on the other hand, such as Q192R or V183T, 
only affect the interaction of MID1 with α4 but not with the microtubules, which is another 




importance of an intact Bbox2 for the proper functioning of Bbox1, even when the protein is 
correctly folded and positioned.  
Interestingly, mutations in a zinc-binding ligand in Bbox1, such as C145S, seem not to 
have similar drastic consequences on the global structure of the entire MID1. This might be due 
to an extra cysteine at position 139 of Bbox1 that has also been proposed to participate in zinc 
binding (Borden et al., 1995b; Reymond et al., 2001). This cysteine is commonly conserved in 
Bbox1 domains along RBCC proteins, while the Bbox2 and the XNF7-Bbox have a conserved 
aspartic acid at that position (Figure 4.1, blue residues). Therefore, this residue could further 
stabilise the structure of this domain, and of the entire protein (Borden et al., 1995b), and would 
keep effects of a C145 mutation mild.  
In summary, during this thesis it could be shown that the Bbox2 domain acts as a flexible 
regulatory junction that provides the different domains of MID1 with their proper relative 
disposition, thus linking different components necessary for the MID1-ubiquitin ligase function. 
This would explain why in vitro experiments, which do not present the steric effects encountered 
in an in vivo system, allow the interaction of MID1 constructs having an intact α4-binding 
interface in Bbox1, despite having mutations in Bbox2. Further, they describe a novel 
Figure 4.2. Pathomechanism model  
After displacement of A and B subunits, microtubule-associated PP2Ac binds to the B-Box1 of
MID1 via the α4 linker protein. In this conformation, microtubule-associated PP2Ac becomes
ubiquitinated through MID1-E3 ubiquitin-ligase function and is degraded by the proteasome (left
model-wild-type). Mutations in either the Bbox1 or the Bbox2 lead to a loss of MID1/α4/ PP2A
interaction (right drawing- Bbox1/Bbox2 mutated MID1). Ubiquitination and degradation of PP2Ac
is no longer possible and PP2Ac enriches at the microtbules. Two arrows indicate the parts of
MID1 influenced by Bbox2 (adapted from Schweiger and Schneider, 2003).  
B-box1














































pathomechanism for the development of Opitz BBB/G syndrome in patients with mutations in 
either the Bbox1 or the Bbox2 (Figure 4.2). In both cases, loss of interaction with α4 seems to 
be crucial, fact that once again underlines the importance of this protein as a linker between 
PP2Ac and the ubiquitin ligase MID1 (Schweiger and Schneider, 2003; Trockenbacher et al., 
2001).  
4.2 The MID1 multiprotein complex 
4.2.1 MID1 forms part of a ribonucleoprotein complex  
In addition to its previously identified association with tubulin (Schweiger et al., 1999), 
during this thesis it was found by affinity chromatography and MS, and subsequently verified by 
immunoprecipitation, that the MID1 complex includes several ribosomal proteins of the small 
subunit (S3, S8). Several other proteins that are also closely related to ribosome function 
namely EF-1α, NPM, RACK1 and p40, were found as well (Filipenko et al., 2004; Ford et al., 
1999; Nilsson et al., 2004; Okuwaki et al., 2002; Tarapore et al., 2006; Vedeler and Hollas, 
2000) in the protein complex. ANXA2 was also identified within the MID1 complex, fact that 
further supports a role for the MID1 complex at the ribosome (Filipenko et al., 2004; Vedeler 
and Hollas, 2000). Moreover, several heat shock proteins, Hsp90, Hsc70 and Hsc60 were 
identified in the complex, together with another multifunctional chaperone protein, p32 (Storz et 
al., 2000). Among these heat shock proteins, special attention should be drawn to Hsp90. 
Besides assisting protein folding, and in contrast to other heat shock proteins, Hsp90 is known 
for having many different substrates or “clients” and facilitating their functions (Richter and 
Buchner, 2001). Interestingly, it has been shown this year that Hsp90 also regulates ribosomal 
function by protecting several ribosomal proteins including S3 (novel component of the MID1 
complex) and S6 (a downstream factor of the TOR pathway, to which the MID1 complex is 
related (Schweiger and Schneider, 2003)), from ubiquitination and proteasome dependent 
degradation, thereby regulating their stability and activity (Kim et al., 2006). 
Association of MID1 complex with the big ribosomal subunit, 60S, was confirmed by 
immunoprecipitation experiments. Following, MID1 complex association with the entire 
ribosome was confirmed and characterised by discontinuous sucrose gradients. Different 
experimental conditions demonstrated it to be a stable association, which was only disrupted by 
high concentrations of salt or by substances that cause ribosomal disruption, such as EDTA or 
puromycin. Some other members of the complex such as RACK1 or NPM (Nilsson et al., 2004; 
Okuwaki et al., 2002), which are known to be more closely related to ribosomes, remained 
bound under all conditions tested. However, although an interaction of the MID1 complex with 
ribosomes could be demonstrated, it remains unclear whether MID1 itself associates directly or 




Similar to other well-characterised proteins forming RNPs, such as FMRP (Tamanini et 
al., 1996), RNase A treatment prior to gradient loading demonstrated that the association of the 
MID1 complex with ribosomes is RNA-dependent. In addition, association of the complex to 
poly-rG ribopolymers and G-quartet like RNA structures in Eph receptor and ephrin mRNAs 
could be proven in this thesis. Since direct association of MID1 through its zinc-binding domains 
with RNA could not be confirmed and MID1 does not contain any of the known RNA binding 
domain, MID1 most probably incorporates RNA into the complex through any of the RNA-
binding proteins of the complex or through an RNA helicase that has been found previously to 
interact with MID1 in a yeast two-hybrid screen (R. Schneider, unpublished data). 
4.2.2 The components of the MID1 complex associate with 
microtubules 
In agreement with MID1 association with microtubules (Schweiger et al., 1999), most of 
the novel members of the MID1 complex could be found in microtubule fractions, pointing to an 
important function of the complex exerted at the microtubules. Supporting this hypothesis, the 
majority of the proteins identified in the MID1 complex have previously been reported to 
associate with microtubules. Thus, EF-1α, one of the most abundant proteins, has been 
reported to participate in the compartmentalisation of protein translation at the cytoskeleton 
(Condeelis, 1995). In addition, it has been shown to be a microtubule-associated protein that 
binds, stabilises and promotes assembly of microtubules in vitro, independently of its role in 
protein translation (Moore and Cyr, 2000; Moore et al., 1998; Ohta et al., 1990; Shiina et al., 
1994).  
Hsp90, another abundant cytosolic protein, and several Hsc70 homologues have also 
been found to localise at microtubules (Czar et al., 1996; Liang and MacRae, 1997). Since 
some of its clients need to be transported in the cell as a prerequisite to carry out their function, 
Hsp90 has been proposed to participate in microtubule-based movements (Craig et al., 1994). 
Moreover, it has been shown to be a component of the main microtubule organizing centre 
(MOTC), the centrosome, ensuring its correct functioning, including microtubules nucleation and 
centrosome duplication (de Carcer, 2004; de Carcer et al., 2001; Doxsey, 2001; Lange et al., 
2000). Similarly, NPM has been found to participate in centrosome duplication upon 
phosphorylation by CDK2/cyclin E on Thr199 (Okuda, 2002; Tokuyama et al., 2001). In addition, 
it participates in a variety of mitotic processes, upon phosphorylation of Ser4 through polo-like 
kinase1 (Plk1), the major mitotic regulator kinase (de Carcer, 2004; Zhang et al., 2004). 
ANXA2 and RACK1 have also been shown to exert some of their functions in 
collaboration with the cytoskeleton. ANXA2 is the most abundant protein in fractions containing 
cytoskeleton-bound polysomes (Vedeler and Hollas, 2000), and RACK1 was found to reside in 




The fact that many of the proteins identified in the MID1 complex have previously been 
localized to microtubules, in addition to their ribosomal function, appears to be of outstanding 
significance for the putative function of the complex. This implies that the MID1 complex, 
including PP2A and α4, could well be the core of a microtubule-associated translation unit that 
carries active polysomes and RNA. 
4.2.3 The MID1 complex and its role in translation at the 
microtubules 
RNPs are often described as functional venues that carry pre-mRNAs and mRNAs in the 
cell. Proteins participating in these complexes mostly exercise functions on mRNA export, 
localisation, translation and stability. At the same time, contained mRNAs need to have mRNA 
localisation signals, which are commonly situated in the 3´UTR, where they are the least likely 
to interfere with any other function. In addition, RNPs are highly dynamic complexes, in which 
their components, usually fulfilling a large variety of functions, come and go, responding to the 
necessities of the complex at a given moment (reviewed in Dreyfuss et al., 2002; Mohr and 
Richter, 2001; St Johnston, 2005). A central function of RNPs is the active transport along the 
cytoskeleton in order to ensure asymmetric mRNA localisation in the cell. Some of the best-
studied systems in which asymmetric RNA localisation has been reported to be fundamental are 
oocyte polarisation, embryonic axis formation (Bashirullah et al., 1998; Driever and Nusslein-
Volhard, 1988; Lasko, 1999; Lehmann and Nusslein-Volhard, 1986), and local protein synthesis 
in dendrites and growth cones (Steward and Schuman, 2003; Steward and Worley, 2001).  
FMRP, mutated in patients with Fragile X syndrome (FXS, one of the most frequent 
causes of mental retardation), is a well-established example of an RNP in charge of translation 
and mRNA transport along the cytoskeleton in neurons (Antar et al., 2004; Bagni and 
Greenough, 2005; Zalfa and Bagni, 2005). A subset of brain mRNAs, including EF-1α (Sung et 
al., 2003), has been identified to associate with FMRP-containing RNPs (Brown et al., 1998; 
Sung et al., 2000; Zalfa et al., 2003). In addition, its association with polyribosomes and 
subsequent link with translation has also repeatedly been reported (Ceman et al., 1999; Feng et 
al., 1997; Tamanini et al., 1996; Zalfa and Bagni, 2005).  
Another RNA-binding protein, Staufen, also forms an RNP complex with transport-cargo 
properties along the cytoskeleton. It has been in-depth studied for its role in mRNA trafficking 
and translation in Drosophila, where it plays an essential role in the localisation of oskar and 
bicoid mRNAs in the oocyte to the posterior and anterior poles respectively (Li et al., 1997; St 
Johnston, 2005). In mammals, the two homologues of Staufen, have also been shown to form 
RNPs, to associate with polyribosomes, and to participate in microtubule-dependent transport of 
RNA in neurons (Kanai et al., 2004; Kiebler et al., 1999; Tang et al., 2001b; Thomas et al., 




nucleolin, tubulin, protein phosphatase 1, HuR and RNA helicase A (Thomas et al., 2005; 
Villace et al., 2004), showing that mammalian Staufen is closely related to the previously 
described FMRP-RNP. 
After having characterised the MID1 complex, it is striking noticeable its properties 
resemble many of the characteristics required to be a RNP in charge of transport along 
microtubules, supporting a novel model for the function of the MID1 complex (Figure 4.3). 
Similar to FMRP and Staufen, the MID1 complex associates with polyribosomes, the translation 
related protein EF-1α, several multifunctional proteins, microtubules and RNA. Moreover, PP2A 
and its regulatory subunit, α4, are also main components of the complex, which integrate the 
MID1 complex into the TOR pathway, one of the main translation regulatory pathways 
(Schweiger and Schneider, 2003). However, MID1 has never been found in the nucleus, where 
the target mRNAs to be transported should be recruited, which suggests that any of the other 
members of the complex would bring the mRNAs from the nucleus to the microtubules. An 
attractive candidate would be NPM, which binds RNA, is involved in ribosome biogenesis, and 
has been shown to shuttle between the nucleus and the cytosol.  
A required motor protein, which would allow the movement of the MID1 complex along the 
microtubules remains to be identified.  
4.2.4 The MID1 complex and translational repression 
For the successful completion of mRNA localisation and compartmentalisation of protein 
production in the cell, the translation of the transported mRNAs needs to be repressed during 
transport and until their protein functions are required. Although little is known about the 
mechanisms governing translational repression during transport, some processes have been 
already described (St Johnston, 2005). 
For example, in Drosophila oocytes and early embryos, translation of the anteriorly 
localised bicoid mRNA transcripts is regulated by delayed cytoplasmic polyadenylation of the 
respective mRNAs, which formerly carry a very short poly(A) tail incompatible with efficient 
protein translation. A more complicated process that has been described for mRNAs localised 
to the posterior pole, such as oskar, involves the binding of the translation repressor Bruno to 
cis-elements in its 3´UTR while the transcript is being transported to the pole and, once there, 
Bruno falls off and translation is derepressed. However, in recent years, the role of RNA 
silencing in translational repression as a novel mechanism for translational repression has 
gained attention. At least two genes that encode components of the RNA silencing pathway, 
namely aubergine and armitage (involved in microtubule polarisation), have been implicated in 
the localisation of oskar transcripts (Kavi et al., 2005; Kloc and Etkin, 2005; Wilhelm and 
Smibert, 2005). Similar mechanisms for the regulation of translation have been attributed to the 




microRNAs (miRNA) that contain sequences complementary to FMRP target mRNAs and 
thereby, represses their translation (Jin et al., 2004a; Jin et al., 2004b; Zalfa et al., 2005). 
 During this thesis, it was described an interaction of a microtubule-associated translation 
unit with PP2A and its negative regulators α4 and MID1, all essential players of the mTOR 
pathway, that regulates the translation of selected capped and 5´TOP mRNAs (Duvel and 
Broach, 2004; Fingar and Blenis, 2004; Peterson et al., 1999). Selective up-regulation of PP2A 
activity at low MID1/α4 levels or activities during transport could therefore be another 
mechanism of translational inhibition in mRNPs (Figure 4.3). Interestingly, last year, it was 
reported that RACK1 mRNA contains a TOP motif and that its translation depends on a 
rapamycin-sensitive pathway, such as the mTOR pathway (Loreni et al., 2005). Since RACK1 is 
one of the complex components, this would suggest self-regulatory properties of the complex. 
Nevertheless, it would also be interesting to know whether the MID1 complex carries any 
miRNAs or ncRNA that could assist the complex in regulating the translation of transported 
Figure 4.3. MID1 complex translation at the microtubules 
Model of the MID1/α4/PP2A complex at the microtubules in association with ribosomes,
various other novel components, and RNA. 
EFNB1 mRNA associates to the complex via four G-quartets in its 3’UTR, is transported
along the microtubules and translated at the cell pole. 
















mRNAs. In addition, the identification of mRNAs carried by the complex will also shed light on 
how the MID1 complex regulates the translation of its target mRNAs. 
4.2.5 MID1 complex and development of the ventral midline 
development: implications in cell migration 
 As mentioned previously, improper function of the MID1 complex leads to X-linked OS, 
which is characterised by defective fusion of ventral midline structures, whose establishment 
heavily rely on polarised cells, including asymmetric distribution of signalling molecules and 
reorganization of the cytoskeleton. Two fundamental processes during midline development 
governed by this mechanism are NCC migration and EMT of epithelial cells (Jones and Trainor, 
2005; Roessler and Muenke, 2001; Schweiger and Schneider, 2003). Dysfunctional transport of 
mRNA along the microtubule in defective MID1-containing RNPs would, as suggested in this 
thesis, inhibit asymmetric protein production in cells involved in these processes and therefore, 
would form the molecular basis for an attractive model for the development of OS.  
Cell polarisation, adhesion and migration are fundamentally related processes that require 
the asymmetric concentration of cellular activities mediated by the cytoskeleton. Cell migration 
involves the formation of protrusions such as lammellipodia and filopodia at the leading edge of 
the cell, followed by nuclear translocation and retraction of the cell rear (Small and Kaverina, 
2005). During migration, adhesion to the extracellular matrix, commonly mediated by integrins, 
needs to be carefully regulated for the cell to move properly. The family of small Rho GTPases 
has an essential role in the regulation of adhesion formation and cytoskeleton reorganization. 
Although cell migration has often been described in terms of actin cytoskeleton reorganization, 
already in 1970 it was shown that also the disruption of microtubules in fibroblasts leads to 
disruption of cell polarity and arrest of direct locomotion (Vasiliev et al., 1970). However, how 
actin and microtubule cytoskeletons collaborate to provide correct migration is only starting to 
be understood (Kole et al., 2005). 
Microtubules are often discussed as cellular highways that transport signalling molecules 
to modulate the tension of the actin cytoskeleton and the disassembly of cell adhesions. They 
have been shown to meet actin at focal adhesions formed at the cell front and rear during 
migration and negatively regulate them by promoting their turnover or impeding their growth 
(Kaverina et al., 1999; Krylyshkina et al., 2003; Palazzo and Gundersen, 2002). In addition, 
active transport along the microtubules has been shown to be essential for cell migration; 
kinesin inhibition mimics the changes in cell polarisation and adhesion found during microtubule 
disruption with nocodazole (Kaverina et al., 1997; Krylyshkina et al., 2002). In addition, focal 
adhesions have microtubule-capturing and -stabilizing abilities that could help to prolong the 
communication of the microtubules with focal adhesions and thereby, allow the delivery of more 




Recently, novel adhesion structures have been defined, namely spreading initiation 
centres (SICs), which only appear in early stages of cell migration. Despite being highly similar 
to focal adhesions, they have been shown to also contain RNA, RNA-binding proteins and 
RACK1, one of the MID1/α4 interaction partners, supporting that asymmetric mRNA transport 
and compartmentalised protein translation of proteins is required for the formation of focal 
adhesions (de Hoog et al., 2004). In line, it has previously been shown that cytoskeleton 
dependent recruitment of mRNA and ribosomes to focal adhesions provides local synthesis of 
proteins in response to integrin-mediated signalling from the extracellular matrix and mechanical 
tension (Chicurel et al., 1998). According to these results, it has been proposed that not only 
molecular trafficking, but also translation, might be required in the early establishment of focal 
adhesions (Nilsson et al., 2004).  
Knowing that the MID1 protein bundles and stabilize microtubules, a critical step for the 
organization of the leading edge (Schweiger et al., 1999), and that the MID1 complex, which 
contains RNA-binding proteins, ribosomes, RNA and RACK1, participates in mRNA localisation 
via microtubules, it is very appealing to think that it could also participate in the transport of 
mRNAs required for the formation and regulation of early focal adhesions or SICs. Moreover, 
the MID1 complex contains some proteins, such as RACK1 or ANXA2, that also associate with 
the actin cytoskeleton; therefore, the complex might as well provide a link for the cross-talk 
communication between actin and microtubules. 
4.2.6 The MID1 complex components and their involvement in cell 
migration, polarisation and adhesion 
Apart from associating with SICs, RACK1 has previously been shown to be a scaffolding 
protein that participates in cell spreading, establishment of early focal adhesions and cell-cell 
contacts. To fulfil these functions, it recruits Src, STATs and PKCs, among others, and links 
them to integrin receptors upon activation by insulin-like growth factor I receptor (IGF-IR) 
signalling (Cox et al., 2003; Hermanto et al., 2002; Meares et al., 2004; Miller et al., 2004; Sklan 
et al., 2006; Zhang et al., 2006). As mentioned before, RACK1 has also been proposed to be 
involved in the localisation of translation by the recruitment of RNA and ribosomes to focal 
adhesions (Nilsson et al., 2004). In addition to RACK1, p32, another interaction partner of the 
MID1/α4 complex, bind atypical PKC isozymes (Sklan et al., 2006; Storz et al., 2000), which 
respond to integrin signalling and are central players in the regulation of cell spreading and focal 
adhesion assembly (Disatnik et al., 2002; Henrique and Schweisguth, 2003). Independent 
studies have also shown that activation of p32, in collaboration with integrins, induces cell 
adhesion and spreading in endothelial cells (Feng et al., 2002; Ghebrehiwet et al., 2003). 
Interestingly, p32 (also referred as to Hyaluronan binding protein 1, HABP1) interacts with 




mitosis or cell migration and, in combination with HA, p32 has been shown involved in the 
regulation of adhesion and de-adhesion (Sengupta et al., 2005). 
Another member of the complex that has been closely related to cell adhesion is p40, a 
conserved receptor of laminin. Laminin is a very abundant extracellular molecule in basal 
laminae synthesized in very early embryos or in epithelial cells (Ford et al., 1999). Curiously, 
p40 has always attracted attention for its dual function in cell adhesion and ribosomal assembly 
and maintenance. Recently, it has been found that midkine also binds to p40 thereby competing 
with laminin, and that this interaction leads to enhanced protein translation (Kazmin et al., 
2003). Interestingly, coming back to the mechanisms of ventral midline development, midkine is 
highly expressed in mouse NCC during development and plays an important role in cell 
migration (Mitsiadis et al., 2003; Mitsiadis et al., 1995; Qi et al., 2001). 
Also ANXA2, another complex partner, has been shown to participate in cell adhesion and 
migration. Thus, it rapidly localises to cell-cell contacts after IGF-RI stimulation (Meares et al., 
2004; Zhao et al., 2003), and has been suggested to be responsible for the initial recruitment of 
GTPase activity, that is essential for the formation of filopodia at the leading edge of migrating 
fibroblasts and epithelial cells (Balch and Dedman, 1997; Hansen et al., 2002; Nobes and Hall, 
1995). 
The importance of the microtubule-organizing centre, the centrosome, in cell polarisation 
and migration should also not be forgotten. The centrosome determines the direction of 
migration by placing itself in front of the nucleus, and projecting microtubules to the leading 
edge (Badano et al., 2005). After generation of the leading edge, and for the successful 
progression of migration, the nucleus must be translocated towards the front, a process that is 
highly governed by the centrosome. Alterations of this process have been linked to monogenic 
disorders. For instance, some mutations in lissencephaly gene 1 (LIS1) and doublecortin gene 
(DCX), the protein products of which localise to centrosomes, lead to defects in neural migration 
and microtubule dynamics. A connection between these proteins and the MID1 complex has 
been suggested previously since their phosphorylation status is regulated by microtubule-
associated PP2A activity (Schweiger and Schneider, 2003; Trockenbacher et al., 2001). 
Interestingly, two novel members of the MID1 complex, namely NPM and Hsp90, have been 
shown to also play key roles in centrosome function.  
In our group, we have observed that overexpression of α4 in HeLa or COS-7 cells results 
in the formation of filopodia to which α4 locate, indicating that it might play a role in the 
formation or regulation of filopodia. These protrusions are no longer observed when MID1 
recruits α4 to microtubules in non-polarised cells (Schweiger et al, unpublished data). Given 
that filopodia formation in the leading edge is essential for cell migration, further studies would 




where protrusions need to arise in polarised cells, and whether α4 indeed plays a role in 
filopodia formation or regulation. 
Last but not least, ephrin molecules (ligands and receptors), and specially ephrin-B1, the 
mRNAs of which were shown during this thesis to be associated to the MID1 complex, are also 
involved in cell migration and, in particular, in the migration of NCC. Apart from being known for 
having Rho family GTPases as the major downstream targets, which points at a central 
involvement in the formation of focal adhesions (see above), it has been shown that EphB-
ephrin-B engagement is a critical determinant of integrin-mediated responses (Huynh-Do et al., 
1999; Pasquale, 2005). In line, it has been shown that ephrin-B1 and EphB2 regulate the 
cytoarchitecture and spatial organization of kidney cells through Rho family GTPases, and that 
EphB activation promotes cell adhesion and induces focal adhesion enlargement (Ogawa et al., 
2006).  
In summary, most of the proteins that compose the MID1 complex have been reported to 
participate in cell adhesion, migration and local protein synthesis. Therefore, a concerted 
organization of their functions in the MID1 complex is an attractive model for the regulation of 
proper cell migration, polarisation, and adhesion, all essential processes for the correct 
development of the ventral midline. 
4.2.7 EphB and ephrin-B mRNAs can be integrated in the MID1 
complex 
As earlier outlined, Eph receptors and ephrins have key roles in the regulation of cell 
migration, polarisation and adhesion during development. Their functions, often described in the 
context of NCC pathfinding, heavily rely on the establishment of asymmetric gradients of their 
proteins in polarised cells (Pasquale, 2005; Poliakov et al., 2004; Robinson et al., 1997). This 
makes them particularly attractive mRNA candidates to be positioned in the cell via a 
mechanism involving mRNA transport along the microtubules.  
Within the frame of this study, it was demonstrated that the MID1 complex associates to 
G-quartet like structures mainly in the 3´UTRs of EphB receptor and ephrin-B mRNAs. G-
quartets were identified in two ephrins (B1 and B2) and five Eph receptor mRNAs (B1, B2, B3, 
B4, B6), indicating that probably only those ephrin molecules participate in functions exerted by 
the MID1 complex. However, it is not possible to exclude a role for the others in the MID1 
complex, which might contain another not-yet-targeted sequence in their mRNAs that also 
associates with the MID1 complex. Interestingly, it was possible to shown that the number of 
identified G-quartets varies among the ephrin molecules with up to four motifs identified in the 
EFNB1 mRNA, mutations of which lead to craniofrontonasal dysplasia (Wieland et al., 2004). 
While G-quartets were present in 22% of all genes available from the ESEMBL database, only 




further showed that increasing numbers of G-quartets in EFNB1 lead to an increase in protein 
binding affinity, which is not dependent on the length of the transcript. Consequently, the 
additive effect of the protein binding affinity seen with the EFNB1 mRNA combined with a 
systematic displacement of lower affinity binding mRNAs might be an effective mechanism for a 
highly specific inclusion of G-quartet containing mRNAs in the described mRNPs. 
As mentioned previously, the phenotypes of craniofrontonasal dysplasia syndrome and 
OS present striking overlaps, both of them being characterised by malformations of the facial 
ventral midline, such as hypertelorism/telecanthus or broad nasal bridge. This kind of 
malformation is most probably caused by defective cell migration and/or polarisation, and most 
likely affects NCC-migration and -orientation (Schweiger and Schneider, 2003; Wieland et al., 
2004). Interestingly, recently, it has been reported that cardiac and cranial NCCs, but not trunk 
NCCs, require EFNB1 to migrate properly during development in mice (Davy et al., 2004). 
Moreover, these NCCs require EFNB1 autonomously and non-autonomously to properly 
complete craniofacial development, especially during palate elevation and fusion, an important 
process disrupted in many patients with OS and craniofrontonasal dysplasia. Furthermore, it 
has been shown that ephrin-B1, in addition to other EphB receptors and B-class ligands, 
participates in regulating the formation of the corpus callosum (Mendes et al., 2006), which also 
presents with defects in some OS patients. Given that EFNB1 is localised at chromosomal 
position Xq12-q13.1, it was also suggested as a candidate gene for FG syndrome, another 
ventral midline malformation syndrome, which has been mapped to Xq12-q21.3. 
Therefore, the findings of this thesis, which involve the MID1 complex assisted transport 
of Eph receptor and ephrin mRNAs to the required places of the migrating cell in order to 
establish a protein gradient, are an attractive explanation for the conspicuous phenotypic 
overlap between OS and craniofrontonasal dysplasia and other midline malformation 
syndromes. 
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5 Conclusions and Outlook 
During this thesis, a novel pathomechanism for OS was identified with a basis in 
mutations in Bbox1 or Bbox2 domains of MID1. Bbox1 was shown to be responsible for the 
interaction of MID1 with α4, a regulatory subunit of PP2A, and Bbox2 was demonstrated to act 
as a regulatory arm that couples the MID1 ubiquitin ligase function to the microtubules by 
regulating the association of MID1 with both α4 and microtubules. The inefficient MID1-α4 
binding observed with mutations in any of the Bboxes causes accumulation of PP2Ac at the 
microtubules and hypophosphorylation of its downstream proteins, thus leading to the 
development of OS. A possible explanation for the striking dependence of Bbox1 function on 
Bbox2 could be a putative zinc atom shared by both domains. Consequently, zinc-binding 
stechiometry has to be analysed in next series of experiments. 
As main focus of this thesis, MID1 was demonstrated to form part of an mRNP complex, 
which associates to microtubules and RNA, and is likely to participate in the transport of mRNAs 
to the poles of the cell, providing asymmetric mRNA localisation and protein production. 
Compartmentalised protein translation is an important prerequisite for NCC to migrate and 
polarised cells to step into EMT, both essential processes during ventral midline development. 
Therefore, the data obtained during this thesis suggest a molecular basis for both the 
development of the ventral midline and the pathogenesis of OS.  
However, several lines of investigation remain open. The exact pathomechanism derived 
from MID1 mutations in other domains rather than the C-terminus or, now, the Bboxes remains 
unknown. Therefore, in further experiments, the effects of diverse MID1 forms carrying 
mutations in different domains on RNA or ribosome binding should be studied and hopefully, 
regions involved in this association will be narrowed down.  
In addition, direct association of MID1 with RNA could not be proven during this work. 
Further experiments will also have to show which members, if not MID1 itself, are involved in 
the incorporation of RNA into the complex. As mentioned in the discussion, attractive 
candidates would be the RNA helicase identified by yeast two-hybrid experiments or any of the 
other RNA-binding proteins contained in the complex. The study of RNA-MID1 complex 
association should be also extended to the identification of further mRNAs that associated with 
the complex, via for instance protein-RNA experiments. In theory, gene products of the 
identified mRNAs could collaborate with ephrins during ventral midline development. 
Despite having all the characteristics of a cargo transport, no motor protein that provides 
movement along the microtubules was found to associate to the complex. Further experiments, 
such as immunoprecipitations with the different complex members or candidate specific co-
immunoprecipitations with motor proteins, should allow the identification of such a protein 
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integrated in the complex. Furthermore, immunofluorescence experiments in living cells should 
be done, thus aiming to visualize movement of the whole mRNP in vivo. 
In addition, the role of the MID1 complex in cell migration would also open a new area of 
study, in which the involvement of the complex in focal adhesions and cytoskeleton remodelling 
should be studied. Moreover, polarisation studies, including activation of integrin receptors by 
different effectors or by activation of EFNB1, could shed light on the functions of the MID1 
complex in cell polarisation and migration. These studies could be extended to OS patient cell 
lines, which might show defects in migration compared to control cell lines. 
While underlying genetic defects in patients with autosomally inherited OS remain totally 
unknown, mutations in MID1 have only been found in 68% of cases with X-linked OS. Since 
during this thesis it was shown that ephrin mRNAs are integrated into the MID1 complex via G-
quartet structures, these structures appear as good candidates to harbour the “missing” 
mutations. Therefore, mutation analysis of G-quartet structures in ephrin mRNAs in OS patients 
not holding mutations in MID1 should be done. 
Last but not least, direct influence of the MID1 complex on EFNB1 mRNA translation 





Opitz BBB/G syndrome (OS) is a congenital disorder characterised by malformations of 
the ventral midline, with hypertelorism and hypospadias being the two cardinal phenotypic 
manifestations. OS is genetically heterogeneous, with an autosomal and an X-linked locus. 
While the gene at the autosomal locus remains to be identified, the X-chromosomal form has 
been shown to be caused by mutations in the MID1 gene, which harbours mutations in 
approximately 68% of patients with X-linked OS. Most of the mutations identified in OS patients 
are located at the 3′ end of the MID1 open reading frame, thus affecting the C-terminus of the 
MID1 protein. 
The MID1 protein belongs to the RFP subfamily of the RBCC family of proteins. At its N-
terminal end it contains a RING finger, two Bboxes (Bbox1, Bbox2), and a coiled-coil domain 
(RBCC domain), which are followed by a FNIII domain and a B30.2 domain (RFP domain) at its 
C-terminal end. MID1 has been shown to form macromolecular cellular complexes, the 
components of which were, up to now, mainly unknown. Similar to other RBCC proteins, MID1 
contains several putative protein-protein interaction domains. Recently, we have shown that the 
C-terminally microtubule-associated MID1 protein binds α4, a regulatory subunit of phosphatase 
2A (PP2A), through the Bbox1 domain, thereby targeting the catalytic subunit of microtubule-
associated PP2A (PP2Ac) towards ubiquitin-specific modification and degradation. MID1 
mutations in the C-terminal end of the protein lead to disruption of microtubule association of 
MID1 and subsequent formation of clumps in the cytosol. Despite preserving its association with 
α4, C-terminally mutated MID1 can not approach the vicinity of microtubule-associated PP2Ac 
and, therefore, the ubiquitination and degradation of microtubule-associated PP2Ac becomes 
disrupted, leading to hypophosporylation of its downstream targets.  
During this thesis, basic functions of Bbox1 and Bbox2, with respect to MID1-α4 and 
MID1-microtubule interactions, were studied in detail by immunofluorescence, 
immunoprecipitation and yeast two-hybrid experiments. In this way, a novel pathomechanism 
for OS could be identified based on mutations in Bbox1 or Bbox2 domains of MID1 rather than 
C-terminal mutations. While the Bbox1 was shown to be responsible for the interaction of MID1 
with α4, the Bbox2 was demonstrated to act as a regulatory arm that couples the MID1 ubiquitin 
ligase function to the microtubules by regulating the association of MID1 with both α4 and 
microtubules.  
As the main focus of this thesis, the MID1 multiprotein complex was elucidated via affinity 
chromatography and mass spectrometry. Besides tubulin association, which has previously 
been reported, MID1 was shown to associate with several proteins of the small ribosomal 




which also associate with ribosomes and RNA. In addition, heat shock proteins, such as Hsp60, 
Hsc70, and the multifunctional chaperones Hsp90 and p32, were identified in the complex. 
Through further characterisation of the MID1 protein complex, it could be demonstrated 
during this thesis that the MID1 protein, together with the mTOR target α4, forms a microtubule-
associated mRNP that contains active polyribosomes and RNA, and thus links the translation 
regulatory mTOR pathway with a microtubule-associated translation unit. This complex is likely 
to participate in the transport of mRNAs to the poles of the cell, providing asymmetric mRNA 
localisation and protein production. Compartmentalised protein translation is an important 
prerequisite for neural crest cells to migrate and polarised cells to step into epithelial-
mesenchymal transition, both essential processes during ventral midline development. 
Therefore, the results of this thesis suggest a molecular basis for both the development of the 
ventral midline and the pathogenesis of OS. 
Moreover, it could be shown that the MID1/α4 complex integrates mRNAs of ephrinB 
molecules (ligands and receptors) through G-quartet structures located in their 3´UTRs. Ephrins 
and Eph receptors participate in the regulation of essential processes during the development of 
the ventral midline, such as cell attachment, cell migration and embryonic patterning. Therefore, 
this thesis suggests a central role for the MID1/α4 protein complex in the microtubule-
associated compartmentalised translation of EphB receptors and ephrins-B. Interaction of the 
MID1 protein complex with the mRNA of ephrin-B1 (EFNB1) is of particular interest since 
mutated EFNB1 leads to the development of craniofrontonasal dysplasia, a monogenic disorder 
with manifestations that are highly reminiscent of the OS phenotype. Consequently, the model 
proposed here also provides an attractive explanation for the conspicuous phenotypic overlap of 






El síndrome de Opitz BBB/G (OS) es un desorden congénito que se caracteriza por 
anomalías de la línea media ventral del cuerpo y que presenta como manifestaciones más 
prominentes hipertelorismo e hipospadias. OS es una enfermedad genéticamente heterogénea 
para la que existen dos loci, uno autosomal y otro ligado al cromosoma X. El gen causante de 
la herencia de carácter autosómico aún no ha sido identificado. Por otro lado, se ha 
demostrado que la herencia ligada al cromosoma X se debe a mutaciones en el gen MID1, que 
se presenta con mutaciones en aproximadamente un 68% de los pacientes con OS ligado al 
cromosoma X. La mayoría de las mutaciones identificadas en pacientes con OS, están situadas 
en el extremo 3´ de la región codificante de MID1 y por lo tanto afectan al extremo carboxilo de 
la proteína MID1. 
La proteína MID1 pertenece a la subfamilia RFP de la familia RBCC de proteínas. En la 
parte amino-terminal, MID1 comprende un RING-Finger, dos Bboxes (Bbox1 y Bbox2) y un 
dominio “Coiled-coil” (dominio RBCC), seguidos de los dominios FNIII y B30.2 en el extremo 
carboxilo de la proteína. MID1 tiene la capacidad de formar grandes complejos 
macromoleculares, cuyos componentes eran hasta ahora desconocidos. Como otras proteínas 
de la familia RBCC, MID1 tiene varios dominios que participan en interacciones entre proteínas. 
Recientemente demostramos en nuestro laboratorio que MID1, asociada a través de su 
extremo carboxilo con los microtúbulos, interacciona con alpha4 (α4), una subunidad 
reguladora de la proteína fosfatasa 2A (PP2A), por medio de Bbox1. De este modo, MID1 es 
capaz de ubiquitinar la subunidad catalítica de PP2A (PP2Ac), que en consecuencia, será 
degradada por el proteasoma. Las mutaciones en el extremo carboxilo de MID1 hacen que ésta 
pierda su asociación con los microtúbulos y se formen agregados en el citoplasma de la célula. 
A pesar de seguir unida a α4, MID1 ya no puede acercarse a PP2Ac y ubiquitinarla, por lo tanto 
PP2Ac se acumula en los microtúbulos, lo que provoca la hipofosforilación de proteínas que de 
ella dependen. 
Durante esta tesis, la base experimental para el estudio de las funciones básicas de 
Bbox1 y Bbox2 en lo concerniente a la interacción de MID1 con los microtúbulos y con α4 
fueron experimentos tales como immunofluorescencias, immunoprecipitaciones y “yeast two-
hybrid system”. De esta manera y por primera vez se pudo describir un nuevo mecanismo 
patológico para MID1 con mutaciones en uno de los Bboxes en lugar de en el extremo 
carboxilo. Concretamente, los resultados de esta tesis demostraron que sólo Bbox1 interviene 
directamente en la interacción de MID1 con α4 y que Bbox2 tiene un papel regulador en la 




El principal objetivo de esta tesis fue identificar el complejo multiproteico formado por 
MID1 usando técnicas como cromatografía de afinidad y espectrometría de masas. Además de 
la ya demostrada interacción de MID1 con tubulina, en el complejo se identificaron varias 
proteínas pertenecientes a la subunidad pequeña del ribosoma (S3, S8 y p40) en conjunto con 
diversas proteínas mutifuncionales, tales como NPM, RACK1 y ANXA2, que se han visto 
anteriormente asociadas con ARN y ribosomas. También fueron encontradas en el complejo 
varias proteínas de choque térmico, tales como Hsp60, Hsc70 y las chaperonas 
multifuncionales Hsp90 y p32, fueron encontradas en el complejo. 
El complejo multiproteico formado por MID1 se estudió en detalle y se encontró que, junto 
con α4 (una proteína diana de mTOR), MID1 forma un complejo ribonucleoproteico que se 
encuentra asociado con los microtúbulos y contiene polisomas y RNA y por lo tanto, sirve de 
vinculo entre la vía de mTOR (reguladora de la traducción de proteínas) y una nueva unidad de 
traducción situada en los microtúbulos. Probablemente, este complejo participa en el transporte 
de ARN mensajero (ARNm) a los polos de la célula y de ese modo proporciona la requerida 
asimetría en la distribución ARNm y en la producción de proteínas. Para que células de la 
cresta neural migren y células polarizadas entren en transición epitelial-mesenquimal, procesos 
esenciales durante el desarrollo de la línea ventral media, es necesario que la producción de 
proteínas se distribuya en compartimentos diferentes. Por consiguiente, los resultados de esta 
tesis sugieren una base molecular para el desarrollo de la línea media y para la patogénesis de 
OS. 
Asimismo, se demostró que el complejo multiproteico de MID1/α4 integra ARNm 
pertenecientes a efrinas y sus receptores a través de estructuras en forma de “G-quartets” que 
se ubican en sus 3´UTRs. Las efrinas y sus receptores participan en la regulación de procesos 
fundamentales durante el desarrollo de la línea ventral media, tales como adhesión y migración 
celular y desarrollo embrionario. Así pues, esta tesis plantea un papel central para el complejo 
multiproteico MID1/α4 en la distribución de la traducción de efrinas y sus receptores en la 
célula a través del transporte de sus ARNm por los microtúbulos. Se debe hacer hincapié en la 
interacción que el complejo de MID1 presenta con la efrina-B1 (EFNB1), ya que mutaciones en 
este gen causan displasia craneofrontonasal, un desorden monogénico cuyos pacientes 
presentan un fenotipo altamente similar al de los pacientes con OS. Por lo tanto, el modelo que 
en esta tesis se propone, también proporciona una explicación muy atractiva para el llamativo 





Das Opitz BBB/G Syndrom (OS) ist eine Erbkrankheit, die durch Fehlbildungen der 
ventralen Mittellinie, insbesondere Hypertelorismus und Hypospadie, charakterisiert ist. OS ist 
mit einem autosomalen und einem X-chromosomalen Locus genetisch heterogen. Während das 
Gen auf dem autosomalen Genlocus noch nicht identifiziert wurde, konnte die X-chromosomale 
Form auf Mutationen im MID1-Gen zurückgeführt werden. Im offenen Leserahmen dieses Gens 
konnten bei etwa 68% der Patienten mit X-chromosomalem OS Mutationen gefunden werden. 
Die meisten Mutationen, die bei OS-Patienten identifiziert wurden, befinden sich im 3´Bereich 
des offenen Leserahmens des MID1-Gens und wirken sich somit auf den C-terminalen Bereich 
des MID1-Proteins aus. 
Das MID1-Protein gehört zur RFP-Familie, die eine Unterfamilie der RBCC-Familie ist. 
Am Ende des N-Terminus befinden sich ein RING-Finger, zwei Bboxen (Bbox1, Bbox2) und 
eine Coiled-coil Domäne (RBCC-Domäne). Am C-terminalen Ende schließt sich eine FNIII-
Domäne und eine B30.2-Domäne (RFP-Domäne) an. Es wurde gezeigt, dass MID1 
makromolekülare Komplexe bildet, deren Komponenten zu Beginn dieser Arbeit weitestgehend 
unbekannt waren. Ähnlich wie andere Proteine der RBCC-Familie besitzt MID1 verschiedene 
Domänen, die an Proteininteraktionen beteiligt sind. Wir konnten vor kurzem zeigen, dass das 
Mikrotubulus-assoziierte MID1-Protein mit seiner Bbox1 an das α4-Protein, einer 
regulatorischen Untereinheit der Phosphatase 2A (PP2A), bindet. Dies führt zur Übertragung 
von Ubiquitin auf die katalytische Untereinheit der Mikrotubulus-assoziierten PP2A (PP2Ac) und 
zu deren Aufbau im Proteasom. Auch MID1 mit Mutationen am C-terminalen Ende bindet an 
das α4 Protein. Es hat jedoch die Fähigkeit, an Mikrotubuli zu binden, verloren und bildet 
Aggregate im Zytoplasma. Eine Interaktion mit der Mikrotubulus-assoziierten PP2Ac kann somit 
nicht mehr stattfinden, was dazu führt, dass die Ubiquitinierung und Degradierung der 
Mikrotubulus-assoziierten PP2Ac verhindert wird und ihre Zielproteine hypophosphorylieren.  
Im Rahmen dieser Arbeit wurden grundsätzliche Funktionen von Bbox1 und Bbox2 im 
Zusammenhang mit MID1-α4 und MID1-Mikrotubuli-Interaktionen im Detail untersucht. Durch 
Immunfluoreszenz-, Immunprecipitation- und Yeast-Two-Hybrid-Experimente konnte ein neuer 
Pathomechanismus für OS nachgewiesen werden, der eher auf Mutationen der Bbox1 oder 
Bbox2-Domänen von MID1 basiert als auf Mutationen des C-Terminus. Während sich die 
Bbox1 für die Interaktion zwischen MID1 und α4 verantwortlich zeigte, ist die Bbox2 an der 
Regulierung der Assoziation von MID1 mit α4 und den Mikrotubuli beteiligt.  
Als Hauptanliegen dieser Arbeit wurde der MID1-Multiprotein-Komplex mit Hilfe von 
Affinitätschromatographie und Massenspektrometrie identifiziert und analysiert. Neben der 




Proteine der kleinen ribosomalen Untereinheit (S3, S8, p40) und andere multifunktionale 
Proteine wie NPM, RACK1 und ANXA2, welche ebenfalls mit Ribosomen und RNS assoziieren, 
bindet. Weiterhin wurden Hitzeschock-Proteine, wie Hsp60, Hsc70 und die multifunktionalen 
Chaperone Hsp90 und p32, im Komplex identifiziert. 
Durch weitere Charakterisierung des MID1-Protein-Komplexes, konnte im Rahmen dieser 
Arbeit gezeigt werden, dass das MID1-Protein, zusammen mit dem mTOR-Zielprotein α4, ein 
Mikrotubulus-assoziiertes mRNP bildet, welches aktive Polyribosome und RNS enthält, und so 
den regulierenden Translations-mTOR-Weg mit einer Mikrotubulus-assoziierten Translations-
Einheit verbindet. Dieser Komplex reguliert wahrscheinlich den Transport der mRNS zu den 
Polen der Zelle, was zu asymmetrischer mRNS Lokalisierung und Protein-Produktion führt. 
Asymmetrische Protein-Translation ist eine wichtige Voraussetzung, damit die Zellen der 
Neuralleiste migrieren können und polarisierte Zellen in die Epithelial-Mesenchymale-Transition 
treten können. Beides sind essenzielle Prozesse bei der Entwicklung der ventralen Mittellinie. 
Daher bereiten die Ergebnisse dieser Arbeit eine molekulare Basis sowohl der Entwicklung der 
ventralen Mittellinie als auch der Pathogenese von OS. 
Darüber hinaus wurde in dieser Arbeit gezeigt, dass der MID1/α4-Komplex an G-Quartet-
Strukturen in den 3´UTR von ephrin-B Molekülen (Liganden und Rezeptoren) bindet. Dies weist 
darauf hin, dass der MID1/α4-Komplex die asymmetrische Translation der ephrin-B Moleküle in 
Subkompartimenten der Zelle steuert. Die Regulation wichtiger Prozesse der Entwicklung der 
ventralen Mittelinie durch Ephrine, wie z.B. Zellhaftung und Zellmigration könnte durch diese 
Steuerung gewährleistet werden. Die Interaktion des MID1-Protein- Komplexes mit mRNS des 
Ephrin-B1 (EFNB1) ist besonders interessant, da mutiertes EFNB1 zu craniofrontonasaler 
Dysplasie führt, einer monogenen Störung, die zu einem sehr ähnlichen Phänotypen führt wie 
OS. Dementsprechend bietet das hier vorgeschlagene Modell auch eine attraktive Erklärung für 
die offensichtliche phänotypische Übereinstimmung der zwei Krankheiten. 
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